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SUMMARY 
 
The present dissertation is based on characterization of mouse models for inborn 
errors of metabolic disorders concomitant with monoamine neurotransmitter 
deficiency and investigation of potential therapeutic approaches. Following an 
introduction (Chapter 1), this dissertation deals with the three metabolic diseases 
tyrosine hydroxylase deficiency (THD; chapter 2), tetrahydrobiopterin deficiency (BH4 
deficiency; chapter 3), and classical phenylketonuria (cPKU; chapter 4). 
 
Chapter 2: Tyrosine hydroxylase knock-in (Th-ki) mouse model with 
catecholamine depletion and impaired motor control: Characterisation and 
treatment studies 
 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the synthesis of 
catecholamine neurotransmitters, hormones and a marker for dopaminergic neurons. 
Mutations in the TH gene are associated with the autosomal recessive 
neurometabolic disorder TH deficiency (THD), which manifests with phenotypes 
varying from infantile parkinsonism and L-Dopa-responsive dystonia to complex 
encephalopathy of perinatal onset. The most recurrent mutation in THD patients is 
TH-p.Arg233His (hTH1-p.Arg202His, isoform 1), which is mostly associated to a 
severe THD phenotype, often concomitant with non-responsiveness to L-Dopa 
treatment. While Th knock-out mice are not viable, homozygous Th-knock-in (Th-ki) 
mice expressing the Th-p.Arg203His mutation (equivalent to hTH1-p.Arg202His) 
showed normal survival and food intake but hypotension and moderate growth 
retardation. The mutant enzyme exhibited impaired inhibitory feedback and stabilizing 
dopamine binding, which lead to progressive disappearance of TH associated to 
gradual loss of catecholamines in the brain. Specially, unstable mutant TH was 
absent in striatum. Accordingly, mutant mice showed reduced motor coordination, 
ataxia and catalepsy with diurnal fluctuation, and non-responsiveness to L-Dopa 
treatment. This hypomorphic Th-ki mouse model with encephalopathy and impaired 
motor control thus provides understanding on molecular pathogenic mechanisms for 
THD, replicates the most severe form of the disease, and provides a platform for the 
evaluation of novel therapeutics (manuscript Korner et al., in preparation for 
submission).   
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In follow up-studies (not included in the above manuscript), Th-ki mice were studied 
for the effect of (oral) treatment with synthetic tetrahydrobiopterin (BH4) cofactor and 
two pharmacological chaperones (compound III and IV). BH4 and these 
pharmachaperone compounds were previously reported to stabilize mutant hTH-
Arg202His in vitro and wild-type TH in mouse brains by increasing the amount of TH 
protein and its activity. However, in Th-ki mice, none of these compounds led to an 
improvement or normalization in brain catecholamine levels, TH activity, protein 
amount or behavioural changes.  
 
In the final part, an alternative treatment approach was tested by “in situ” 
biosynthesis of L-Dopa in the liver of Th-ki mice using an adeno-associated virus 
serotype 8 vector (rAAV2/8) expressing the wild-type Th-cDNA in liver. Theoretically, 
the hepatic synthesized L-Dopa should lead to an increase of brain catecholamines, 
which is potentially more effective then the treatment with L-Dopa, and might lead to 
the correction of motor dysfunction in the mutant mice. Although the wt TH was 
expressed in the liver of mutant mice, there was no effect on brain catecholamines or 
any improvements in motor function.  
 
Chapter 3: Characterisation of mouse models with mildly compromised BH4 
biosynthesis: Pts-ki/ki and Pts-ki/ko  
 
Tetrahydrobiopterin (BH4) is an essential cofactor for the aromatic amino acid 
hydroxylases, alkylglycerol monooxygenase and nitric oxide synthases (NOS). Inborn 
errors of BH4 metabolism lead to severe insufficiency of brain monoamine 
neurotransmitters while augmentation of BH4 by supplementation or stimulation of its 
biosynthesis is thought to ameliorate endothelial NOS (eNOS) dysfunction, to protect 
from (cardio-) vascular disease and/or prevent obesity and development of the 
metabolic syndrome. We have previously reported that homozygous knock-out mice 
for the 6-pyruvolytetrahydropterin synthase (PTPS; Pts-ko/ko) mice with no BH4 
biosynthesis die after birth. We generated a Pts-knock-in (Pts-ki) allele expressing 
the murine PTPS-p.Arg15Cys with low residual activity (15% of wild-type in vitro) and 
investigated heterozygous (Pts-ki/wt), homozygous (Pts-ki/ki) and compound 
heterozygous (Pts-ki/ko) mutants. Mice were viable and, depending on the severity of 
the Pts alleles, exhibited up to 90% reduction of PTPS activity in liver and brain. 
Although neopterin was elevated in brain and liver, BH4, blood L-phenylalanine and 
the brain monoamine neurotransmitters dopamine and serotonin were all unaffected. 
Summary 
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Unexpectedly, Pts-ko/wt and Pts-ki/ki mice exhibited increased body weight and 
elevated intra-abdominal fat tissue. Comprehensive phenotyping of Pts-ki/ki mice 
revealed alterations in energy metabolism with higher fat content, lower lean mass, 
and increased blood glucose and cholesterol. Transcriptome analysis of liver 
indicated changes in glucose and lipid metabolism. Furthermore, differentially 
expressed genes associated with obesity, weight loss, hepatic steatosis and insulin 
sensitivity were consistent with the observed phenotypic alterations. Our study 
associates a novel single gene mutation with monogenic forms of obesity. We 
conclude that reduced PTPS and potentially BH4-biosynthetic activity in mice leads to 
abnormal body fat distribution and abdominal obesity potentially through mildly 
elevated neopterin and/or compromised eNOS function (manuscript Korner et al., 
submitted). 
 
In the additional work, not published in the context of the above observation, I 
challenged a claim by Dea Adamsen in her PhD thesis (University of Zurich, 2011). D. 
Adamsen described in her work that Pts-ki/ko had different phenotypes depending on 
the maternal genotype: “affected” Pts-ki/ko newborns with lethality 3-4 days after birth 
and “unaffected” Pts-ki/ko offspring with normal survival. Furthermore, “unaffected” 
Pts-ki/ko mice had a similar phenotype like homozygous Pts-ki/ki mice. The definition 
of “affected” mice included all hallmarks of lethal BH4 deficiency with low biopterin 
and monoamine neurotransmitter levels, increased neopterin levels and 
hyperphenylalaninemia (HPA). D. Adamsen also claimed that the “affected” mice only 
appear if the mother was homozygous for the knock-in mutation. Here we found that 
newborns (day 1) and 3-4 days old pups from different breeding combinations of Pts-
ki/ki, Pts-ki/wt and Pts-ko/wt parents revealed that there were only minor deviations 
between Pts-ki/ko newborns from different breeding combination and that none of 
them showed the severe (“affected”) phenotype.  
 
Chapter 4: Study of a muscle-directed non-viral gene therapeutic approach for 
PKU and attempt to generate a mouse model expressing BH4 in muscle  
 
Deficiency of the hepatic phenylalanine hydroxylase (PAH), catalyzing the conversion 
from L-phenylalanine (L-Phe) to L-Tyr, is the cause for classical phenylketonuria 
(cPKU). Complete correction of cPKU in a mouse model was previously shown by 
muscle targeting using a recombinant rAAV vector expressing the complete 
phenylalanine hydroxylating system, i.e. coordinate expression of the Pah minigene 
Summary 
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plus the two genes (cDNAs) guanosine triphosphate cyclohydrolase I (Gch1) and Pts, 
essential for BH4-cofactor biosynthesis in muscle tissue. As an alternative to the 
(AAV) viral approach, the potential of such a triple-cistronic gene transfer using 
naked DNA/minicircle (MC) vectors to target skeletal muscle in PKU mice was 
investigated. Testing triple-cystronic gene vectors included a combination of various 
modifications such as codon-optimization, insertion of intronic sequences, and 
transcription or gene expression latency elements like the woodchuck hepatitis post-
transcriptional regulatory element (WPRE) and the scaffold/matrix attachment region 
(S/MAR). Transgene expression from these vectors was validated under cell culture 
conditions before they were injected into PKU mice by hydrodynamic limb vein 
infusion or by electroporation. Although high concentrations of MCs were applied (up 
to 6.8 x1014 vector particles), normalization of blood L-Phe levels in the treated PKU 
mice not yet be achieved with any of these vectors. Further efforts and optimization 
towards a non-viral gene transfer to muscle to treat cPKU is discussed in an 
additional chapter.  
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Zusammenfassung 
 
Die vorliegende Dissertation behandelt die Charakterisierungen von Mausmodellen, 
welche angeborene Stoffwechselerkrankungen in der Monoamin-Neurotransmitter 
Synthese aufweisen, sowie die Untersuchung von möglichen therapeutischen 
Ansätzen. Nach einer Einführung (Kapitel 1) beschäftigt sich diese Dissertation mit 
den drei Stoffwechselerkrankungen Tyrosin-Hydroxylase-Mangel (Kapitel 2), Tetra-
hydrobiopterin-Mangel (Kapitel 3), und der klassischen Phenylketonurie (Kapitel 4). 
 
Kapitel 2: Tyrosin-Hydroxylase Knock-in (Th-ki) Mausmodell mit progressivem 
Katecholamin-Abbau und eingeschränkter motorischer Kontrolle: Charakter-
isierung sowie mögliche Behandlungsansätze 
 
Tyrosin-Hydroxylase (TH) ist das geschwindigkeitsbestimmende Enzym bei der 
Synthese von Katecholaminen-Neurotransmittern und Hormonen, und ein Marker für 
Dopaminerge-Neuronen. Mutationen im TH-Gen führen zu einem autosomal rezessiv 
vererbten TH-Mangel (THD), welche sich mit unterschiedlichen Phänotypen von 
infantilen Parkinsonismus und L-Dopa ansprechenden Dystonie bis hin zur komplexe 
Enzephalopathie mit perinatalem Auftreten manifestiert. Die häufigste Mutation bei 
THD Patienten ist die TH-p.Arg233His Mutation (hTH1-p.Arg202His, Isoform 1), 
welche meistens zu einem schweren Verlauf der Erkrankung führt, die nicht auf eine 
L-Dopa-Behandlung anspricht. Während Th-knock-out Mäuse nicht lebensfähig sind, 
waren die homozygoten Th-knock-in-Mäuse (Th-ki), welche die Th-p.Arg203His 
Mutation (entspricht hTH1-p.Arg202His) exprimieren, lebensfähig und wiesen eine 
normale Nahrungsaufnahme auf, jedoch zeigten sie Hypotonie und eine moderate 
Wachstumsverzögerung. In vitro Untersuchungen zeigten, dass das mutierte TH 
Enzym Dopamin nicht binden kann, was zu einer verminderten Protein-Stabilität und 
wahrscheinlich zum fortschreitenden Verschwinden der mutierten TH führte, und 
schliesslich den allmählichen Verlust der Katecholamine zur Folge hatte. Weitere 
Immunohistochemistrie-Analysen zeigten, dass die instabile TH Mutante im Striatum 
kaum vorhanden war. Dementsprechend zeigten die transgenen Mäuse eine 
verminderte Bewegungskoordination, Ataxie und Katalepsie mit tageszyklischen 
Schwankungen und sprachen nicht auf die L-Dopa-Behandlung an. Dieses 
hypomorphe Th-ki-Mausmodell mit Enzephalopathie und beeinträchtigter motorischer 
Steuerung bietet somit Einblicke zum Verständnis der molekularen Patho-
Zusammenfassung 
 17
mechanismen für THD, repliziert die schwerste Form der Erkrankung und ermöglicht 
das Testen neuer Therapiemöglichkeiten (Manuskript Korner et al.). 
 
In einer weiterführenden Studie (nicht im Manuskript enthalten), wurden Th-ki-Mäuse 
auf die Wirkung nach (oraler) Behandlung mit dem synthetischen Tetrahydrobiopterin 
(BH4) Kofaktor und zwei pharmakologischen Chaperons untersucht (Chaperon III und 
IV). Bereits zuvor publizierte Studien zeigten, dass BH4 und die Pharmachaperons 
die TH-Arg202His Mutante in vitro und die Wildtyp TH Enzyme in Mäusegehirnen 
stabilisierten, was zu Erhöhung der Menge von TH-Protein und seiner Aktivität im 
Hirn führte. In Th-ki Mäusen führte jedoch keine dieser Verbindungen zu einer 
Verbesserung bzw. Normalisierung der Gehirn Katecholamine, TH-Aktivität, 
Proteinmenge oder zu einer Verhaltensänderung. 
 
Im letzten Teil dieser Arbeit wurde ein alternativer Behandlungsansatz getestet, 
welcher die "in situ" Biosynthese von L-Dopa in der Leber von Th-ki Mäusen durch 
die Behandlung eines Adeno-assoziierten Virus mit Serotyp 8 Vektors (rAAV2/8), 
welcher die wildtyp Th-cDNA in der Leber exprimiert, untersucht. Diese 
Behandlungsmethode ist möglicherweise effektiver als die Behandlung mit L-Dopa 
und theoretisch sollte das in der Leber synthetisierte L-Dopa zu einer Verbesserung 
der Katecholamine im Hirn führen. Dies bewirkt dann möglicherweise eine Korrektur 
der Bewegungsstörungen in den transgenen Mäusen. Obwohl die wildtyp TH in der 
Leber der transgenen Mäuse exprimiert war, ergaben sich weder Veränderungen der 
Katecholamine im Gehirn noch Verbesserungen in der Motorik. 
 
Kapitel 3: Abnormale Körperfettverteilung und abdominale Adipositas in einer 
Maus-Mutante mit einer leicht beeinträchtigtem Tetrahydrobiopterin Kofaktor-
Biosynthese 
 
Tetrahydrobiopterin (BH4) ist ein essentieller Kofaktor für die aromatischen 
Aminosäure-Hydroxylasen, die Alkylglycerinsulfate Monooxygenase und die 
Stickstoffmonoxid-Synthasen (NOS). Angeborene Fehler im BH4 Metabolismus 
führen zu schwerer Monoamin-Neurotransmitter-Insuffizienz im Gehirn, während 
angenommen wird, dass die Augmentation von BH4 durch Ergänzungen oder 
Stimulation der BH4 Biosynthese die endotheliale NOS (eNOS) Dysfunktion 
verbessert, vor (Herz-) Gefäßerkrankungen schützt und/oder Fettleibigkeit und 
Entwicklung des metabolischen Syndroms verhindert. Es wurde bereits publiziert, 
dass homozygote knock-out-Mäuse für die 6-Pyruvoly-Tetrahydropterin Synthese 
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(PTPS; Pts-ko/ko), welche über keine BH4-Biosynthese verfügen, kurz nach der 
Geburt sterben. Daher wurde das Pts-knock-in (Pts-ki) Allel generierten, welches die  
murine PTPS-p.Arg15Cys Mutation exprimiert die zu einer geringen PTPS 
Enzymaktivität führt (15% Aktivität in vitro im Vergleich zum Wildtypen) und 
heterozygote (Pts-ki/wt), homozygote (Pts-ki/ki) und komplex heterozygote (Pts-ki/ko) 
Mutanten wurden charakterisiert. Die transgenen Mäuse waren lebensfähig und 
zeigten, je nach Kombination der Pts-Allele, eine bis zu 90% Reduktion der PTPS 
Aktivität in Leber und Gehirn. Obwohl Neopterin im Gehirn und in der Leber erhöht 
war, zeigte sich das der BH4 Level, das L-Phenylalanin im Blut und die Gehirn 
Monoamin-Neurotransmitter Dopamin und Serotonin unverändert waren. 
Überraschenderweise wiesen Pts-ko/wt und Pts-ki/ki Mäuse ein erhöhtes 
Körpergewicht und vermehrtes intra-abdominales Fettgewebe auf. Eine umfassende 
Phänotypisierung der Pts-ki/ki Mäusen zeigte Veränderungen im Energiestoffwechsel 
mit einem erhöhten Fettgehalt, einer geringeren Magermasse, und einem erhöhten 
Blutzucker- und Cholesterinspiegel. Die Transkriptom-Analyse der Leber deutete auf 
Veränderungen im Glukose- und Fettstoffwechsel hin. Darüber hinaus wurden 
differentiell exprimierte Gene gefunden, welche in Verbindung mit Übergewicht, 
Gewichtsverlust, Fettleber und Insulinempfindlichkeit stehen und die beobachteten 
phänotypischen Veränderungen der transgenen Tiere unterstützen. Unsere Studie 
verbindet eine neuartige Genmutation mit den monogenen Formen der Adipositas. 
Wir schliessen daraus, dass die reduzierte PTPS und die potentiell auch reduzierte 
BH4-Biosynthese-Aktivität bei Mäusen zur abnormalen Körperfettverteilung und 
abdominaler Adipositas führt, welche möglicherweise durch das leicht erhöhte 
Neopterin und/oder durch die beeinträchtigte eNOS Funktion verursacht wird 
(Manuskript Korner et al.). 
 
Ein weiteres Kapitel befasst sich mit der Validierung einer Beobachtung von Dea 
Adamsen aus ihrer Dissertation (Universität Zürich, 2011). D. Adamsen beschrieb in 
ihrer Arbeit, dass Pts-ki/ko verschiedene Phänotypen aufwiesen, welche angeblich 
vom Genotyp der Mutter abhängig ist: "betroffene" Pts-ki/ko Neugeborene, welche 3-
4 Tage nach der Geburt verstarben und "nicht betroffene" Pts-ki/ko Nachkommen, 
welche sich normal entwickelten. "Nicht betroffene" Pts-ki/ko Mäuse zeigten einen 
ähnlichen Phänotypen wie die homozygoten Pts-ki/ki Mäuse. "Betroffene" Mäuse 
hatten alle Anzeichen des letalen BH4-Mangels mit geringem Biopterin und 
Monoamin-Neurotransmittern, erhöhtem Neopterin und Hyperphenylalaninemia 
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(HPA). Ferner behauptete D. Adamsen, dass der "betroffenen" Mäuse Phänotyp nur 
auftrat, wenn die Mutter homozygot für die knock-in Mutation war. Es wurden 
Neugeborene (1 Tag alt) und 3-4 Tage alte Jungtiere aus verschiedenen 
Zuchtkombinationen von Pts-ki/ki, Pts-ki/wt und Pts-ko/wt Eltern untersucht. Dabei 
wurden lediglich geringe Abweichungen zwischen Pts-ki/ko Neugeborenen von 
unterschiedlichen Zuchtkombination gefunden und keines der Jungtiere zeigte die 
schweren ("betroffen") Phänotyp. 
 
Kapitel 4: Eine Studie über Muskel-orientierten nicht-viralen Gentransfer zur 
Behandlung der klassischen PKU in der Maus und das Bestreben zur 
Generierung eines Mausmodells, welches BH4 im Muskel exprimiert 
 
Der Mangel des Leberenzymes Phenylalaninhydroxylase (PAH), dass für die 
Umwandlung von L-Phenylalanin (L-Phe) zu L-Tyr verantwortlich ist, stellt die 
Ursache für die klassische Phenylketonurie (cPKU) dar. Die vollständige Korrektur 
der cPKU wurde zuvor in einem Mausmodell durch muskelspezifische Behandlung 
unter Verwendung eines rekombinanten AAV-Vektors publiziert, welcher das 
komplette Phenylalaninhydroxylierungsystems exprimiert, d.h. mit einer koordinierten 
Expression der Pah-Minigens sowie die beiden Gene (cDNAs) Guanosintriphosphat 
Cyclohydrolase I (Gch1) und Pts, welche man für die BH4-Kofaktor-Biosynthese im 
Muskelgewebe benötigt. Alternativ zum (AAV) viralen Ansatz sollte das Potential 
eines solchen triple-cistronischen Gentransfers unter Verwendung nackter 
DNA/Minicircle (MC) Vektoren zur Behandlung der Skelettmuskulatur von PKU-
Mäusen untersucht werden. Die dafür getesteten triple-cistronischen Genvektoren 
verfügen über verschiedene Modifikationen wie Codon-Optimierung, Einfügen von 
intronischer Sequenz, Transkription oder Genexpression verstärkenden Elementen 
wie dem Woodchuck Hepatitis post-Transkriptionsregulationselement (WPRE) und 
der Scafold/Matrix-Attachment Region (S/MAR). Die Transgenexpression der 
Vektoren wurde unter Zellkulturbedingungen geprüft, bevor sie durch 
hydrodynamische Schenkel-Veneninfusion oder durch Elektroporation in die PKU-
Mäuse appliziert wurden. Obwohl hohe Konzentrationen der MCs verabreicht wurden 
(bis zu 6,8 x1014 Vektorpartikel), normalisierte sich die Blut L-Phe Konzentration in 
den behandelten PKU-Mäusen mit keinem der Vektoren.  
 
Weitere Optimierungsmöglichkeiten für eine nicht-viralen Gentransfers für den 
Muskel zur Behandlung von cPKU wurden in einem weiteren Kapitel diskutiert. 
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1.1 TYROSINE HYDROXYLASE DEFICIENCY 
 
1.1.1 DESEASE CHARACTERISTICS 
 
Tyrosine hydroxylase deficiency (THD: OMIM 605407), also called autosomal 
recessive Segawa syndrome, is an autosomal recessive disorder resulting from 
cerebral catecholamine deficiency (Szentivanyi et al., 2012). THD is a rare metabolic 
disease with approximately 70 reported cases (www.biopku.org/pnddb and personal 
communication with Jan Haavik, University of Bergen, Norway). Tyrosine 
hydroxylase (TH; EC 1.14.16.2) catalyzes the conversion of L-tyrosine (L-Tyr) to L-
dihydroxyphenylalanine (L-Dopa), which is the rate-limiting step in the biosynthesis of 
the catecholamines dopamine, norepinephrine and epinephrine (see Fig. 1) 
(Goldstein et al., 2006, Willemsen et al., 2010).  
Figure 1: Chemical pathway of catecholamine synthesis and metabolism (Goldstein et al., 2006). 
AADC, L-amino acid decarboxylase; AD, aldehyde dehydrogenase; AR, aldehyde reductase; BH4, 
tetrahydrobiopterin; COMT, catechol-O-methyltransferase; DβH, dopamine-β-hydroxylase; DHPG, 3,4-
dihydroxyphenylglycol; DOPAC, dihydroxyphenylacetic acid; DOPAL, 3,4-dihydroxyphenyl-
acetaldehyde; L-Dopa, L-dihydroxyphenylalanine; DOPEGAL, 3,4-dihydroxyphenylglycolaldehyde; 
HVA, homovanillic acid; L-Tyr, L-tyrosine; MAO, monoamine oxidase; MHPG, 3-methoxy-4-
hydroxyphenylethyleneglycol; MN, metanephrine; NMN, normetanephrine; PNMT, phenyl-
ethanolamine-N-methyltransferase; 3-OMD, 3-O-methyldopa; q-BH2, dihydrobiopterin; TH,  tyrosine 
hydroxylase; VMA, vanillylmandelic acid.  
Dopamine, norepinephrine and epinephrine are involved in the regulation of motor 
coordination, behaviour, learning and memory, sleep-wake cycle regulation, 
endocrine and visceral functions and arousal in adults (Wevers et al., 1999). In 1971, 
the first report of THD described patients with an early onset, progressive L-Dopa-
responsive dystonia (DRD) (Castaigne et al., 1971, Willemsen et al., 2010). In 2003, 
neonates with a more severe phenotype were described as progressive, L-Dopa-non-
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responsive encephalopathy (Hoffmann et al., 2003). Therefore, THD is classed into 
two clinical phenotypes: type A (mild form) with an infantile progressive hypokinetic-
rigid syndrome with dystonia and type B (severe from) with a neonatal complex 
encephalopathy (Szentivanyi et al., 2012). THD is a movement disorder with a very 
early onset: type B patients had an age onset within the first months of life, whereas 
most of the type A patients showed signs in the first year of life. Approximately 69% 
of all patients suffered from type A THD. Symptoms included unilateral or asymmetric 
limb dystonia, postural tremor, gait disorder or involuntary eye movements (Swoboda 
and Furukawa, 1993, Willemsen et al., 2010). Severity of dystonia may fluctuate 
during the day and is generally worse in the afternoon, but it can also fluctuate within 
days (Willemsen et al., 2010). Type B patients show infantile parkinsonism included 
developmental motor delay, truncal hypotonia, limb rigidity, hypokinesia, and 
neuropsychiatric features like attention deficit or impulsivity, learning disabilities, 
excessive anxiety, depression, or obsessive-compulsive symptoms (Swoboda and 
Furukawa, 1993, Furukawa, 2003, Hoffmann et al., 2003, Furukawa et al., 2004). 
Speech delay or difficulty with articulation can also occur. Autonomic dysfunction like 
constipation, reflux, poor feeding, temperature instability, hypoglycemia, and difficulty 
regulating blood pressure may be present (de Rijk-Van Andel et al., 2000, De Lonlay 
et al., 2000). More severely affected children have intellectual disability and 
hyperprolactinemia (dopamine is a prolactin-inhibiting factor) (Swoboda and 
Furukawa, 1993, Hyland, 1999). Another form is the progressive infantile 
encephalopathy in which children have persistent encephalopathy and motor 
disability (Swoboda and Furukawa, 1993, Hoffmann et al., 2003). Diurnal fluctuations 
of symptoms are present to a minor degree but are generally absent (Willemsen et al., 
2010).  
 
 
1.1.2 DISEASE CAUSING GENE 
 
The only gene associated with THD is the human TH (hTH) gene encoding the hTH 
enzyme, which is the rate-limiting enzyme in catecholamine biosynthesis (Swoboda 
and Furukawa, 1993). The hTH gene lies on chromosome 11p15.5 and consists of 
14 exons (13 exons in mice) spanning approximately 8.5 kb (Swoboda and 
Furukawa, 1993, Nagatsu, 1995, Wevers et al., 1999).  In humans there are up to 
eleven types of mRNA produced through alternative splicing of which the most 
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important are hTH type 1–4 mRNAs encoding for the four TH isoenzymes with tissue-
specific distribution (http://www.ensembl.org, Alterio et al., 1998). The hTH 1 variant 
(1491 bp; 497 amino acids)  is the shortest encoding hTH isoform B, whereas hTH2–
4 variants have inserts that lead to the expression of proteins containing 4, 27 and 31 
(4 + 27) amino acids N-terminal to Ser31 in the hTH type 1 isoform. hTH type 4 (1584 
bp; 528 amino acids) is the longest transcript encoding for the hTH isoform A 
(Swoboda and Furukawa, 1993, Gordon et al., 2009, Dunkley et al., 2004). The 
human brain (and adrenals) contains all four distinct isoforms of hTH, but the 
presence or relative amount of each isoform may differ among catecholaminergic cell 
populations and between catecholaminergic neurons and terminal fields (Lewis et al., 
1993). hTH type 1 and hTH type 2 are the two major isoforms in the brain, comprising 
together approximately 90% of hTH in brain (Swoboda and Furukawa, 1993, Gordon 
et al., 2009, Dunkley et al., 2004). The native form of the hTH is a homotetramer, 
which consists of four identical subunits each with a molecular weight of 
approximately 60 kD (He, 1996). The amino acid sequence is highly conserved 
between species (Wevers et al., 1999). TH uses oxygene and tyrosine as substrates, 
and tetrahydrobiopterin (BH4) as cofactor. More than 40 different mutations are 
described for hTH gene and patients carry homozygote or compound heterozygote 
mutations (Willemsen et al., 2010, Szentivanyi et al., 2012). Most mutations are 
single nucleotide substitutions, but single nucleotide deletions resulting in frame shift, 
protein truncation or mutations in the TH promoter were described (Swoboda and 
Furukawa, 1993, Nagatsu, 1995). The most prevalent mutation is the missense 
mutation c.698G>A/p.Arg233His (nomenclature refers to hTH type 4) associated with 
the severe form of THD (Willemsen et al., 2010).  
 
 
1.1.3 DIAGNOSIS 
 
The patterns of CSF neurotransmitter metabolites and pterins support the diagnosis 
of TH deficiency but only sequence analysis of the hTH gene to identify mutations 
can confirm THD (Swoboda and Furukawa, 1993). THD patients have normal 
biopterin, neopterin and 5-hydroxyindoleacetic acid (5-HIAA; metabolite of serotonin) 
levels but reduced homovanillic acid (HVA; metabolite of dopamine) and 3-methoxy-
4-hydroxy-phenylethyleneglycol (MHPG; a metabolite of noradrenaline) levels in their 
CSF (Swoboda and Furukawa, 1993, Brautigam et al., 1998, Wevers et al., 1999). If 
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biopterin and neopterin are detected low, guanosine-5'-triphosphate (GTP) 
cyclohydrolase (GTPCH; EC 3.5.4.16)-deficient DRD associated with mutations in 
GCH1 should be considered since the clinical phenotypes of GTPCH-DRD and mild 
TH deficiency overlap significantly (Swoboda and Furukawa, 1993, Furukawa et al., 
1996). 
 
 
1.1.4 MANAGEMENT AND TREATMENT APPROACHES 
 
In almost all patients with type A THD, successful treatment with L-Dopa leads to 
improvement of the neurological conditions, whereas in type B, L-Dopa treatment 
does not improve all signs equally, and it may take months before all effects of 
treatment can be noticed (Szentivanyi et al., 2012). Furthermore, hypersensitivity due 
to the L-Dopa treatment is an important management problem in many of type B 
patients and therefore, it is necessary to start with low L-Dopa dosages, which can be 
increased over periods of weeks or months. Carbidopa, which is a L-amino acid 
decarboxylase (AADC, EC. 4.1.1.28) inhibitor, has to be applied in addition to L-Dopa 
to prevent the peripheral metabolism of L-Dopa into dopamine (can not cross the 
BBB) (Hoffmann et al., 2003). While responsiveness to L-Dopa was absent or 
moderate in more than 80% of type B patients, it was good in proximally 84% of the 
type A patients (Willemsen et al., 2010). L-Dopa treated type A patients showed no 
evidence of progressive disease, and tolerate L-Dopa well during many years 
(Schiller et al., 2004). Compared to type A THD, prognoses of the outcome are worse 
for type B THD patients regarding their motor and cognitive functions (Willemsen et 
al., 2010).  
 
 
1.1.5 MOUSE MODELS  
 
In 1995, the disruption of the murine Th (mTh) gene (null mutation) in mouse 
embryonic stem (ES) cells by homologous recombination generated the Th (-/-) 
knock-out mouse model. Th (-/-) mice showed mid-gestational lethality of about 90% 
of mutant embryos between embryonic days 11.5 and 15.5, probably caused by 
cardiovascular failure. Administration of L-Dopa to pregnant females results in 
complete rescue of mutant mice in utero, but without further treatment the Th (-/-) 
mice died before weaning (Zhou et al., 1995). Heterozygous mice were apparently 
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normal showing less than 50% TH. Their catecholamine levels were decreased 
moderately in developing animals and maintained normal at adulthood, suggesting 
the presence of a regulatory mechanism for ensuring the proper catecholamine levels 
during animal development. To confirm that the mutant Th (-/-)  phenotype observed 
derived from the disruption of the mouse mTh locus without effects on other 
chromosomal positions in the ES cell genome, the hTH transgene was introduced 
into the Th (-/-) homozygous mice, by crossing hTH transgenic mice carrying the hTH 
gene with the heterozygous Th (+/-) mice. The rescued mutants appeared normal 
showing recovered TH activity in the brain and restored catecholamine levels similar 
as wild-type mice. These results also indicated that the hTH transgene can replace 
the function of the mTH gene (Kobayashi et al., 1995).  
 
Another THD mouse model has been created in 1995, which was unable to 
synthesize dopamine in dopaminergic neurons by inactivating the mTh gene then by 
restoring TH function in noradrenergic cells (DA-/- mice). These DA-/- mice were born 
at expected frequency but became hypoactive and hypophagic 3-4 weeks after birth 
and died without L-Dopa intervention. Continued administration of L-Dopa led to 
normal developed and the DA-/- mice became more active and consumed more food 
(Zhou and Palmiter, 1995). On the other hands, these mice showed hypersensitivity 
to dopamine 1 and 2 (D1 and D2) receptor agonists (Kim et al., 2000). The midbrain 
dopaminergic neurons, their projections, and most characteristics of their target 
neurons in the striatum appeared normal. These studies indicated that dopamine is 
essential for movement and feeding, but is not required for the development of neural 
circuits that control these behaviours (Zhou and Palmiter, 1995).  
 
 
1.1.6 GENE THERAPEUTIC APPROACHES 
 
None of the described THD mouse models were used to study gene therapeutic 
approaches so far. Patients with DRD (type A THD) have clinical similarities to 
Parkinson's disease (PD) patients. A consistent neurochemical abnormality in PD is 
the degeneration of dopaminergic neurons in substantia nigra, leading to a reduction 
of striatal dopamine levels. Since TH catalyses is the rate-limiting step in the 
biosynthesis of dopamine, the PD can be considered as a TH-deficiency syndrome of 
the striatum. Therefore, a treatment strategy for PD consists of L-Dopa, dopamine 
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agonists, inhibitors of dopamine metabolism, or brain grafts with cells expressing TH. 
A direct pathogenetic role of TH has also been suggested, as the enzyme is a source 
of reactive oxygen species (ROS) in vitro and a target for radical-mediated oxidative 
injury. Therefore, it is suggested that TH is involved in the pathogenesis of PD at 
several different levels, and is a promising candidate for developing new treatments 
of this disease (Haavik and Toska, 1998). Some of these approaches are described 
in this chapter. 
 
There are several studies describing viral and non-viral gene therapeutic approaches 
using TH transgenes to treat symptoms in PD induced animal models. In this PD 
induced animal models (mainly in rats) the nigrostriatal dopaminergic pathway is 
lesioned using neurotoxin like 6-hydroxydopamine (6-OHDA). 6-OHDA is a 
catecholaminergic neurotoxin, which shares some structural similarities with 
dopamine and norepinephrine and exhibiting a high affinity for several 
catecholaminergic plasma membrane transporters such as the dopamine and 
norepinephrine transporters. 6-OHDA selectively destroys dopaminergic and 
noradrenergic neurons in the brain leading to the damage of the nigrostriatal 
dopaminergic pathway, generating experimental PD animal models used to test new 
medicines and treatments (Bove et al., 2005).  
 
Already in 1994, a gene therapeutic approach to treat PD using partially denervated 
striatum of 6-OHDA lesioned rats treated with a defective herpes simplex virus type 1 
vector expressing hTH transgene led to long-term recovery of striatal expression of 
mRNA, TH enzyme activity, extracellular dopamine concentration and behaviour 
(During et al., 1994). In the same year, another study showed successfully 
intracerebral gene transfer of an adenoviral vector expressing hTH in the rat model of 
PD (Horellou et al., 1994, Horellou et al., 1995). 1998 and 2000, studies with adeno-
associated virus (AAV) vectors showed improved treatment of double or even triple 
gene therapy approaches by using hTH in combination with the human DDC gene 
(expresses AADC) and GCH1 gene (Fan et al., 1998, Shen et al., 2000). Already co-
expression of TH and AADC, using two separate AAV vectors, resulted in more 
effective dopamine production and more remarkable behavioural recovery in 6-OHDA 
lesioned Parkinsonian rats, compared with the expression of TH alone (Fan et al., 
1998). Not only levels of TH and AADC but also levels of BH4 and GTPCH, which is 
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the rate-limiting enzymes for BH4 biosynthesis, are reduced in Parkinsonian striatum. 
Triple transduction with AAV-TH, AAV-AADC, and AAV-GTPCH resulted in more 
dopamine production than double transduction with AAV-TH and AAV-AADC in vitro 
and in vivo, and improved the rotational behaviour of the rats more efficiently than 
double transduction. These results suggest that GTPCH, despite TH and AADC, is 
important for effective gene therapy for PD (Shen et al., 2000). These findings were 
further supported by a lentivirus study in 2002, showing that multicistronic lentiviral 
vector-mediated striatal gene transfer of TH, AADC and GTPCH induces sustained 
transgene expression, dopamine production, and functional improvement in a rat 
model of PD (Azzouz et al., 2002).  
 
In 2003, it was described that intravenous non-viral gene therapy caused 
normalization of striatal TH and reversal of motor impairment in an experimental 6-
OHDA rat model of PD (Zhang et al., 2003).  In this approach, 6-OHDA treated rats 
with lesion in the striatum were intravenously injected with a TH expression plasmid 
which is encapsulated inside an 85-nm polyethylene glycol (PEG) chemical 
conjugated (pegylation) immunoliposome (PIL) that is targeted with the OX26 murine 
monoclonal antibody to the rat transferrin receptor (TfR). TfRMAb-PIL enters the 
brain via the transvascular route and enables the nanocontainer carrying the gene to 
undergo both receptor-mediated transcytosis across the BBB and receptor-mediated 
endocytosis into neurons behind the BBB by accessing the TfR. The measured TH 
enzyme activity was more then seven times higher and TH immunocytochemistry 
showed that the entire striatum was immunoreactive for TH after the intravenous 
gene therapy (Zhang et al., 2003). Further studies demonstrated that that ectopic 
gene expression is eliminated with the use of brain-specific gene promoters (Zhang 
et al., 2004).  
 
Although there are several gene therapeutic approaches using TH gene transfer into 
brain, there are no clinical trails using TH transgenic vectors to treat PD so far. 
 
 
 
Introduction 
 28
 
1.2 TETRAHYDROBIOPTERIN DEFICIENCY   
 
1.2.1 DESEASE CHARACTERISTICS 
 
In 1958, the first description was presented of a cofactor required for the enzymatic 
conversion of L-phenylalanine (L-Phe) to L-Tyr by the phenylalanine hydroxylase 
(PAH; EC 1.14.16.1), which is nowadays known as BH4 (Kaufman, 1958). BH4 is de 
novo synthesized from GTP by the three enzymes GTPCH (EC 3.5.4.16), 6-pyruvoyl-
tetrahydropterin synthase (PTPS, EC 4.6.1.10), and sepiapterin reductase (SR, EC 
1.1.1.153) and can be regenerated by the pterin-4a-carbinolamine dehydratase 
(PCD; EC 4.2.1.96) and dihydropteridine reductase (DHPR, EC 1.6. 99.7) (Thöny et 
al., 2000, Thöny et al., 2000). Enzyme deficiencies in any of these genes have been 
reported to cause BH4 deficiency (GTPCH: OMIM 233910; PTPS: OMIM 261640; 
SR: OMIM 612716; DHPR: OMIM 261630; PCD: OMIM 264070), also called atypical 
phenylketonuria (aPKU), in an autosomal recessive mode of inheritance (Shintaku, 
2002, Thöny and Blau, 2006). The incidence of BH4 deficiency is approximal one 
case per 1,000,000, responsible for 1-2% of all hyperphenylalanine (HPA) cases 
(Shintaku, 2002, Blau, 2008b, Blau et al., 2010).  BH4 is not only required to convert 
L-Phe to L-Tyr by PAH, but also by TH and tryptophan hydroxylase 1/2 (TPH1/2, EC 
1.14.16.4) which synthesizes the monoamine neurotransmitter precursors L-Dopa 
and 5-OH-tryptophan (5-HTP), respectively. L-Dopa and 5-HTP are further converted 
into dopamine and serotonin by AADC, respectively. Furthermore, BH4 is a cofactor 
for all three nitric-oxide synthases (NOSs; EC 1.14.13.39) for nitric oxide production, 
as well as for the alkylglycerol monooxygenase (AGMO, EC 1.14.16.5), which 
catalyzes the hydroxylation of alkylglycerols (Wei et al., 2003, Werner et al., 2003, 
Watschinger et al., 2010). Biosynthesis and regeneration of BH4 including the 
metabolic defects are shown in Fig. 2. 
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Figure 2: Biosynthesis and regeneration of BH4 including metabolic defects; modified from (Blau, 
2008b). GTPCH, guanosine triphosphate cyclohydrolase 1; PTPS, 6-pyruvoyl-tetrahydropterin 
synthase; SR, sepiapterin reductase; DHPR, dihydropterindine reductase; PCD, pterin-4a-
carbinolamine dehydratase; PAH, phenylalanine hydroxylase; TH, tyrosine hydroxylase; TPH, tyrosine 
hydroxylase; NOS, nitric-oxide synthase; AGMO, alkylglycerol monooxygenase; AADC, aromatic L-
amino acid decarboxylase; L-Phe, L-phenylalanine;  L-Tyr, L-tyrosine; Arg, argimnine; NO, nitric oxide; 
HVA, homovanillic acid; L-Dopa, dihydroxyphenylalanine; 5-HTP, 5-hydroxytryptophan; BH4, 
tetrahydrobiopterin; OH-BH4, hydroxytetrahydrobiopterin; q-BH2, quinone-dihydrobiopterin. 
 
Autosomal inherited  deficiency in GTPCH, PTPS, PCD or DHPR is associated with a 
broad spectrum of phenotypes ranging from mild and peripheral, concerning only the 
peripheral hepatic L-Phe hydroxylating system, to severe and central, affecting all 
organs, including the central nervous system (CNS), and influencing mainly the L-
Phe catabolism, and the brain neurotransmitters biosynthesis (Thöny and Blau, 2006, 
Blau, 2008b). Out of 250 BH4 deficiency patients 58% revealed mutations in the Pts 
gene, encoding for the PTPS enzyme, followed by 35% affecting the DHPR enzyme 
and 3-4% have PCD or GTPCH deficiency (Blau, 2013). Patients with GTPCH, PTPS 
or DHPR deficiency have progressive mental and/or psychomotor retardation despite 
L-Phe diet, including symptoms such as hypotonia or hypertonia, temperature 
instability, seizures, microcephaly, and hypersalvation. PCD deficient patients are 
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reported despite having HPA, transient alterations in tone, and excretion of 
primapterin through the urine, with hypomagnesemia and renal magnesium wasting, 
and are at risk to develop diabetes with characteristics of maturity onset diabetes of 
the young (MODY) type 3 (Shih et al., 2001, Blau, 2008b, Ferre et al., 2014). MODY, 
renal malformations and hypomagnesemia are probably caused due to the relation of 
PCD as a dimerization cofactor for the transcription factor homeodomain protein 
hepatocyte nuclear factor (HNF). Mutations in the HNF genes have been shown to 
cause, renal malformations and hypomagnesemia and MODY, because HNF 
involved in glucose-stimulated insulin secretion, insulin synthesis, and β-cell 
differentiation (Shih et al., 2001, Ferre et al., 2014).  
 
Two disorders of BH4 metabolism are present without HPA, the DRD (dominant form 
of Segawa syndrome) caused by a autosomal dominant mutation in the GCH1 gene, 
and sepiapterin reductase deficiency inherited in an autosomal recessive trait and 
thus can not be detected by the neonatal screening for PKU (Blau et al., 2001). 
Characteristic features of SR deficient patients is the progressive psychomotor 
retardation and similar signs as described for the other enzyme deficiencies, whereas 
DRD patients show in particular dystonia and parkinsonism symptoms (Blau, 2008b).  
 
 
1.2.2 DISEASE CAUSING GENES 
 
BH4 deficiency is caused by affecting the three enzymes of biosyntheses and the two 
enzymes for recycling. An overview of the affected genes is shown in table 1 (Lang, 
2009).  
 
Table 1: Genetic causes of BH4 deficiency a. 
Enzyme EC No. Subunit composition AA
b (MW) Defective gene Chromosome No. of exon Inheritance 
        
GTPCH 3.5.3.16 Homodecamer 250 (37.9 kDa) GCH1 14q22.1-q22.2 6 ARc or ADd 
PTPS 4.6.1.10 Homohexamer 145 (16.4kDa) PTS 11q22.3-q23.3 6 ARc 
SR 4.2.1.96 Homodimer 261 (28.0kDa) SPR 2p13.2 3 ARc 
PCD 4.2.1.96 Homotetramer 103 (11.9kDa) PCBD 10q22 4 ARc 
DHPR 1.6.99.7 Homodimer 244 (25.8 kDa) QDPR 4p15.3 7 ARc 
aModified (Lang, 2009); bamino acid; cautosomal recessive; dautosomal recessive. 
 
 
There are more than 140 known mutations scattered over the entire GCH1 gene of 
which approximately 95% cause the dominant inherited DRD and only 5% autosomal 
recessive form of inheritable HPA. Compound heterozygous or homozygous 
mutations are spread over the entire genes for PTS with proximally 57 mutations, for 
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PCBD with 10 mutations, and for QDPR with approximately 39 mutations.  There are 
13 different mutant alleles in the SPR gene located in exons 2 or 3, in intron 2 and 
the 5’-UTR (Thöny and Blau, 2006).  
 
 
1.2.3 DIAGNOSIS 
 
BH4 deficiency among newborns with HPA have to be rapidly diagnosed and 
distinguished from classical PKU (cPKU) because of the different treatments 
requirements to prevent irreversible neurological damage (Blau et al., 1992). 
Newborns with a positive Guthrie test (see chapter 1.3.3) with even mild HPA (>120 
μmol/L) as well as children without HPA but with neurological symptoms should be 
screened for BH4 deficiency (Blau, 2008b). The characteristic patterns of pterins 
excreted by the urine or found in blood serum lead to the identification of all four 
variants of BH4 deficiency concomitant with HPA (GTPCH, PTPS, PCD and DHPR) 
(Blau, 1988, Blau et al., 1992, Shintaku, 2002, Blau, 2008b). Urine can be collected 
on a filter paper and pteridines can be measured by high performance liquid 
chromatography (HPLC) (Blau et al., 1992). DHPR enzyme activity can be measured 
in dried blood samples to recognize and confirm DHPR deficiency (Lenzi et al., 
1989). For DRD and SR deficiency, neurotransmitter metabolites and pterines 
needed to be tested in the cerebrospinal fluid (CSF).  Enzyme activity measurements 
in cytokine-stimulated or unstimulated fibroblasts are useful tools to determine 
GTPCH or PTPS, SR, DHPR and PCD deficiency, respectively (Bonafe et al., 2001, 
Blau, 2008b). Analysis of L-Phe and L-Tyr in blood before and after BH4 challenge 
also discriminates between cPKU and the biopterin variants or helps to identify BH4-
responsive PAH deficiencies (Blau, 2008b). Screening policy for differential diagnosis 
of HPA (Fig. 3 A) and non-HPA (Fig. 3 B) variants is summarized in two diagnostic 
flowcharts in Fig. 3. 
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Figure 3: Diagnostic flowchart in differential diagnosis for HPA (A) and non-HPA (B) variants; modified 
version from (Blau, 2008b). GTPCH, guanosine triphosphate cyclohydrolase 1; PTPS, 6-pyruvoyl-
tetrahydropterin synthase; SR, sepiapterin reductase; DHPR, dihydropterindine reductase; PCD, 
pterin-4a-carbinolamine dehydratase; DRD, Dopa-responsive dystonia; Phe, phenylalanine; Tyr, 
tyrosine; Neo, neopterin; Bio, biopterin; Pri, primapterin; CSF, cerebrospinal fluid;  FB, fibroblasts; B, 
blood; U, urine; P, plasma; Y, yes; N, no. * Cytokines-induced cells. 
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1.2.4 MANAGEMENT AND TREATMENT APPROACHES 
 
The treatment of BH4 deficiencies depends on the enzyme deficiency and consists of 
BH4 supplementation or diet to control blood L-Phe concentration, replacement 
therapy with monoamine neurotransmitters precursors L-Dopa and 5-HTP in 
combination with carbidopa because carbidopa prevents the conversion of L-Dopa 
and 5-HTP into dopamine and serotonin (can not cross BBB) in the periphery, 
respectively (Hoffmann et al., 2003). Supplementation of folinic acid has to be added 
in DHPR deficient patients (Shintaku, 2002, Blau, 2008b). An overview of each 
treatment is shown below:  
 
o GTPCH deficiency:    BH4, L-Dopa, 5-HTP and carbidopa  
o PTPS deficiency:   BH4, L-Dopa, 5-HTP and carbidopa 
o DHPR deficiency:   L-Dopa, 5-HTP, carbidopa, low L-Phe diet and folinic acid 
o PCD deficiency:    Evtl. low L-Phe diet, BH4 and/or MODY treatment  
o SR deficiency:   BH4, L-Dopa and carbidopa  
o DRD:     L-Dopa and carbidopa 
 
 
1.2.5 MOUSE MODELS  
 
1.2.5.1 GTPCH 
 
The GTPCH deficient hph-1 mouse generated in 1988 by N-ethyl-N'-nitrosourea 
(ENU) mutagenesis is a model for the dominantly inherited GTPCH deficiency DRD. 
Homozygous mice showed low brain levels of BH4, catecholamines, serotonin, 
together with low levels of TH protein within the striatum (Bode et al., 1988, Hyland et 
al., 2003).  
 
 
1.2.5.2 PTPS 
 
In the year 2001, a Pts knock-out (Pts-ko) mouse model was described that was 
unable to synthesize BH4 due to the disruption of the Pts gene through homologous 
recombination. Homozygous mice showed a severe and central form of BH4 
deficiency with neonatal lethality (died within 48 hours). Analysis of brain lysate of 
homozygous mutant neonates revealed HPA and extremely low levels of biopterin, 
catecholamines and serotonin. Furthermore, the BH4 depletion led also to the 
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impairment of the TH enzyme with reduced immunoreactivity in the nerve terminals 
(Sumi-Ichinose et al., 2001). Daily oral administration of BH4 and neurotransmitter 
precursors led the survival of the Pts-ko/ko mice but the mice were sexual immature 
and showed dwarfism due to lowered insulin-like growth factor-1 (IGF-1) levels. 
Biochemical analysis revealed no HPA, almost normal brain serotonin levels, but 
reduced dopamine levels (3% of normal) (Elzaouk et al., 2003).  
 
Since the Pts-ko/ko mouse model showed a very severe phenotype, a Pts knock-in 
(Pts-ki) mouse model was generated by homologous recombination introducing the 
missense mutation p.Arg15Cys in exon 1 (c.43 C>T; 15% of activity in comparison to 
wild-type), which is equivalent to the human PTS-p.Arg16Cys (c.46 C>T; 12% of 
activity in comparison to wild-type), by Rossana Scavelli (University of Zurich, 2006). 
Homozygous Pts-ki/ki mice showed a mild and peripheral phenotype with reduced 
PTPS activity, but normal biopterin and monoamine neurotransmitter levels in the 
CNS and no HPA. Neopterin levels were elevated in the liver but not in the brain (see 
chapter 3.1). To generate a more severe and central phenotype without newborn 
lethality, compound heterozygous Pts mice (Pts-ki/ko) were generated by breeding 
the p.Arg15Cys knock-in allele into the Pts-ko mouse strain. The first phenotypical 
analysis of these compound heterozygous Pts-ki/ko mice was performed by Dea 
Adamsen (University of Zurich, 2011). She reported that Pts-ki/ko mice from Pts-ki/ki 
mouse mothers showed two distinguishable phenotypes: the “unaffected” Pts-ki/ko 
mice with a slightly more severe BH4 deficiency phenotype then Pts-ki/ki mice and 
the “affected” Pts-ki/ko mice, which showed a severe and central form of BH4 
deficiency 3-4 days after birth causing their lethality. In detail, “affected” Pts-ki/ko 
mice had low PTPS activity, reduce biopterin, increased neopterin, HPA, and 
reduced monoamine neurotransmitters and therefore, these mice reflected all 
hallmarks of severe PTPS deficiency. 
 
 
1.2.5.3 SR 
 
In 2006, a mouse model, which is deficient in the Spr (-/-) gene, display disturbed 
pterin profiles and diminished levels of dopamine, norepinephrine, and serotonin, 
exhibit PKU, dwarfism, and impaired body movement. Oral supplementation of BH4 
and neurotransmitter precursors completely rescued the dwarfism phenotype and 
restored the L-Phe metabolism (Yang et al., 2006).  
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1.2.5.4 PCD 
 
PCD not only regenerates BH4 but it is also a cofactor that regulates dimerization of 
the mammalian HNF-1α. Therefore PCD is also known as the dimerization cofactor 
of HNF (DCoH) (Mendel et al., 1991). In 2002, the Dcoh-null mouse model was 
generated displaying HPA and a predisposition to cataract formation. The HNF 
function was only slightly impaired in these Dcoh-null mice, suggesting that Dcoh 
activity was partially complemented by Dcoh2 (Bayle et al., 2002).  
 
 
1.2.6 GENE THERAPEUTIC APPROACHES 
 
So far, none of the existing mouse models for BH4 deficiency were used to 
investigate gene therapeutic approaches. 
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Figure 4: Schematic representation of cPKU. 
 
1.3 CLASSICAL PHENYLKETONURIA 
 
1.3.1 DESEASE CHARACTERISTICS 
 
In 1934, the Norwegian biochemist and physician Ivar Asbjørn Følling was the first 
who described the inherited metabolic disorder phenylketonuria (PKU, OMIM 
261600), also known as Følling's disease, by identifying affected individuals by the 
abnormal excretion of phenyl-
pyruvic acid in their urine (Folling, 
1938, Centerwall and Centerwall, 
2000). The name PKU was 
actually given by Lionel Sharples 
Penrose in 1937, who described 
the autosomal recessive nature of 
PKU (Penrose, 1935). In 1953, 
George Jervis showed that the 
hepatic enzyme deficiency of 
PAH,  catalyzing L-Phe to L-Tyr, 
was the responsible cause of PKU (Fig. 4) (Jervis, 1953). Hydroxylation by PAH 
needs the cofactor BH4, in the presence of molecular O2, to produces L-Tyr. 
Alternative metabolism of L-Phe by decarboxylation or transamination produces 
various metabolites, i.e. phenylpyruvic acid, phenylacetic acid and phenyllactic acid, 
which are excreted through the urine (Williams et al., 2008). The prevalence of PKU 
is one case per 10,000 Caucasian live births and therefore, it is the most prevalent 
disorder caused by an inborn error of amino acid metabolism (de Baulny et al., 2007, 
Blau et al., 2010). 98% of HPA cases result from mutations in the PAH enzyme,  
whereas the remaining cases are caused by biosynthesis defect of its cofactor BH4 
(aPKU) (de Baulny et al., 2007). The clinical phenotypes of HPA due to PAH 
deficiency are classified from classical PKU (cPKU, blood L-Phe > 1200 μmol/L) to 
mild PKU (600–1200 μmol/L) and mild HPA (120–600 μmol/L) (Lagler et al., 2010). 
Untreated cPKU patients have systemic HPA concomitant with lowered levels of 
brain monoamine neurotransmitters leading to mental retardation and impairment, 
seizures, growth failure, microcephaly and hypopigmentation due to reduced L-Tyr 
levels needed for the production of melanin (Matalon and Michals, 1991, Blau et al., 
2010).  
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The pathology underlying cognitive dysfunction in cPKU is unknown, although it is 
clear that the high L-Phe plasma concentrations influence the BBB transport of large 
neutral amino acids (LNAA) (van Spronsen et al., 2009). “System L” is a major 
nutrient transport system responsible for the transport of LNAA including four 
mammalian transmembrane proteins, the L-type amino acid transporters (LAT) 1-4 
(Christensen, 1990, Yanagida et al., 2001).  LAT1 and LAT2 (isoform of LAT1) are 
expressed in the brain and transport LNAA like L-Phe, L-Tyr for catecholamine 
synthesis or L-tryptophan for serotonin synthesis across the BBB (Segawa et al., 
1999, Yanagida et al., 2001). The excess transport of L-Phe into the brain tissue 
seems to be the causative factor for PKU-related pathological symptoms (Yanagida 
et al., 2001, Bik-Multanowski and Pietrzyk, 2006).  
 
 
1.3.2 DISEASE CAUSING GENE 
 
The disease causing gene in cPKU is the iron- and BH4-dependent monooxygenase 
PAH that catalyses the rate limiting step in the conversion of L-Phe to L-Tyr, which is 
the major degradation pathway for L-Phe. L-Phe catabolism and PAH activity is 
mainly associated with the liver.  The human PAH gene lies on chromosome 
12q23.2, where the gene comprises 13 exons extending over 171 kb of genomic 
DNA. The PAH enzyme exists as a mixture of tetramers and dimers; the monomer is 
51.9 kDa in size and is comprised of 452 amino acids.  There are more than 850 
disease-causing mutations identified in patients with PKU or HPA caused by PAH 
deficiency usually with less then 1% of PAH activity (Flatmark and Stevens, 1999, 
Williams et al., 2008, Blau et al., 2010). Most mutations are missense mutations 
(62%), followed by small or large deletions (13%), splicing defects (11%), silent 
polymorphisms (6%), nonsense mutations (5%) and insertions (2%) (Williams et al., 
2008). The most prevalent PAH mutation is the missense mutation c.1,222C>T/        
p.Arg408Trp (Lee et al., 2008).  
 
 
1.3.3 DIAGNOSIS 
 
In 1963, Robert Guthrie described a mass screening test for newborns using dried 
blood spots for a bacterial inhibition assay test (Guthrie and Susi, 1963). The test 
uses the growth of the Bacillus subtilis bacteria strain on a specially prepared agar 
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Figure 5: Schematic representation of foods 
allowed on the diet for PKU (http://depts. 
washington.edu/pku/about/ diet.html). 
plate containing B-2-thienylalanine, which inhibits the growth of the bacterium. L-Phe, 
phenylpyruvate, and/or phenyllactate, which are present in high amounts in the blood 
or urine of PKU patients, restore the growth of the bacterium which is an indicator for 
PKU (Guthrie and Susi, 1963, Blumenfeld et al., 1966). It was reported that with this 
Guthrie test one out of 25 PKU patients failed to be detected when screened at three 
days of age or less leading to “false negative” results (Blumenfeld et al., 1966). 
Nowadays, newborn blood testing for PKU is screened by using tandem mass 
spectrometry (MS/MS) (Banta-Wright and Steiner, 2004). Newborn screening for 
HPA, instituted in Switzerland in the sixties and practiced now throughout the 
Western world, has provided the opportunity to diagnose PKU in the neonate and to 
initiate therapy before the onset of severe and irreversible clinical manifestations 
(Bickel, 1987, Metzger et al., 2013). In addition, the oral BH4 loading test (20 mg/kg), 
first described in 1999, can be used to identify BH4-responsive PAH deficient 
patients, showing a positive response when the blood L-Phe decreases at least 30% 
during 48 h after the BH4 challenge (Kure et al., 1999, Desviat et al., 2004, Burton et 
al., 2011, Anjema et al., 2013).  
 
 
1.3.4 MANAGEMENT AND TREATMENT APPROACHES 
 
In 1953 Horst Bickel described that dietary protein intake for PKU patients must be 
severely restricted to reduce L-Phe accumulation in their body by restricting or 
eliminating foods with high L-Phe content 
like for example meat, chicken, fish, eggs, 
nuts, cheese, vegetable and milk (Fig. 5) 
(Ievers-Landis et al., 2005, Blau et al., 2011, 
Camp et al., 2012). Starchy foods like 
potatoes, bread, pasta, and corn must be 
monitored (Bickel, 1987, Blau et al., 2010, 
Blau et al., 2011, Argyros, 2012, Camp et 
al., 2012). The sweetener aspartame, 
which is present in many diet foods and 
soft drinks, must also be avoided since 
aspartame consists of the two amino acids 
L-Phe and aspartic acid. Such an extreme protein restriction can only be 
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accomplished through the use of synthetic medical foods devoid of L-Phe, a lifelong 
unpalatable, rigid, and complicated diet. The supplementation of amino acids like L-
Tyr and other necessary nutrients by pills, formulas, and specially formulated foods, 
are necessary for a normal development (Ievers-Landis et al., 2005, de Baulny et al., 
2007, Argyros, 2012, Camp et al., 2012). Infants can be breastfed but the quantity 
must also be monitored. A low L-Phe diet should be initiated within the first days of 
life for newborns with elevated blood L-Phe levels above 600 μmol/L and should be 
continued until teenage age to control blood L-Phe levels between 120 and 300 
μmol/L (de Baulny et al., 2007). Thereafter, a progressive and controlled relaxation of 
the diet is allowed, below 1200 μmol/L in adulthood (Ievers-Landis et al., 2005, de 
Baulny et al., 2007). It is recommended for PKU women to control their blood L-Phe 
levels during pregnancy to avoid maternal HPA, which can cause microcephaly, 
mental retardation, and structural birth defects in the unborn (the so-called maternal 
PKU syndrome) (Matalon and Michals, 1991). Untreated PKU patients have systemic 
high level of L-Phe concomitant with lowered levels of the brain monoamine 
neurotransmitters, leading to mental retardation (Butler et al., 1981, de Baulny et al., 
2007, Blau et al., 2011). Later on, it was examined that the long-term treatment with 
BH4 (sapropterin dihydrochlorid; trade name: Kuvan), improves L-Phe tolerance 
mainly in mild HPA patients but also in some cPKU cases (Thöny et al., 2000, 
Hennermann et al., 2005, Blau, 2008a). Although the mechanism of action underlying 
this therapeutic effect is not entirely understood, it is thought that BH4 reduces L-Phe 
serum levels by improving the folding conformation of certain types of mutant PAH 
enzyme resulting in increased L-Phe catabolism (Christ et al., 2013).  
 
The most obvious treatment for cPKU would be the substitutions with PAH enzyme, 
but this treatment approach is challenging because PAH is inherently unstable, 
making large-scale isolation and purification extremely challenging. In addition its 
complex activity and cofactor requirement, plus its inherent protease sensitivity and 
potential immunogenicity in human lacking the functional enzyme further (Sarkissian 
and Gamez, 2005). To overcome this problems, truncated forms of PAH were 
generated showing increased stabilization and catalytic activity (Erlandsen et al., 
2003, Sarkissian and Gamez, 2005). Furthermore, protection of PAH against immune 
response has been achieved by pegylation (Gamez et al., 2004, Sarkissian and 
Gamez, 2005). Nevertheless, the drawbacks of PAH as therapeutic drug are 
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debatable. An alternative to PAH is the substitution with the phenylalanine ammonia 
lyase (PAL, EC 4.3.1.5), a bacteria-derived enzyme involved in L-Phe degradation to 
trans-cinnamic acid and ammonia without a cofactor requirement (Sarkissian et al., 
1999, Sarkissian and Gamez, 2005, Argyros, 2012). It is predicted that by PAL 
produced trans-cinnamic acid is harmless in humans and that the ammonia formed 
would be metabolically insignificant (Hoskins et al., 1980, Hoskins et al., 1984, 
Sarkissian and Gamez, 2005). Various formulations and mechanisms have been 
tested to avoid immune response and prevent protease inactivation and are currently 
investigated in clinical trials (PAL-001, NCT00634660) (Bourget and Chang, 1986, 
Chang and Prakash, 1998, Sarkissian et al., 1999, Argyros, 2012). Nevertheless, L-
Phe levels have to be stringently monitored to prevent hypophenylalanemia since 
there is no regulatory system for PAL in humans in contrast to PAH which is activated 
by L-Phe and inhibited by tetrahydrobiopterin (BH4) (Argyros, 2012, Fitzpatrick, 2012). 
Recently, it was described that aminoglycoside antibiotics induced read-through of 
nonsense PAH mutations in vitro led to partially restoration of enzymatic activity 
comparable to a missense mutation associated with mild PKU (Ho et al., 2013).  
Although nonsense read-through drugs are a potential form of treatment for PKU, the 
high needed dosage of aminoglycosides can not be used for clinical setting because 
of its toxicity (Ho et al., 2013).  
 
 
1.3.5 MOUSE MODELS  
 
Mutant cPKU mice exhibiting heritable HPA have been isolated after ENU 
mutagenesis of the germ line (McDonald et al., 1990, Shedlovsky et al., 1993). The 
first mouse mutant line, the Pahenu1/1 mouse model (originally called PAHhph-5) carried 
the mutation p.Val106Ala in exon 3 and showed a mild HPA phenotype and was BH4 
responsive, but failed to exhibit the biological effects associated with human cPKU. 
The Pahenu2/2 mouse model harbouring the null mutation p.Phe263Ser in exon 7 
resulted in nonfunctional PAH enzyme, exhibiting symptoms found in human cPKU 
patients like slow growth, microencephaly, hypopigementation, behaviour 
disturbances, seizures, epilepsy and maternal PKU (Shedlovsky et al., 1993, Cho 
and McDonald, 2001, Martynyuk et al., 2007, Argyros, 2012). In addition, the 
compound heterozygous mouse Pahenu1/2 was generated bearing a mild and a severe 
mutation (p.Val106Ala/p.Phe363Ser) to study further the therapeutic efficacy of BH4, 
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since the majority of BH4 responsiveness patients (87%) with PAH deficiency are 
compound heterozygous carrying two different mutations with about 26% of the 
alleles being putative null-mutations (Lagler et al., 2010). The Pahenu2/2 mouse model 
is the most used mouse model to test gene therapeutic approaches for cPKU 
(Shedlovsky et al., 1993, Fang et al., 1994, McDonald et al., 2002, Ding et al., 2006, 
Rebuffat et al., 2010, Thöny, 2010, Yagi et al., 2011).  
 
 
1.3.6 GENE THERAPEUTIC APPROACHES 
 
1.3.6.1 Viral gene therapies 
 
It was reported that treated cPKU patients have more cognitive deficits, learning 
difficulties and emotional problems in comparison to the general population. 
Furthermore, adults with cPKU off the strict diet regime are at risk for new onset of 
neurological deficits (Waisbren and White, 2010). Also maternal HPA during 
pregnancy very frequently causes birth defects in the fetus. For this reason, gene 
therapy is an attractive, experimental and very promising approach to treat cPKU not 
at least because of the fact that 5-10% of normal enzymatic activity in the mouse liver 
is sufficient to restore normal serum L-Phe levels (Fang et al., 1994, Eisensmith and 
Woo, 1996, Templeton, 2005). In 1994, recombinant adenoviral vector containing the 
human PAH complementary DNA (cDNA) completely normalized the 
hyperphenylalaninemic phenotype of Pahenu2/2 mice within 1 week of treatment, 
although this therapeutic effect did not persist due to neutralizing antibodies against 
the viral vectors (Fang et al., 1994, Nagasaki et al., 1999).  
 
AAV is one of the most used viral vectors for transgene delivery because it is not 
pathogenic, induces a minimal immune response, infects dividing and non-dividing 
cells, and the transgene expression persists for long time in cells (Choi et al., 2014). 
In 2006, the liver-directed gene therapeutic approach using recombinant AAV2 
(rAAV2) pseudotyped with serotype 8 capsid (rAAV2/8) expressing the mPah in 
Pahenu2/2 mouse liver stable corrected the serum L-Phe levels (Ding et al., 2006, 
Harding et al., 2006). Although these treatment therapies are very promising, the high 
amount of rAAV needed to treat the liver of cPKU patients is still challenging and 
harbours unknown risks like the development of hepatocellular carcinoma (Donsante 
et al., 2001, Bell et al., 2006, Donsante et al., 2007). Therefore, there is the need of 
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alternative treatable tissues, despite the fact that in cPKU there is no liver pathology 
making it not necessary to target the liver for treatment. In 2008, an alternative gene 
therapeutic approach for cPKU by targeting the limb muscles of Pahenu2/2 mice with a 
rAAV2 pseudotype 1 (rAAV2/1) let to life-long treatment. The multicistronic vector 
used in this approach not only expressed mPah but also the mGch1 and mPts genes, 
necessary to synthesis the essential metabolic cofactor BH4, which is not occurring 
naturally in muscle tissue (Ding et al., 2008). Overall, the skeletal muscle as target for 
gene therapy has the advantages that it is easier accessible and it is a not essential, 
vital organ, which would facilitate the treatment. Furthermore, muscle cells have 
lower cell turnover time than liver cells, which positively influences the latency of 
gene therapeutic efficacy (Jang et al., 2011). Therefore, in 2010 the intramuscular 
injection of rAAV2 with the pseudotype 1, 2 or 8 expressing the mPah gene let to 
effective clearance of serum L-Phe for up to 1 year in Pahenu2/2 mice (Rebuffat et al., 
2010). The long-term correction of HPA by rAAV-mediated gene transfer led also to 
recovery of altered behaviour in the PKU mice (Mochizuki et al., 2004).  
 
 
1.3.6.2 Non-viral gene therapies and minicircle technology 
 
Despite the success with AAV-based gene transfer in small and large animal disease 
models, AAV can trigger immunogenicity, inflammatory response, severe malignancy 
and eventually complete shutdown of transgene expression in humans. In this 
context, non-viral vectors for gene therapy have recently gained considerable 
momentum, and are becoming very attractive approaches to treat PKU. The first 
described studies of non-viral gene therapy in 2005/2007, using the phiBT1 
bacteriophage integrase system, was retracted in 2010 (Chen and Woo, 2005, 2007, 
Woo, 2010). Recently in 2014, life-long treatment of PKU using minicircle-based 
(MC) naked-DNA vectors expressing the mPah cDNA by targeting the liver in 
Pahenu2/2 mice was achieved (Viecelli et al., 2014). Minicircles are circular episomal 
DNA vectors containing the expression cassettes devoid of any bacterial plasmid 
DNA (Kay et al., 2010). The MC producing parental plasmid (PP) contains the 
bacterial origin of replication (ORI), the antibiotic resistance gene for kanamycine 
(KanR), the endonuclease I-SceI restriction site and an expression cassette 
containing the gene(s) of interest flanked by the recombination bacterial attachment 
site (attB) and the phage attachment site (attP). MCs are generated in the E.coli 
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strain ZYCY10P3S2T, which contains the L-arabinose inducible phage øC31 
integrase gene and the endonuclease I-SceI restriction gene. The induction of the 
ZYCY10P3S2T E.coli with L-arabinose leads to the production of the øC31 integrase 
and the I-SceI endonuclease. The øC31-mediated intramolecular recombination 
between the attB and attP sites results in the formation of two circular DNA 
molecules, the MC containing the expression cassette, and one including the plasmid 
bacterial backbone (BB), which is digested by the  I-SceI endonuclease and finally 
degraded (Fig. 6). MC DNA can be isolated from the bacteria by routine plasmid 
purification procedures such as one-step affinity column revealing high and over 96% 
pure titers (Chen et al., 2005, Stenler et al., 2014). It is proposed that the MC 
technology offers an improved safety profile over viral vectors and has the potential 
successful gene therapy for heritable liver diseases (Viecelli et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Schematic representation of MC production (Modified from http://www.biocat.com). Pr, 
promoter; attB, bacterial attachment site; attP, phage attachment site; attL, left attachment site; attR, 
right attachment site; pUC ORI, bacterial origin of replication; KanR, kanamycine resistance gene.  
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1.4 TOOLS FOR GENE TARGETING AND GENOME ENGENEERING 
TO GENERATE RECOMBINANT MICE 
 
Transgenesis is applicable to a wide range of mammalian species, including mice, 
rats, rabbits, sheep, pigs, and cattles, resulting from an inheritable genetic 
modification induced by the artificial transfer of an exogenous DNA fragment (Hofker 
and Breuer, 1998, Houdebine, 2002). This chapter summarizes the most widely used 
strategies for generating transgenic mice.  
 
Recombinant mice are appropriate animal models to investigate the genetic basis of 
human diseases and for obtaining insight into human physiology (Carlson and 
Largaespada, 2005). In 1974, Rudolf Jaenisch created the first genetically modified 
mouse by injecting SV40 DNA into mouse blastocysts, although the introduced DNA 
was not stably inherited (Jaenisch and Mintz, 1974). There are several different ways 
to produce transgenic mice. Generation of recombinant mice include chemical and 
insertional mutagenesis or gene-targeting methods (Cho et al., 2009, Wang et al., 
2013). Chemical mutagens such as ENU are potent mutagens of the mouse germ-
line producing random, single base-pair changes throughout the genome, and can 
produce a high frequency of mutant phenotypes (Carlson and Largaespada, 2005). 
The disadvantage of this method is that the random induced mutations require labor-
intensive screening processes. Therefore, gene-targeting methods commonly are 
used to introduce mutations through homologous recombination in mouse ES cells. 
Traditionally, there are two main methods used to generate a transgenic mouse: 
pronuclear microinjection and the ES cell injection (Houdebine, 2002). In the 
pronuclear microinjection method, the DNA is directly injected into the pronuclei of a 
fertilized oocyte or zygote, which is then re-implanted into recipient foster mice (Fig. 7 
A). It takes approximately a year from making the DNA construct for pronuclear 
injection to establishing a new transgenic mouse strain with some phenotypic 
characterization. The drawback of this method is that the DNA inserts at random 
positions in the host chromosome, which could lead to multiple copies of the 
transgene in the genome, insertion into in a coding sequence or disruption of 
regulatory sequences in the genome (Feng et al., 2004, Cho et al., 2009). In the ES 
injection method, DNA is introduced into ES cells derived from an early mouse 
embryo. The targeted DNA sequence contains the gene of interest, the neomycin 
resistant gene that inactivates the antibiotic neomycin to screen for positive cells, and 
the gene encoding for thymidine kinase (TK), an enzyme that 
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phosphorylates ganciclovir. The addition of ganciclovir in the growth medium 
eliminates cells that contain the TK gene due to random insertion of the transgene 
since non-functional phosphorylated ganciclovir inserts into freshly-replicating DNA 
leading to the cell death. Cells that pass the neomycin and the ganciclovir selection 
have the DNA integrated into the desired genomic site by homologous recombination 
(Capecchi, 2005) (Fig. 7 B). The neomycin selection marker (flanked by FRT or LoxP 
sites) can be removed from the transgene by using the site-specific recombination 
Flp/FRT- or Cre/loxP-system (Dymecki, 1996, Metzger and Chambon, 2001). 
Targeted ES cells are injected into mouse wild-type blastocysts that can contribute to 
the germline of chimeric animals, generating mice containing the targeted gene 
modification. Heterozygous mice need to be interbred to produce  homozygous 
experimental animals (Cho et al., 2009) (Fig. 7 A). It is a costly and time consuming 
method limited to species with established ES cell lines (Wang et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
Figure 7: (A) Generation of transgenic mice. Method 1: Targeting of ES cells; method 2: Pronuclei 
injection (modified from http://users.rcn.com); (B) Positive-negative selection for targeted ES cells 
(modified from Tsai et al, 2007) 
 
Alternative methods to generate transgenic mice include intracytoplasmic sperm 
injection, transfection of spermatozoa with exogenous DNA/DMSO complexes or 
retroviral-mediated approaches to make transgenesis easier in terms of time, 
expertise and equipment needed. The intracytoplasmic sperm injection, are used to 
introduce large genomic transgenes but the efficiency of transgenesis by pronuclear 
approach is relative low. The retroviral-mediated approaches, as another example, 
have the drawback to cause multiple chromosomal integration of the transgene (Ittner 
and Gotz, 2007). 
Method 1 
Method 2 
A B 
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New technology for more efficient and less time-consuming gene targeting in mice 
include zinc-finger nucleases (ZFNs, Fig. 8 A), transcription activator-like effector 
nucleases (TALENs, Fig. 8 B) or clustered regularly interspaced short palindromic 
repeats (CRISPRs, Fig. 8 C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic representation of new technology for gene targeting: (A) ZFN, (B) TALEN, (C) 
CRISPR (http://www.zhihu.com).  
 
ZFNs are fusions of specific DNA-binding zinc finger proteins engineered to target 
desired DNA sequences and a nuclease domain, such as the DNA cleavage domain 
of a type II endonuclease of FokI (Carbery et al., 2010). Donor plasmid DNA and 
respective ZFN mRNA were co-injected into the pronucleus of one-cell embryos (Cui 
et al., 2011). A pair of zinc finger proteins target specifically, and their nuclease 
domains dimerize to cleave the DNA, generating double strand breaks, leading to 
insertions or deletions via DNA repair by the error-prone non-homologous end joining 
(NHEJ) pathway or high-fidelity homologous recombination. ZFN technology has the 
advantages that the targeted gene disruption is highly efficient, faster (couple of 
months) and can be applied in various genetic backgrounds since it is ES cell 
independent. In addition, no exogenous sequences need to be introduced because 
antibiotic selection is not necessary (Carbery et al., 2010). Although the potential of 
ZFN genome modification is big, the method is technical limited on embryo-injection 
and culturing of primary cells, the design and assembly is labor-intensive and there is 
the limitation of available target sites (Carlson et al., 2012). Furthermore, decreased 
ZFN specificity could lead to cellular toxicity via off-target cleavage (Pinkert, 2014).  
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TALENs, are artificial sequence-specific endonucleases that contain Xanthomonas 
transcription activator-like effector (TALE) and a nuclease domain of FokI restriction 
endonuclease. The DNA binding domain of TALE consists of a tandem repeat of 33–
35 amino acid motifs in which there are two adjacent amino acid pairs called a 
repeat-variable diresidue that determines the binding specificity for single nucleotide. 
One repeat-variable diresidue recognizes one nucleotide. Using this code, a TALEN 
can be constructed with a DNA binding motif recognizing the desired nucleotide 
sequence. When two TALENs bind to the genome, the nuclease domain of FokI 
dimerizes and generates a double-strand break. The lesion is frequently repaired via 
NHEJ resulting in the introduction of small insertion or deletion mutation (Kato et al., 
2013). Most importantly, TALENs appear to be superior to ZFNs in terms of simple 
and straightforward design and assembly strategies, making TALENs manufacturing 
more effective, significantly cheaper and faster than for ZFNs (Carlson et al., 2012). 
 
Recently, the type II bacterial CRISPR/Cas system has been demonstrated as an 
efficient gene-targeting technology with the potential for multiplexed genome editing 
generating transgenic mice in just weeks. Bacteria and archaea have evolved an 
RNA-based adaptive immune system that uses Cas9 (CRISPR-associated) proteins, 
CRISPR RNAs (crRNAs), and trans-activating crRNA (trcrRNA) to form a 
ribonucleoprotein complex, which targets and degrades foreign nucleic acids from 
invading viruses and plasmids. The Cas9 endonuclease from Streptococcus 
pyogenes type II CRISPR/Cas system can be programmed to produce sequence-
specific double strand breaks by providing a synthetic “guide RNA” (gRNA) 
containing a 20-base match to the genomic target. The CRISPR/Cas system drives 
both NHEJ-based gene disruption and homology directed repair-based precise gene 
editing to achieve highly efficient and simultaneous targeting of multiple genes in 
stem cells and mice which is not possible to achieve with the ZFN or TALEN methods. 
Furthermore, this new technique does not rely on engineering ES cells, but it 
introduces the genetic changes directly into the developing mouse embryos. Despite, 
the CRISPR/Cas system not only makes the production of transgenic mice faster and 
easier, but it should also theoretically work with other organisms whose ES cells are 
difficult to engineer and manipulate. The limitations of the CRISPR/Cas technology 
are limited target spaces for Cas9, the challenge of designing gRNAs, the need for 
more information about the potential off-target cleavage sites and the risk of 
unwanted mutation of the second allele through NHEJ (Wang et al., 2013). 
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1.5 AIM OF STUDY 
 
Animal models for inborn errors of metabolism (IEM)  are needed to study and further 
understand the disease causing pathogenic mechanism (Herschkowitz, 1982). 
Furthermore, animal models are useful to test new treatment approaches such as 
gene therapy. The aim of this study was the characterization of new mouse models 
for IEM and/or appropriate gene therapeutic approaches for three metabolic 
diseases, namely THD, PTPS deficiency (BH4 deficiency) and cPKU (chapter 2, 3, 
and 4, respectively). 
 
Chapter 2: A new knock-in mouse model expressing the recurrent mutation TH-
p.Arg203His (equivalent to the hTH-p.Arg202His) to study the severe form of THD 
was generated. The main aim of this study was to conduct the biochemical and 
behaviourally characterization of this mouse model. Subsequently, these mice should 
be used to perform treatments experiments, including the standard application of L-
Dopa/carbidopa, the TH cofactor BH4, and pharmacological chaperons that have 
previously shown to stabilize wt-TH. Furthermore, a hepatic AAV based gene therapy 
study expressing the murine Th-cDNA should be examined. 
 
Chapter 3: The first aim of this study was to perform the final characterization of the 
p.Arg15Cys knock-in mouse models with heterozygous Pts-ki/wt, homozygous Pts-
ki/ki and compound heterozygous Pts-ki/ko mice, which were described with lowered 
PTPS activity and abnormal obese phenotype in the dissertation by D. Adamsen 
(University of Zurich, 2011). Furthermore, it should be investigated what conditions 
could lead to the appearance of “affected” compound heterozygous Pts-ki/ko mice. 
Especially the two hypotheses by Dea Adamsen that differences in biopterin amounts 
in mother milk and/or that the “mother effect” (Pts-ki/ki females) in combination with 
“allelic effect” (homozygosity) led to these two diverse phenotypes. Therefore, 
newborn mice from different breeding combination of Pts-ki and Pts-ko parents and 
3-4 days old pups from homozygous Pts-ki/ki mothers should be investigated for 
biochemical and phenotypical differences. With this gain of knowledge, “affected” 
compound heterozygous Pts-ki/ko mice could be specifically bred and used to study 
hepatic viral and non-viral gene therapy approaches. 
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Chapter 4: The aim of this study was to achieve a non-viral-vector gene therapy 
using naked DNA/MC vectors to target skeletal muscle of PKU mice to correct cPKU. 
The transgenic mouse model (Tg/Pahenu2) which expressed mPah and mGch1 in 
skeletal muscle, was unfortunately not anymore available for the present study (Ding 
et al., 2008), and the subsequent efforts failed for generating a similar transgenic 
PKU mouse which expresses mGch1 and mPts for BH4 production in skeletal 
muscle. With such mouse models, non-viral muscle gene therapy would have been 
simplified by using a one-gene vector (expressing Pah), instead of a three-gene 
transfer. Since these mice were not available, non-viral muscle gene therapy should 
be established in the Pahenu2/enu2 (“PKU”) mouse requiring the coordinate expression 
of the three murine genes Pah, Gch1 and Pts. For naked DNA-vector gene delivery, 
MC vectors should be delivered by the hydrodynamic limb vein injection technique or 
by electroporation.  
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ABSTRACT 
 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the synthesis of 
catecholamine neurotransmitters and hormones and a marker for dopaminergic 
neurons. Mutations in the TH gene are associated with the autosomal recessive 
neurometabolic disorder TH deficiency (THD), which manifests with phenotypes 
varying from infantile parkinsonism and L-Dopa-responsive dystonia to complex 
encephalopathy of perinatal onset. The most recurrent mutation in THD patients is 
TH-p.R233H (hTH1-p.R202H, isoform 1), which is mostly associated to a severe 
THD phenotype, often concomitant with non-responsiveness to L-Dopa treatment. 
While Th knock-out mice are not viable, homozygous Th-knock-in mice expressing 
the Th-p.R203H mutation (equivalent to hTH1-p.R202H) showed normal survival and 
food intake but hypotension and moderate growth retardation. The mutant enzyme 
exhibited impaired inhibitory feedback and stabilizing dopamine binding, which lead 
to progressive disappearance of TH associated to gradual loss of central 
catecholamines. Notably, unstable mutant TH was absent in striatum. Accordingly, 
mutant mice showed reduced motor coordination, ataxia and catalepsy with diurnal 
fluctuation, and non-responsiveness to L-Dopa treatment. This hypomorphic Th-ki 
mouse model with encephalopathy and impaired motor control thus provides 
understanding on molecular pathogenic mechanisms for THD, replicates the most 
severe form of the disease, and provides a platform for the evaluation of novel 
therapeutics.  
 
Key words: TH deficiency, infantile parkinsonism, Th knock-in mice, dopamine 
deficiency, catecholamine deficiency, L-Dopa treatment 
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INTRODUCTION 
  
Tyrosine hydroxylase (TH; EC 1.14.16.2) is a homo-tetrameric enzyme that catalyzes 
the conversion of L-tyrosine (L-Tyr) to dihydroxyphenylalanine (L-Dopa) by using 
molecular oxygen as additional substrate and the cofactor (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4)1,2. This hydroxylation is the rate limiting step in the 
synthesis of the catecholamine neurotransmitters dopamine (DA), norepinephrine 
and epinephrine2. In the central nervous system (CNS), TH is expressed in 
dopaminergic neurons of the substantia nigra, ventral tegmental area, hypothalamus, 
and olfactory bulb, in noradrenergic neurons of the locus coeruleus and lateral 
tegmental system, and in the adrenergic neurons of the brain stem3,4. Outside the 
CNS, TH expression is also found in the adrenal medulla and in non-neuronal (renal, 
intestine, pancreatic and lymphoid) tissues. DA is distinctively involved in motor 
control, but also in cognition, memory and reward, and, as a precursor of 
norepinephrine and epinephrine, indirectly regulates attention and helps to maintain 
normal blood pressure, body temperature and blood sugar5. The single human TH 
gene undergoes alternative mRNA splicing generating four main isoforms (hTH1-
hTH4), with variations in the length of the N-terminal, where hTH4 corresponds to the 
longest, full-length isoform (where notation of mutations in the gene are provided), 
and hTH1 to the shortest and most abundant one6. TH activity is tightly controlled by 
regulatory mechanisms at the transcriptional, translational and posttranslational 
levels7. The latter includes phosphorylation at several Ser/Thr residues at the N-
terminal tail8. Notably, phosphorylation at Ser40 by cAMP dependent protein kinase 
A (PKA) activates TH by releasing the feed-back inhibition of catecholamines and 
decreasing the Km for the cofactor BH42. Binding of the catecholamine end-products 
inactivates and stabilizes TH both in vitro9,10 and in vivo11. Another short-term 
regulatory mechanism of TH of important biological significance is substrate 
inhibition, that allows steady synthesis of DA despite fluctuations in blood L-
tyrosine12. 
 
TH deficiency (THD; OMIM *191290), also known as autosomal recessive Segawa 
syndrome, infantile parkinsonism, or L-Dopa-responsive dystonia (DRD; OMIM 
605407), is a rare neurometabolic disorder associated with a phenotypic spectrum 
raging from a mild progressive limb dystonia, postural tremor or hypokinetic rigid 
syndrome that is responsive to L-Dopa (termed type A) to progressive and complex 
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neonatal or early-infancy onset encephalopathy with L-Dopa-unresponsive 
parkinsonism (termed type B)13. An accurate clinical diagnosis of THD must be based 
on central catecholamine deficiency reflected by low homovanillic acid (HVA) and 3-
methoxy-4-hydroxyphenylethylene glycol (MHPG) in cerebrospinal fluid (CSF) from 
lumbar puncture, and by mutation analysis of the TH gene14,15. Peripheral (urinary) 
concentration of catecholamines, HVA and MHPG are non-informative most probably 
due to DA production by residual TH and tyrosinase activity in non-neuronal tissues 
(for a discussion see13). On the other hand, elevated serum prolactin may be used as 
a peripheral biomarker reflecting central neurotransmitter status16, as the release of 
this hormone into the serum from the pituitary gland is under control of hypothalamic 
DA, which is the primary physiological inhibitor of prolactin secretion17. To date, 
approximately 70 patients have been reported with THD (www.biopku.org/pnddb)13,18: 
the most recurrent TH mutation accounting for ~30% of all mutant alleles, is 
c.698G>A/p.Arg233His in exon 6; NM_1999292.2 (corresponding to 
c.605G>A/p.Arg202His in hTH1). While this mutation can be associated with THD 
subtypes A or B13,15 as a homozygous or compound heterozygous allele, about half 
of the patients with THD type B are homozygous for change p.R233H13.  
 
Parkinsonian syndromes or dystonias and related catecholamine deficiencies are 
closely associated with changes in the levels of TH activity and DA levels14,19, and 
the motor features of Parkinson’s disease reflect to the loss of striatal DA due to 
degeneration of dopaminergic neurons20. Various transgenic animal models aiming to 
mimic TH deficiency by inactivating the Th gene have been generated in the past21-23, 
yet neither the complete Th-knock-out which was not viable, nor rescue mutants fully 
reproduced the clinical and pathological feature of THD, although did provide 
valuable insights into the importance of DA and the other catecholamines for mouse 
fetal development21,22 and the functional interdependence of the adrenomedullary 
and adrenocortical systems24.  
 
In order to provide novel insights into catecholamine function and study the 
pathophysiological mechanisms responsible for the severe (type B) THD phenotype, 
we generated a constitutive mouse Th-knock-in mouse with p.Arg203His, equivalent 
to the human TH-p.R233H (hTH1-p.R202H). This mouse, here termed Th-ki mouse, 
was viable and presented with motor dysfunction due to a progressively reduced TH 
activity and gradual loss of catecholamine metabolites, including DA. The severe 
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phenotype was also characterized by non-responsiveness to L-Dopa treatment, as in 
most patients homozygous for the TH-p.R233H mutation. This novel hypomorphic 
mouse replicates the salient clinical features of human THD type B including motor 
and non-motor functions and diurnal fluctuation of symptoms, and represents 
therefore an ideal model for pathomechanistic studies. Immunohistochemistry, 
measurements in brain extracts and analysis with recombinant enzymes showed the 
direct loss of TH activity due to instability of the mutant TH which could not be 
stabilized by DA, highlighting the importance of feedback stabilizing inhibition by 
catecholamines to maintain TH levels.  
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MATERIALS, METHODS AND MOUSE HUSBANDRY 
 
Generation of the Th-ki mouse allele 
A C57Bl/6 mouse carrying a constitutive knock-in of the point mutation p.Arg203His 
in the Th gene was custom generated by TaconicArtemis (Cologne, Germany; NCBI 
gene ID 21823, transcript variant Th-1 NM_0093771.1; Ensembl gene ID 
ENSMUSG00000000214). Details on the targeting vector for electroporation, 
homologous recombination and selection in mouse embryonic stem cells (Art B6/3.6 
background C57Bl/6 NTac) are given in Supplementary Figures 1A-C. Validation of 
correct and single targeting was done by Southern blot and PCR analyses (details 
can be supplied upon request). For elimination of the NeoR cassette, mice were 
crossed with a Flp-deleter strain (C57Bl/6-Tg(CAG-Flpe)1 Arte) for random 
integration of the CAGGS-Flpe transgene, and subsequently mice were crossed to 
homozygosity.  
 
Genotyping of Th-ki mice   
One primer set was used for testing for the presence of an additional 85 bp FRT 
sequence by fragment size analysis (primers “For” 4601_33: 5’-GAGCTCCCAGAATT 
GACAGC-3’; “Rev” 4601_34: 5’-GATCACACTCCACCATATCAAGG-3’) and one set 
for the presence of the R203H mutation via Sanger sequencing (primers 4602_35: 5’-
TGTCAGAGTTGGATAAGTGTCACC-3’ and 4602_36: 5’-TGACAGCTAACCAGTCA 
CCTCC-3’; see also Supplementary Figures 1B,C). Standard PCR conditions were 
used for DNA amplification.  
 
Mouse husbandry and treatment studies 
Animal experiments were performed in accordance with the guidelines and policies of 
the State Veterinary Office of Zurich and Swiss law on animal protection, the Swiss 
Federal Act on Animal Protection (1978), and the Swiss Animal Protection Ordinance 
(1981). Animal studies received approval from by the Cantonal Veterinary Office, 
Zurich, and the Cantonal Committee for Animal Experiments, Zurich, Switzerland. All 
mice are based on C57Bl/6-background. For treatment studies, 6 tablets containing 
L-Dopa (levodopa 100 mg) and the decarboxylase inhibitor carbidopa (25 mg) were 
purchased from Sinemet, diluted in 20 ml of ddH20. For validation, the final 
concentration of L-Dopa was determined by HPLC43. Newborn Th-ki and wt control 
mice were fed daily per os with a solution containing 10 mg levodopa plus 2.5 mg 
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carbidopa per kg of body weight and per day for a time period of up to 3 weeks of 
age. Before termination, treated mice were tested for motor behaviour, and upon 
sacrifice biochemical analyses were performed. For mock control, Th-ki and wild-type 
mice were given ddH2O in parallel. 
 
Metabolic cage analysis 
Locomotion, food and water intake, O2 consumption and CO2 production were 
determined for single housed mice (females at the age of 9 months) during a 24-h 
period in metabolic cages in an open-circuit indirect calorimetry system as previously 
described44 (PhenoMaster, TSE Systems, Bad Homburg, Germany). After being 
adapted to single caging, mice were placed in cages closed with air-tight lids. Water 
bottles and food cups were placed on scales to measure water and food intake 
continuously. The measurements were saved on a computer in 20 min intervals and 
were used to calculate cumulative food and water intake. Activity data were 
measured using an infrared light-beam. To measure energy expenditure (EE) and 
respiratory exchange ratio (RER), ambient air was pumped through the cage via a 
flow controller. Air entering and leaving each cage was monitored for its O2 and CO2 
concentration. The cages were connected to two analyzers measuring O2/CO2 
concentration of each cage for a period of 2 min in 20 min intervals. EE and RER 
were calculated using the manufacturer's software based on the following equation: 
EE (kcal/h) = (3.941×VO2+1.106×VCO2)/1000; RER=VCO2/VO2. 
 
Behavioural mouse testing 
All experiments were carried out during the light-phase, between 10 am and 5 pm. 
Experiments were carried always at the same time of the day within the same group 
of animals, and all experimental batches were acclimated to the test room for at least 
1-2 days before experiments.  
Open field test45: Plexiglas activity boxes monitored by a video tracking system 
(Ethovision, Noldus) were used to assess total horizontal activity and mean velocity 
of locomotion. Animals were placed in a neutral position of the acrylic boxes (40 x 40 
x 40 cm) and let to explore freely and undisturbed for 30 min. Boxes were carefully 
cleaned between tests to minimize odour cues in the arena. 
Bar test41: Spontaneous catalepsy was determined in wt and Th-ki mice using the 
horizontal bar test in which the time of immobility was assessed. Five trials were 
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performed for each animal with a 180 sec cut-off each. For the analysis, the 
maximum time of immobility for each mouse over the five trials was considered. 
Rotarod test46: Wt and Th-ki mice were individually placed in a neutral position on 
the immobile rotarod treadmill (UgoBasile, Milan, IT, USA). Immediately, the speed 
was increased to 16 revolutions per min (rpm) and each mouse was given a 10 min 
training session. During the training session mice were repositioned on the rod after 
each fall. Mice were tested 3 h later for 3 min at a fixed velocity of 16 rpm, and the 
latency to the first fall was recorded for each subject. 
Gait analysis47-49: Both hind and fore paws of mice were inked with non-toxic blue 
and red ink, respectively. Animals were immediately placed at one end of a 30 cm 
acrylic alley, which floor was covered in white absorbent paper, and encouraged to 
walk to the opposite end. The paper was then removed and labelled with the animal 
ID number for further analysis. The stride length and width were manually measured 
and normalized to body weight (“size”) of each mouse to obtain short-step and ataxia 
indexes, respectively. 
 
Preparation of whole brain lysates from mice 
Immediately after sacrifice, whole brains were resected and shock frozen in liquid 
nitrogen. Frozen brains were grinded to powder under liquid nitrogen; thereafter, all 
procedures were carried out at 4°C. Powdered brains were “dissolved” in 1 ml of 
homogenization buffer containing 50 mM Tris-HCl, pH 7.5, 100 mM KCl, 1 mM DTT, 
0.2 mM PMSF (stock 10 mg/ml in isopropanol), 1 μM leupeptin (stock 5 mg/ml in 
H2O) and 1 μM pepstatin (stock 1 mg/ml in methanol). A TissueLyser II (Qiagen; cat. 
no. 85300) was used for preparation of lysate following the manufacturer protocol.   
 
Gene (mRNA) expression studies  
Total RNA was extracted from powdered mouse brains by the QIAmp RNA Blood 
Mini Kit (Ref. 52304; Hombrechtikon, Switzerland) and cDNA was produced by the 
Promega reverse transcription system (Ref. nr. A3500; Dübendorf, Switzerland). 
Mouse Th, Tph1/2 and Igf-1-mRNA expression levels were performed using the 
commercially available ABI assays (Mm.00447546 for Th -mRNA; NCBI RefSeq 
NM_009377.1; Mm00493798_m1 for Tph1-mRNA, NCBI RefSeq NM_001136084.1; 
NM 009414.2; Mm00557717_m1 for Tph2-mRNA, NCBI RefSeq NM_173391.2; 
Mm00439560_m1 for Igf-1-mRNA, NCBI RefSeq NM_001111274.1). The murine 
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA (ABI assay ID: 
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Mm99999915_g1; NCBI RefSeq NM_008084.2) was used to normalize the relative 
Th and Tph1/2 mRNA levels. Values were calculated as described in a published 
method50.  
 
Determination of protein, neopterin, biopterin and monoamine neurotransmitter 
metabolites  
Protein concentration (in g/L) was determined by using the M-TP Mikroprotein kit 
from Beckman Coulter Synchron LX-System (Beckman Coulter Inc, Brea, CA; kit-no. 
445860). Biopterin, neopterin and monoamine neurotransmitter metabolites were 
determined in brain tissue following published protocols43,51.   
 
Serum IGF-1, total thyroxine (tT4), thyroxine stimulating hormone (TSH) and 
prolactin  
Serum IGF-1 was determined by radioimmunoassay (RIA) using a rat IGF-1 RIA kit 
(DSL-2900, Bühlmann Laboratories AG, Switzerland)51, total thyroxine (tT4) from 
whole blood dried on filter paper was measured with the “GSPTM Neonatal 
Thyroxine kit” from PerkinElmer (Life and Analytical Sciences, Turku, Finland), and 
prolactin were quantified using an ELISA kit for mouse and rat (GenWay Biotech, 
Inc., San Diego, CA) following to manufacturer’s instructions.  
 
Measuring blood pressure in mice 
A non-invasive computerized tail-cuff system for measuring systolic blood pressure in 
mice was applied as described52.   
 
Analytical methods for in vitro and in vivo characterization of (human) hTH1 
and (mouse) mTH wt and mutant enzyme 
Cloning of mouse mTh into pET-MBP-1a The pSL1180 vector containing mouse 
Th (mTh) cDNA was a generous gift from Prof. Hiro Ichinose (Tokyo Institute of 
Technology, Japan) and used as template DNA in a PCR with the following primers: 
5’-GCTTCCATGggaCCCACCCCCAG-3’ and 5’-GCTTGGTACCTTAGCTAATGGCA-
3’. This amplifies the Th gene with an NdeI site in the 5’ end and an Acc65I site after 
the stop codon. Restriction sites in the primers are underlined and lowercase letters 
indicate bases inserted to facilitate restriction (translates into an extra glycine in 
position 2). Cloning of human TH1 (hTH1) into pET-MBP-1a has been described 
previously. The mTH PCR-products and pET-MBP-1a/hTH1 were cut with NcoI and 
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Acc65I and purified before mixed in a ligation reaction to produce pET-MBP-1a/mTH. 
The correct pDNA was detected by colony PCR and verified by sequencing.    
 
Mutagenesis of human and mouse TH, and expression and purification of the 
recombinant human and mouse TH-proteins  The mutagenic primers 5’-
CAGGTGTACCGCCAGCACAGG AAGCTGATTGCTGAG-3’ and 5’-
GCGTATCGCCAGCATCGGAAGCTGATTGC-3’ (and their complements) were used 
to generate the pET-MBP-1a/hTH1-R202H and pET-MBP-1a/mTH-R203H mutants, 
respectively, using QuikChange mutagenesis (Stratagene). The mutated bases are 
underlined. Correct mutations were verified by sequencing. hTH1-wt, mTH-wt, hTH1-
R202H and mTH-R203H were expressed as His-MBP-TH fusion proteins in E. coli 
strain BL21 using LB medium with induction by 1 mM IPTG, isolated on amylose 
resin and eluted with 10 mM maltose. Fusion proteins were cut for 1 hour at 4°C 
using TEV-protease at a TH:TEV ratio of 10:1. Tetrameric TH-proteins were isolated 
using size-exclusion chromatography on a HiLoad Superdex200 column (GE 
Healthcare), leaving the protein in 20 mM NaHepes pH 7, 200 mM NaCl. The 
proteins were homogeneous and contained correct N-terminal sequence (as seen by 
MS-spectroscopy; not shown). 
 
Immunodetection Brain extracts were prepared by homogenization in 4 volumes of 
50 mM Tris-HCl, pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM DTT, 200 mM PMSF and 
protease inhibitor cocktail (Roche). Extracts were clarified by centrifugation at 
20,000g for 15 min at 4°C. Free amino acids and contaminants of low molecular 
weight were removed from the supernatants using Zeba desalting spin columns 
(Thermo Scientific), and then the supernatants were stored in liquid nitrogen prior to 
use. Protein concentration was measured with Direct Detect (Merck Millipore). 
Quantification of TH protein was performed by western blot analyses after SDS-
PAGE (10% acrylamide) with 20 mg total protein in each lane, and transfer to 
nitrocellulose membrane and immunostaining using affinity-purified polyclonal rabbit 
anti-rat TH (Thermo Scientific) in a 1:1,000 dilution was used as the primary antibody. 
Secondary antibody was goat anti-rabbit IgG horseradish peroxidise conjugate (Bio-
Rad) in a 1:2,000 dilution. The membrane was also immunostained with a polyclonal 
antibody against glycerolaldehyde 3-phosphate dehydrogenase (GAPDH; Abcam) as 
a loading control. Purified recombinant hTH1 (10 ng/lane) was used as standard for 
immunoquantification. Detection was performed by enhanced chemiluminescence 
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(ECL; Amersham), and immunoquantification in a Molecular Image using Image Lab 
3.0.1 software (Bio-Rad). 
 
Tyrosine hydroxylase activity assay TH activity in brain extracts was assayed at 
30°C immediately following the preparation of the extracts (see above) as 
described29, with the modifications reported53 in using an incubation mixture 
containing 100 mM Hepes, pH 7.0, 50 mM L-[3,5-3H]-tyrosine, 0.05 mg/ml catalyse, 
20 mM ammonium iron (II) sulphate hexahydrate, and 100 mM 3-hydroxybenzyl 
hydrazine (NSD-1015, an inhibitor of L-aromatic amino acid decarboxylase). The 
enzyme was pre-incubated for 1 min in this mixture, and reaction started by addition 
of 500 mM BH4 and 5 mM DTT. The reaction was stopped after 30 min by addition of 
1 ml of 7.5% activated charcoal suspension in 1 M HCl. After centrifugation at  
10,000 g, the supernatant was counted in a scintillation counter. TH activity of the TH 
enzymes was assayed at 25°C, essentially as described30, with certain modifications. 
The incubation mixture contained 40 mM NaHepes, pH 7.0, 0.1 mg/ml catalase, 10 
µM ferrous ammonium sulphate and 50 µM L-Tyr. To this mixture the enzyme was 
added to a final concentration in the assay of 0.01 mg/mL (0.16 µM subunit, diluted in 
0.1 mg/ml bovine serum albumin and 2 µM ferrous ammonium sulphate, in 20 mM 
NaHepes, pH 7.0, 200 mM NaCl). The reaction was started by adding 200 µM BH4 
(Schircks Laboratories) in 2 mM dithiothreitol (DTT), and stopped after 5 min, by 
adding an equal volume of 2% (v/v) acetic acid in ethanol. The enzyme was 
precipitated at -20°C for at least 30 min and the samples were centrifuged at 20,000 
g for 14 min. L-Dopa was separated and measured by HPLC with fluorimetric 
detection (excitation at 274 nm and emission at 314 nm). The L-Tyr-concentration 
dependence was analyzed in the range 6.25 to 100 µM at a fixed concentration of 
BH4 of 200 µM and 2 mM DTT. The BH4-concentration dependence was analyzed in 
the range 16 to 1000 µM (and fixed DTT and L-Tyr concentrations of 2 mM and 25 
µM, respectively). The results were analyzed using the enzyme kinetics function in 
SigmaPlot, where the Km and Vmax values, in the case of BH4-dependency and the Km 
and Ksi for the substrate inhibition by L-Tyr were obtained using Michaelis-Menten 
and substrate-inhibition equations, respectively.  
 
Differential scanning fluorimetry (DSF) DSF was used to measure the thermal 
stability of hTH1, mTH, hTH1-R202H and mTH-R203H, with and without DA. 0.9 µM 
hTH1 (subunit concentration) was incubated with 3X ferrous ammonium sulphate 
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(FAS) and 5X Sypro Orange before added to DA-containing wells of a 96 well-plate 
(Roche Applied Science). DA-concentrations used were 0.45 µM (0.5X), 0.9 µM (1X) 
and 1.8 µM (2X). A LightCycler 480 Real-Time PCR System (Roche Applied 
Science) was used to heat the plate from 25°C to 90°C at a heating rate of 2°C per 
minute. Thermal denaturation of TH was monitored by detecting the increase in 
Sypro Orange fluoresence (λex = 465 nm, λem = 610 nm) upon its binding to exposed 
hydrophobic patches. The data was scaled to reflect fraction unfolded and midpoint 
denaturation (Tm). Tm-values were determined as maximal temperature in a first-
derivative plot. 
 
Limited proteolysis by trypsin The susceptibility of TH to limited proteolysis by 
trypsin was performed at 25°C, as described54, with some modifications. hTH1 or 
hTH1-R202H (0.14 mg/ml) was incubated with TPCK-treated trypsin (Sigma) at a 
TH:trypsin ratio of 200:1 in 20 mM NaHepes, pH 7.4, 200 mM NaCl, in presence or 
absence of 50 µM DA. 1.5 µg/ml trypsin soybean inhibitor (Sigma) and SDS-buffer 
were added to stop the reaction and perform SDS-PAGE (10 %) at 180 V. The gels 
were stained with Coomassie Brilliant Blue and scanned using ChemiDoc XRS+ from 
BioRad. The raw volume of the bands was measured using the Image Lab 3.0.1 
software.  
 
The amino acid sequence of the bands obtained by limited proteolysis was analyzed 
by MS. Proteins in the excised bands were reduced, alkylated and in-gel trypsinized 
following standard procedure55. The proteolytic reaction was stopped by acidification 
with trifluoroacetic (TFA) acid. Peptides from in-gel digestions were extracted and 
prepared for LC (liquid chromatography)–MS/MS (tandem MS) analysis. Samples 
were applied to micro-columns pre-equilibrated in 60% acetonitrile and 0.1% TFA, 
filtered and collected. After removal of acetonitrile by speed vacuum, the samples 
were injected into a nanoflow HPLC system online with positive electrospray 
ionization on Thermo Scientific Orbitrap Velos Pro hybrid ion trap-Orbitrap mass 
spectrometer. Collision-induced dissociation was the mode used for fragmentation. 
MS analysis was performed essentially as described  by Berle et al. 56 with minor 
modifications. The MS and MS/MS raw data files were processed using Proteome 
Discoverer 1.4 software. The generic files were further processed using an in-house 
Mascot server (version 1.4.0.288) (Matrix Sciences) and searched against the 
Swissprot_HomoSapiens database, selecting for trypsination and allowing for 2 
Th-ki Mouse Model – Manuscript (in preparation) 
 63
missed cleavages. Mascot was searched with a fragment mass tolerance of 0.6 Da 
and a parent ion tolerance of 10 ppm. Scaffold_4.0.5 (Proteome Software) was used 
with additional Search engine X! Tandem (version CYCLONE 2010.12.01.1) to 
validate MS/MS-based peptide and protein identifications. 
 
Tissue Preparation and immunohistochemistry 
Adult mice at the age of 6-7 months were anesthetized with sodium pentobarbital and 
perfused through the left cardiac ventricle with 10 ml of ice-cold 0.9% NaCl followed 
by 30 ml of ice-cold 4% paraformaldehyde in phosphate buffered saline (PBS, pH 
7.4). Brains were immediately removed and post fixed in the same 4% formaldehyde 
solution overnight at 4°C and then cryoprotected in subsequent 10% and 30% 
sucrose in PBS solutions. Brains were stored at -80ºC until further use and eventually 
sectioned in 40 µm slices with a cryostat (Leica, CM3050 S). Cryosections were 
collected in cold potassium phosphate buffer (KPBS; 140 mM NaCl, 20 mM K2HPO4, 
pH 7.4), and used for free-floating immunohistochemistry. Sections were incubated 
for 1 h in 1% H2O2 in KPBS to inactivate endogenous peroxidases and then washed 
twice for 20 min with KPBS. A rabbit polyclonal anti-TH antiserum was used at a 
1:1,000 dilution (Millipore, AB152). Sections were incubated with primary antibody 
over night at 4°C in a solution containing KPBS, 0.3% Triton X-100, and 2% normal 
goat serum. After washing twice for 20 min with KPBS, sections were incubated with 
a solution containing biotinylated goat anti rabbit IgG (1:400, VectorLaboratories, 
Burlingame, CA) diluted in KPBS/0.3% Triton X-100 for 2 h at room temperature 
followed by washing twice with KPBS for 20 min. Sections were then incubated with 
avidin/biotin complex (1:200, ABC Vectastain Elite Kit, Vector) for 1 h at room 
temperature. After washing for 20 min in KPBS, sections were equilibrated for 20 min 
in TBS buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.2–7.6). Finally, sections were 
exposed to a solution of 0.025% diaminobenzidine, 0.05% H2O2 in TBS buffer and 
monitored for colour development before stopping the reaction by rinsing in TBS 
buffer (for a reference see also57).  
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RESULTS 
 
Th-ki/ki mice display moderate growth retardation and hypotension  
A constitutive knock-in containing the Th-p.Arg203His was generated by homologous 
recombination in the C57BL/6 background and bred to homozygosity (see 
Supplementary Figure S1 and Table S1, and Methods for details). The Th-ki litter 
size was normal with an expected Mendelian ratio and an apparently normal 
phenotype initially. After weaning, however, Th-ki mice were found to exhibit a 
moderate and continuous growth retardation with 25-34% less body weight compared 
to their wild-type (wt) or heterozygous littermates (Figure 1A and B). That this was 
not due to feeding abnormalities was confirmed quantitatively by metabolic cage 
analyses showing normal food intake and respiratory quotient. Locomotor activity and 
energy expenditure were, however, slightly reduced (see Supplementary Figure S2). 
Follow up examinations of mutant mice revealed no constipation, and a quantitative 
analysis of the fat and total energy contents in feces also revealed no differences 
between wt and Th-ki, indicating that mutant mice had normal absorption and 
digestion (data not shown). IGF-1 gene expression was normal (in liver and brain 
tissues; not shown) as were IGF-1 serum levels in adult mice at the age of 12 weeks 
(Supplementary Figure S3C). In contrast, Igf-1-mRNA expression from whole brain 
extracts was significantly elevated at the age of 3 weeks (not shown), suggesting that 
the IGF system might be involved in growth as it has been suggested by others (see 
for instance25). We further detected elevation of the total thyroid hormone thyroxine 
(tT4) (Supplementary Figure S3A-B). Th-ki mice also manifested  hypotension similar 
to patients with type B THD26 and mice with norepinephrine and epinephrine 
deficiency27, while we found normal levels of catecholamines in adrenals and heart of 
adult Th-ki mice (data not shown) which indicated central regulation for growth and 
hypotension. Normal catecholamine contents in peripheral tissues was also reported 
for heterozygous Th-knock-out mice with significant reduction of TH activity22, 
similarly as we observed for the mutant TH-R203H (~50% of wt; see below).  
 
Progressive loss of brain catecholamines in Th-ki mice 
Prolactin release, which is under control of DA, is a peripheral biomarker for central 
DA deficiency16,17, and we consistently observed elevated serum prolactin levels in 
mutant mice (Supplementary Figure S3D). Brain catecholamine and serotonin 
metabolites were measured in newborn (day 1), juvenile (3 weeks) and adult mice 
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(12 weeks and one year). HVA, the major biomarker in CSF for TH deficiency in 
patients, was low in Th-ki mice at all ages, whereas L-Dopa, DA, norepinephrine and 
MHPG were initially normal but fell continuously thereafter in mutant mice (Figure 2A-
D). The serotonin pathway, which is typically not compromised in THD, remained 
unchanged and only at an advanced age, when mutant mice exhibited a striking loss 
of catecholamines, a reduction of the serotonin precursor 5-hydroxytryptophan (5-
HTP) was observed.  Other relevant brain parameters, such as serotonin, 5-
hydroxyindoleacetic acid (5-HIAA) and biopterin (and neopterin) content remained 
unchanged at all ages (Figure 2 and Supplementary Figure S4).  
 
Early motor dysfunction in THD mutant mice  
A moderate reduction of motor activity was observed in mutant mice during metabolic 
cage analyses (see above). In order to explore the nature of this motor dysfunction, 
we performed a series of behavioral tests assessing catalepsy, motor coordination, 
amount and velocity of spontaneous locomotion, and gait characteristics at different 
ages. Motor defects were tested in juvenile (3 weeks old), young adult (11 weeks old) 
and one year old mutant male mice plus sex and age-matched wt controls (Figures 
3A to F). In the bar test, Th-ki mice showed increased time of immobility compared to 
their controls, indicating catalepsy, a sign of rigidity and inability to initiate 
movements. In addition, when placed at the bar, Th-ki mice of all ages but particularly 
older adults presented an abnormal body posture and muscle twitching, suggesting 
the presence of a dystonic component. When the same Th-ki male mice were 
challenged with the rotarod, a significantly reduced latency to fall was observed, 
indicating impaired motor coordination. In the open field test, Th-ki mice showed 
significantly reduced levels of horizontal activity (amount and velocity of spontaneous 
locomotion), indicating a hypokinetic and bradykinetic phenotype. Next, we analyzed 
the characteristics of gait (normalized to body weight in order to compensate for the 
size difference between genotypes). Mutant mice had an increased stride width per 
body weight index compared to normal controls, suggestive of a significant ataxia in 
these animals. This was confirmed by a generalized disorganization of the gait, 
including dragging marks, changes in direction and freezing (data not shown). In 
contrast, Th-ki mice did not show abnormal step length, as can be observed by an 
unchanged stride length per body weight index compared to controls. In summary, 
while catecholamine deficiency was progressive, the severe motor dysfunction was 
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present from the first measurements at 3 weeks onwards, and its severity appeared 
independent of age.  
 
Th-ki mutant mice exhibit diurnal fluctuation of motor deficits, a hallmark in 
patients with THD 
THD in humans exhibits marked diurnal fluctuations of motor behaviour13,28. To 
determine whether the motor performance in mutant mice varied with time of the day, 
we performed the bar test at 8 a.m. and 8 p.m. and found that Th-ki mice performed 
significantly better after the rest period (at 8 p.m., note the inverted circadian rhythms 
of mice compared to humans) than after the activity period (at 8 a.m.); wt controls 
presented a stable performance at both times13,28 (see Figure 4).  
 
Gradual reduction of TH protein and activity in brain of Th-ki mice 
Expression of Th-mRNA (but also Tph1 and 2 mRNAs) in the brain was similar in wt 
Th-ki mice at different ages (Supplementary Table S1). In contrast, quantification of 
TH protein content in whole brain extracts showed an increase in TH relative to total 
protein from newborn (1 day) to 3 weeks in normal mice, but not in Th-ki mice (Figure 
5A,B). Wt mice maintained their TH content from 3 weeks to 1 year, whereas Th-ki 
mice presented a clear decrease of TH protein from 3 weeks of age (Figure 5A,B) 
and a progressive loss of TH protein relative to the normal content already from 
newborns, reaching a value as low as ~3% of normal content in 1 year old animals 
(Figure 5B, inset). The specific TH activity in brain extracts under standard conditions 
- measured by a sensitive radiochemical assay29 - followed the same development as 
the protein content for the wt animals (Figure 5B). However, the activity in Th-ki brain 
extracts was below the sensitivity threshold and could not be determined accurately 
by any method tested, with HPLC and fluorimetric detection of L-Dopa30 or by the 
radiochemical assay29.  
 
Immunohistochemistry studies support axonal transport of TH across the 
nigrostriatal projection  
In order to assess TH expression and distribution, we performed TH-
immunohistochemistry on coronal brain sections from perfused adult male Th-ki and 
wt mice (6-7 months old). We observed a similar expression pattern of TH in the 
substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) of Th-ki 
and control mice, possibly with only less dense stained projections in the mutant 
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tissue (Figure 5C) but similar number of cell bodies. However, the results observed in 
the corpus striatum revealed an almost complete lack of immunoreactive processes 
in this brain area, confirming that there is a strong reduction in the amount of TH 
protein (corpus striatum; Figure 5D). Other TH-expressing brain areas did not show 
differential results either (data not shown), suggesting that the most affected brain 
areas are most likely those targeted by projections from TH producing neurons.  
 
The misfolding loss-of-function mutations hTH1-R202H and mTH-R203H are 
not stabilized by DA  
In order to understand better the TH dysfunction in THD patients and in Th-ki mice, 
we studied the molecular and kinetic effects of the p.R202H and the p.R203H 
mutations on the human TH isoform 1 (hTH1) and the mouse (mTH) background 
using purified, recombinant hTH1-wt, mTH-wt, hTH1-R202H and mTH-R203H. First 
we analyzed the substrate and cofactor dependent activity of each enzyme (Figure 
6A,B), and the steady state activity constants are summarized in Table 1. Compared 
with hTH1-wt, mTH-wt showed reduced specific activity, a similar Km(BH4), slightly 
decreased S0.5(L-Tyr) (higher substrate affinity for L-Tyr) and reduced substrate 
inhibition constant (Ksi), in agreement with stronger substrate inhibition. The mutants 
hTH1-R202H and mTH-R203H showed decreased Vmax and Km(BH4) (higher affinity 
for the cofactor), indicating a clear but not severe kinetic deficiency in the mutants. 
Additionally, a destabilizing misfolding effect of the mutation was indicated by a 10-
fold lower yield of purified recombinant mutant enzymes compared with their wt 
counterparts, and predicted by the FoldX algorithm31, which estimated a 
destabilization of 9.96 kcal/mol (∆∆G) for the tetrameric structure of hTH (PDB 
2XSN), including the catalytic and tetramerization domains. To corroborate that the 
mutation caused the destabilization, we performed differential scanning fluorimetry 
(DSF) analyses. This method was chosen due to the small amounts of protein 
required, since protein was limited for the mutants. The mutant enzymes presented 
reduced stability (2-3°C decreased midpoint denaturation (Tm)-values compared with 
the respective wt-forms; Figure 7A). However, reduced stability alone could not fully 
explain the selective and progressive loss of TH protein in the Th-ki mouse (Fig. 5). 
We hypothesized that this progressive loss of the mutant mTH-R203H protein was 
due to a defect in the stabilization by DA and other catecholamines. Stabilization is 
an important outcome of the regulation of TH by the catecholamine feedback 
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inhibitors, which in addition to inhibiting TH activity competitively versus the BH4 
cofactor, act as natural chaperone compounds9,11. In vitro, the stabilization is 
manifested by an increase in the Tm-values and a decrease in its susceptibility to 
proteolysis10. As expected, hTH1-wt and mTH-wt were stabilized by DA binding, 
increasing their Tm-values up to 3°C (Figure 7A,B). However, the mutants were not 
stabilized by DA (Fig. 7C,D). In addition, DA protected the wt enzymes, but not the 
mutants, from limited tryptic proteolysis (shown for hTH1 in Figure 7E-J).  
 
Non-responsiveness of Th-ki/ki mice to L-Dopa treatment 
We determined the effect of L-Dopa treatment on the motor outcome of juvenile Th-ki 
mice and controls. Catalepsy and motor coordination were investigated after daily L-
Dopa (plus carbidopa) or vehicle treatment from birth to 3 weeks of age. No 
significant differences were found either in the bar test or rotarod performance in Th-
ki mice given L-Dopa or vehicle (see Supplementary Figures S5A-B). Similar 
negative results were obtained from treating adult Th-ki mice over a period of 12 days 
(not shown). Nevertheless, monoamine neurotransmitter analysis in brain extracts of 
sacrificed mice showed significant metabolite improvement and all signs of L-Dopa 
treatment (Figure 8), although TH protein was certainly not increased (Fig. 8, inset). 
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DISCUSSION 
 
This mouse model was generated to provide an experimental source for in vivo 
mechanistic studies of TH to investigate its deficiency both in terms of disease 
pathogenesis and the effect of mutations on enzyme function. In the longer term it is 
also hoped that it will provide a model for testing treatments aimed at improving 
diseases related to loss of dopamine. The model presents clinically robust: The Th-ki 
mouse appears normal at birth, but thereafter exhibits moderate thriving problems 
and develops motor features that include abnormal body posture and twitching, 
reduced motor coordination, ataxia and catalepsy, with clear diurnal variation as well 
as lowered blood pressure, all sings that were also reported for THD patients13. The 
biochemical abnormalities include an early and progressive decrease in brain DA or 
catecholamines to critically low levels, associated to a progressive loss of brain TH, 
hyperprolactinemia - a peripheral marker for DA deficiency and the reason for the 
strongly reduced fertility of Th-ki females (not shown) - and elevated thyroxine, also a 
characteristic of THD patients.  
 
The importance of catecholamines for fetal development has been clearly 
demonstrated in earlier studies both with Th-/- and the dopamine β-hydroxylase 
deficient Dbh-/- knock-out mice21,22,32. Both of these mice variants have a high pre-
and perinatal mortality due to cardiovascular failure associated to the lack of 
norepinephrine. TH function and norepinephrine synthesis can be rescued in 
noradrenergic neurons of the Th-/- mice, which then become a specific DA-deficient 
mice which  survive for a short period after birth without treatment13,19. However, DA-
deficient mice present normal norepinephrine levels and are thus not good models for 
THD. A catecholamine-deficient mouse model with 50% survival is the aromatic 
amino acid decarboxylase (AADC) knock-out line, but these mice show also seriously 
reduced serotonin levels33 and are therefore also not a model to investigate the 
pathogenic mechanisms of TH dysfunction. 
 
Newborn Th-ki mice show normal values of catecholamines and other metabolites, 
except for a reduction in HVA. By 3 weeks of age, however, a drastic drop in brain 
norepinephrine is observed in Th-ki, and despite the crucial role of norepinephrine for 
mouse fetal development32, the very low level of norepinephrine in Th-ki mice of ³3 
weeks does not affect survival. The drop in norepinephrine is initially not 
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accompanied by a significant decrease in DA pointing to compensatory mechanisms 
that maintain DA levels, e.g. by down regulation of its degradation. Indeed,  it has 
been shown that  DA  but not norepinephrine levels are regulated by catechol O-
methyltransferase (COMT), at least in the prefrontal cortex34. Furthermore, the large 
decrease in norepinephrine in Th-ki mice occurs at the time when TH protein 
substantially increases in normal mice35, actually a 5-fold increase in TH was 
observed in Th-wt from newborn to 3 weeks, while TH was not increased in Th-ki (5 
fold increase; see Fig. 5B) despite the fact that Th-mRNA levels are similar (Table 
S1). The stabilization of TH necessary to sustain the critical increase in TH protein is 
required for post-natal development of the dopaminergic system and proper transport 
and distribution of TH in the striatum. Both the level of BH4 and catecholamines 
themselves have been implicated in this stabilization, which is impaired e.g. in the 
BH4-deficient mice35,36. In this work, we show that BH4 levels are similar in Th-wt and 
knock-in mice but, pertinently, the mTH-R203H enzyme is not stabilized by DA (or 
norepinephrine; data not shown): this explains the lower accumulation of the mutant 
TH protein in the critical postnatal period, as well as its progressive decay until 1 year 
of age. Furthermore, in agreement with our immuno-histochemical results of TH 
expression in brain of adult Th-ki mice presented here, the absence of TH 
stabilization by catecholamines has been associated with defects in the postnatal 
pattern of striatal TH immuno-reactivity36. It is well known that motor control depends 
on the transmission of DA through the nigrostriatal pathway from the SNpc along the 
processes to the caudate-putamen. Given the observed motor deficits in the Th-ki 
mutant mice, and the lack of L-Dopa responsiveness, our data suggest that these 
animals may not have enough synaptic DA to activate DA receptors in the caudate-
putamen and thus allow proper motor function.  
 
One puzzling feature in the phenotype of the Th-ki and the patients with THD type B, 
especially for those with the mutation hTH1-R202H, is the non-responsiveness to L-
Dopa, both when mice are treated from the first day of life or during the course of the 
disease. This was unexpected in view that DA levels increase considerably and NA 
reaches the levels in Th-wt mice (Figure 8). Other mice models with DA deficiency 
show a partial recovery of some of the dysfunctions, specially related with feeding 
problems, upon DA treatment, though the recovery of motor disturbances is not well 
achieved37, which has been related to brain developmental deficiencies in the fetus 
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and in the perinatal period35,37. In the case of Th-ki, a critical factor for the lack of 
responsiveness is also the inability of the brain catecholamines to stabilizing the 
mutant TH protein. The defective striatal distribution of TH is in itself probably related 
to impaired transport of TH protein - and thus neurotransmission - despite an 
elevated level of total brain DOPA, DA and norepinephrine36. It is therefore still 
crucial to develop novel and non-L-Dopa-based therapeutic strategies for THD type 
B. In this respect the major finding and molecular explanation for this phenotype is 
the direct loss of mutant TH protein and activity, and emerging therapies based on 
protein stabilization, e.g. pharmacological chaperones, appear promising38. The 
diurnal fluctuation of motor deficits is definitively an important hallmark of our Th-ki 
mutant mouse and may also be exploited on the search for novel treatment strategies 
based on therestorative potential of either circadian regulation of TH activity and/or 
restorative properties of sleep. 
 
A few unexpected characteristics of the Th-ki mutant mouse remains unexplained 
and need further attention. For instance the growth retardation in combination with 
normal food intake, normoglycemia (not shown) and reduced energy expenditure 
remains elusive. An interesting observation in this context is the Igf-1 gene over-
expression in brain and thus the potential involvement of IGF-1 in growth attenuation 
in DA-compromised Th-ki mice during the growth period. The IGF-1 system is known 
to be an important mediator of cell growth and differentiation25 but a link to the DA 
system needs in depth investigations for understanding, as thus far, IGF-1 over-
expression in brain was rather described to be involved in neuronal survival than 
growth reduction. Another explanation is that disruption of DA signaling has been 
associated to growth retard due to altered GHRH-somatostatin regulation of GH39. 
Moreover, it was previously reported that mice with selective DA-deficiency in 
dopaminergic neurons, but not in noradrenergic neurons, exhibited abnormal feeding 
behaviour including swallowing difficulties (aphagy)23,37, symptoms we did not 
observe in the Th-ki mice. On the other hand, growth retardation in combination with 
normal food intake was found in total and neuron specific DA-receptor knock-out 
mice which are in agreement with reduced DA signaling40,41. The Th-ki mouse 
therefore may also provide a model to study the role of central catecholamines and 
the control of body growth and food intake.   
 
Th-ki Mouse Model – Manuscript (in preparation) 
 72
In conclusion, there is a large spectrum of phenotypes in patients with THD, resulting 
from diverse deficiencies in absolute and relative DA and norepinephrine levels with 
different impact on systemic and motor function42. This variability would depend on 
the catalytic and conformational defect of the TH mutation and on particular effects 
on regulatory mechanisms for TH, notably those affecting TH protein stability. The 
homozygous Th-ki mice studied in this work presents severe motor deficiencies from 
a juvenile age onwards, and these abnormalities are not corrected by classical 
replacement treatment with L-Dopa. The mutant hTH1-R202H and mTH-R203H 
proteins are not stabilized by DA, leading to intracellular instability, progressive loss 
of TH activity and altered striatal distribution, aiding to interpret a biochemical and 
locomotor phenotype of Th-ki. In addition to contribute to the understanding of the 
biochemical pathogenesis of catecholamine deficiency this mouse model offers a 
useful platform for designing and evaluating new routes to disease therapies not only 
for THD, but also to complement and improve present therapeutic regimes for genetic 
and idiopathic dopaminergic deficiencies. 
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Figure 1. Sex-specific differences in body weight between wt and Th-ki mice. (A) Female and (B) 
male mice fed ad libitum with standard chow. Significant differences between Th-ki and wt combined 
with heterozygotes mice are indicated by **, p<0.01; ***, p<0.001 (Student’s two tailed t-test). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Progressive loss of brain monoamine neurotransmitter metabolites in Th-ki mice. (A) 
Newborn mice at the age of day 1, (B) juvenile mice at the age of 3 weeks, (C) adult mice at the age of 
12 weeks, and (D) adult mice at the age of 1 year. Th-wt mice are shown in black and Th-ki in gray. 
Monoamine neurotransmitter metabolites are depicted in pmol/mg of total brain protein. Significant 
difference from the corresponding wt value is indicated by asterisks: *p<0.05, **p<0.01, ***p<0.001 
(Student’s two tailed t-test). 3-OMD, 3-O-methlydopa; MHPG, 3-methoxy-4-hydroxyphenylethylene 
glycol; HVA, homovanillic acid; 5-HTP, 5-hydroxytryptophane; 5-HIAA, 5-hydroxyindoleacetic acid. 
Significant difference from the corresponding wt value is indicated by asterisks: *, p<0.05; **, p<0.01; 
***, p<0.001 (Student’s two tailed t-test). 
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Figure 3. Behavioral analysis of Th-ki and wt (Th-wt) male mice at different ages. (A) Bar test for 
assessment of catalepsy (sec). (B) Rotarod test for determination of motor coordination (sec). (C) 
Total distance travelled (cm) in the open field test (cm). (D) Mean velocity (cm/s) of locomotion in the 
open field test (E) Gait analysis to test for ataxia (stride width normalized to body weight). (F) Gait 
analysis to test for short-step disorder (stride length normalized to body weight). Th-wt mice are shown 
in black and Th-ki in gray. Significant difference from the corresponding wt value is indicated by 
asterisks: **, p<0.01; ***, p<0.001 (Student’s two tailed t-test or ANOVA for fluctuation bar test).   
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 Figure 4. The bar test for catalepsy reveals diurnal fluctuation of motor deficits. Bar test 
performed at 8 a.m. and 8 p.m. to explore potential fluctuations in catalepsy severity (sec). Th-wt mice 
are shown in black and Th-ki in gray. While there was no difference for Th-wt mice performance at 
different day times, Th-ki mice exhibited a significant difference between morning and evening, 
indicated by the asterisk (*p<0.05; two ANOVA for fluctuation bar test). The difference between the 
two genotypes is repeated from Figure 3A (indicated by the three asterisks; ***, p<0.001 (Student’s 
two tailed t-test).   
   
  
 
 
 
 
 
 
 
 
Figure 5. TH protein content in brain from wt (Th-wt) and Th-ki mice. (A) Representative 
immunoblots for brain extracts of mice of different age; kDa, standard; mTH, purified recombinant 
mouse TH. (B) TH protein content in brain extracts from wt (black bars) and Th-ki mice (grey bars) by 
density of the 59 kDa TH band relative to the intensity of the GAPDH band. The grey striped bars 
indicate enzyme activity for wt TH (scale for activity on the right). Inset: % of TH protein content in 
brain extracts of Th-ki vs. Th-wt. For both panels: newborn (1 d), 3 weeks (3 w), 12 weeks (12 w) and 
one year (1 y), in Th-wt (wt) and Th-ki (ki) mice. Asterisks: *, p<0.001 (Student’s two tailed t-test).  
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(C-D) Immunohistochemical staining of TH in brain of Th-wt and Th-ki mutant mice, at the age of 6 
months. (C) Substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) of Th-wt and 
Th-ki mice present a similar degree of neuronal staining indicating lack of neuro-degeneration, and (D) 
A striking lack of TH staining was observed in the corpus striatum in Th-ki mice compared to their 
controls, indicating that a reduced amount of TH protein is accumulated in these neuronal processes.   
 
 
 
 
 
 
 
Figure 6. Steady-state kinetics characterization of recombinant purified human TH1 (hTH1) and 
mouse TH (mTH), and the respective mutants R202H and R203H. Specific activity of hTH1-wt (●), 
mTH-wt (○), hTH1-R202H (▼) and mTH-R203 (△) measured (A) at different concentrations of the 
cofactor BH4 (0−1000 μM) at fixed L-tyrosine concentration (25 μM), and (B) at different 
concentrations of the substrate (0−200 μM) and fixed BH4 concentration (200 μM). Results are 
means ± S.D. for three different experiments.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The stability of recombinant purified human TH1 (hTH1) and mouse TH (mTH) and the 
respective mutants R202H and R203H, and effect of DA. (A-D) Differential scanning fluorimetry 
profiles. Thermal denaturation profiles (fluorescence at 610 nm vs. temperature) for hTH1-wt (A), 
mTH-wt (B), hTH1-R202H (C) and mTH-R203 (D), analyzed at a concentration of 0.9 µM subunit 
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R202H (lanes 6-10) in the absence (2,3,7,8) and the presence of 50 µM DA (4,5,9,10); 1 and 6 are the 
respective controls in the absence of trypsin. Conditions: 2.5 µM subunit hTH or hTH-R202H were 
incubated with trypsin for 30 s (2,4,7,9) or 60 s (3,5,8,10) at 25°C, at a TH:trypsin ratio of 200:1. The 
gels were stained with Coomassie Brilliant Blue and scanned. The raw volume of the bands was 
measured using the Image Lab 3.0.1 software and represented for lanes 1, 3, 5, 6, 8 and 10 in F, G, H, 
I, J and K, respectively. At the selected conditions, hTH1-wt, with an apparent molecular weight of 60 
kDa, was converted by trypsin into two different truncated forms of 57 and 54 kDa. Both these 
truncated forms lack the N-terminal peptide MPTPDATTPQAKGFR, indicating that hTH1 undergo 
proteolysis at the N-terminal (analyses by MS spectroscopy; data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Outcome of L-Dopa treatment of Th-ki mice on brain monoamine neurotransmitter 
metabolites and TH protein. Mutant Th-ki and Th-wt mice were treated after birth for a period of 3 
weeks with L-Dopa (10 mg/kg/d) plus carbidopa (2.5 mg/kg/d) or vehicle (controls). (A) Brain 
monoamine neurotransmitter metabolites are depicted in pmol/mg protein. (B) TH protein relative to 
GAPDH is shown for wt and mutant mice with or without L-Dopa treatment. In both A and B, significant 
difference from the corresponding wt value is indicated by asterisks: *, p<0.05; **, p<0.01; ***, p<0.001 
(Student’s two tailed t-test).  
A 
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Table 1. Steady-state kinetics parameters for recombinant purified human TH1 (hTH1) and 
mouse TH (mTH), and the respective mutants R202H and R203H. See also Figure 2. Results are 
means ± S.D. for three different experiments. 
Enzyme ________  BH4 ________ ___________   L-Tyr ___________ 
  Vmax 
(nmol of L-
dopa/min×mg) 
Km (BH4) 
(µM) 
Vmax 
(nmol of L-
dopa/min×mg) 
S0.5 (L-Tyr) 
(µM ) 
Ksi* 
(µM) 
hTH1-wt 400  ± 11 50 ± 6 782 ± 41 22 ± 1 54 ± 5 
mTH-wt 252 ± 141* 47 ± 10 583 ± 461* 15 ± 11* 28 ± 41* 
hTH1-R202H 162 ± 31* 34 ± 31* 344 ± 501* 28 ± 3 60 ± 9 
mTH-R203H 132 ± 32* 21 ± 22* 280 ± 402* 23 ± 5 49 ± 62* 
For BH4 concentration dependency, data were fit to the Michaelis-Menten model and for L-Tyr 
concentration dependency to the substrate inhibition model. 
Ksi, substrate inhibition constant 
1*, p< 0.5 with respect to corresponding values for hTH1-wt 
2*, p< 0.5 with respect to corresponding values for mTH-wt 
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Suppl. Figure S1. Generation of the Th-ki mouse. (A) Schematic representation of the Th-ki mouse 
gene containing 13 exons with the Th-wt allele R203 in exon 5 (in red; the gene is not drawn to scale; 
NCBI gene ID 21823, transcript variant Th-1 NM_0093771.1; Ensembl gene ID 
ENSMUSG00000000214). The targeting vector contains a 3.8 kb short homology arm (SHA) and a 6.1 
kb long homology arm (LHA), including the mouse R203H mutation in exon 5’. At the bottom, the 
targeted mutant Th-ki allele is shown with location of primers for PCR-genotyping (see below). For 
validation of correct recombination, Southern blot analyses were performed (see be supplied upon 
request). FRT, flippase recognition target site; NeoR, neomycin resistance gene for positive selection; 
TK, thymidine kinase gene for negative selection. (B) Details of the DNA sequence of exon 5 of the wt 
(left) and mutant (right) alleles. The wt sequence of the R203 codon overlaps with a HaeII 
endonuclease recognition site which is destroyed in the mutant allele R203H. (C) Conventional 2% 
agarose gel of representative PCR-genotyping for the Th-ki allele with a size difference of 85 bp due to 
the additional FRT site in the Th-ki allele which is in cis with the R203H mutation. Position of the 
primer pair is indicated in A (for more details see Materials and Methods).  
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 Suppl. Figure S2. Similar food intake and respiratory quotient but reduced energy expenditure 
in Th-ki compared to Th-wt mice. Food intake (A), respiratory quotient (B), locomotor activity (C) 
and energy expenditure (D) were determined in an open-circuit indirect calorimetry system equipped 
with an infrared light-beam and a feeding monitor system as described in Materials and Methods. After 
mice were adapted to single caging, data were obtained during a 24-h period in Th-wt (black bars) and 
Th-ki (gray bars) mice and results are depicted either over the whole 24-h period or separated into 
light and dark phase (n = 4-5). Error bars represent SEM. *, p<0.05; **, p<0.01; ***, p<0.001 (Student’s 
t-test). 
 
 
 
 
 
 
 
 
 
 
Suppl. Figure S3. Serum parameters including total thyroxine (tT4), IGF-1 and prolactin, as well 
blood pressure measurements in wt and Th-ki mice.  (A) Serum total thyroxine (nM), (B) systolic 
blood pressure (mm of Hg), (C) serum IGF-1 (ng/ml), and (D) serum prolactin (ng/ml) in Th-wt and Th-
ki mice. Th-wt are shown in black bars and Th-ki in grey bars; the number of mice per group is 
indicated. Significant difference is indicated by *, p<0.05 (Student’s two tailed t-test).  
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Suppl. Figure S4. Biopterin content in whole brain extracts (in pmol/mg of total protein) at 
different ages of Th-wt and Th-ki mice. See text for details.    
 
 
 
 
 
 
 
 
 
 
Suppl. Figure S5. Bar and rotarod tests in Th-wt and Th-ki mutant mice after treatment with L-
Dopa. Th-ki and Th-wt mice were treated after birth for a period of 3 weeks with L-Dopa (10 mg/kg/d) 
plus carbidopa (2.5 mg/kg/d), or with vehicle. (A) Bar test to assess catalepsy, and (B) rotarod test to 
determine motor coordination. Treatment with ddH20 (vehicle) or L-Dopa/carbidopa are shown in black 
or black-white stripes for Th-wt mice, and in gray or gray-white stripes for Th-ki. Significant differences 
from the corresponding wt values are indicated by asterisks: ***, p<0.001 (Student’s two tailed t-test). 
 
Supplementary Table S1: Gene expression of Th and Tph1/2 in brain of mice at different age 
a Normalized relative to Gapdh-mRNA (Livak and Schnittgen, Methods 25(4):402-408, 2001) 
Th tyrosine hydroxylase; Tph1/2 tryptophan hydroxylases 1 and 2; Gapdh, glyceraldehyde 3-phosphate dehydrogenase 
Genotype Age Th-mRNAa   Tph1-mRNAa   Tph2-mRNAa   
     
Th-wt newborn 1 day 1.00 (0.65 - 1.55) 0.09 (0.03 - 0.23) 0.06 (0.01 - 0.31) 
Th-ki newborn 1 day 1.06 (0.74 - 1.53) 0.06 (0.06 - 0.07) 0.08 (0.03 - 0.26) 
     
Th-wt juvenile 3 weeks 1.48 (0.71 - 3.10) 0.03 (0.02 - 0.03) 0.14 (0.03 - 0.61) 
Th-ki juvenile 3 weeks 1.62 (1.31 - 2.01) 0.03 (0.02 - 0.05) 0.07 (0.03 - 0.20) 
     
Th-wt adult 12 weeks 1.46 (0.94 - 2.27) 0.04 (0.03 - 0.04) 0.05 (0.02 - 0.10) 
Th-ki adult 12 weeks 1.96 (1.23 - 3.41) 0.03 (0.02 - 0.05) 0.03 (0.01 - 0.06) 
     
Th-wt adult 1 year 1.60 (0.84 - 3.03) 0.04 (0.02 - 0.07) 0.03 (0.01 - 0.06) 
Th-ki adult 1 year 1.46 (0.89 - 2.42) 0.04 (0.02 - 0.05) 0.01 (0.00 - 0.04) 
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2.2 ORAL TREATMENT STUDY WITH BH4 AND PHARMA-
COLOGICAL CHAPERON IN TH-KI/KI MICE TO STABILZE THE 
MUTANT TH ENZYME AND INCREASE BRAIN CATECHOLAMINE 
LEVELS 
 
 2.2.1 ABSTRACT 
 
A comprehensive characterization of the novel constitutive Th knock-in (Th-ki) mouse 
model with progressive loss of brain TH and catecholamines, and severe motor 
dysfunction was presented in the previous chapter 2.1. This initial characterization 
included a treatment attempt with oral loading of newborn Th-ki/ki mice for three 
weeks with L-Dopa (10 mg/kg/d plus 2.5 mg/kg/d carbidopa), which resulted in 
normalization of brain catecholamines (except dopamine) but persistent motor 
deficits. Here we attempted to perform treatment with chemical pharmachaperons, 
the so called  compounds III and IV (CIII and CIV) that were previously shown to 
stabilize mutant mTH-p.R203H in cell culture studies, and increased total TH activity 
in wild-type mouse brain (Calvo et al., 2010). Furthermore, treatment with BH4-
cofactor, which showed to stabilize TH in brain of wild-type mice, was included in the 
present loading study (Thöny et al., 2008). Young adult Th-ki/ki were treated by oral 
loading over a period of 12 days with CIII or CIV (each 5 mg/kg/d), with BH4 (100 
mg/kg/d) or with L-Dopa (10 mg/kg/d plus 2.5 mg/kg/d carbidopa). A follow-up study 
included treatment of newborn Th-ki/ki mice for 3 weeks with CIII (5 mg/kg/d). Mice 
were tested for motor function after treatment, and analyzed for Th gene expression 
and TH enzyme activity and protein amount, as well as monoamine neurotransmitter 
metabolites in whole brain extracts. Only treatment with L-Dopa/carbidopa led to 
partial normalization of brain catecholamines without changing the behavioral deficits, 
while treatment with CIII, CIV or BH4 had no effect whatsoever. Unexpectedly, 
changes in gene expression in brain were observed in Th-ki/ki mice treated for 12 
days with L-Dopa, BH4, CIII or CIV, i.e. increase in Tph2 and decrease in the 
dopamine receptor genes Drd1a and Drd5. In addition, oral application of BH4 
reduced gene expression of the insulin growth factor-1 (Igf-1). In contrast, the 3 
weeks CIII treatment only led to decreased Drd5 mRNA-expression level. 
Furthermore, 3 weeks mutant mice have increased Igf-1 expression independent 
form the treatment. These unprecedented observations in treated Th-ki/ki mice will be 
discussed also in the context of previously published results from similar treatment 
studies in wild-type mice.   
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2.2.2 INTRODUCTION 
 
The homozygous Th-ki/ki mouse, expressing the Th-p.R203H mutation, is a model 
for the severe form of THD: Treatment with L-Dopa/carbidopa led to a remarkable 
improvement in their brain catecholamines, but it did not improve their motor 
coordination deficits (see chapter 2.1). Here we performed diverse treatment 
approaches to potentially not only correct their brain monoamine neurotransmitter 
deficit but to also improve their motor behavior. The Th-p.R203H mutation leads to 
highly instable mutant TH protein probably caused by the lack of stabilization by 
decreased levels of dopamine (see chapter 2.1). Several studies showed that 
chemical pharmachaperons, which are small molecules that can assist in vivo protein 
folding, enhances protein stabilization (Morello et al., 2000, Cohen and Kelly, 2003). 
Recently, it was shown that the pharmacological chaperon 3-amino-2-benzyl-7-nitro-
4-(2-quinolyl)-1,2-dihydroisoquinolin-1 (termed compound III/CIII) and 5,6-dimethyl-3-
(4-methyl-2-pyridinyl)-2-thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H) (compound IV/ 
CIV) stabilized in wild-type mice the brain TH enzyme by increasing TH activity and 
amount of protein without affecting gene expression or monoamine neurotransmitter 
metabolites. This study was performed in wild-type mice treated for 12 days with 5 
mg/kg/d CIII or CIV (Calvo et al., 2010). The fact that the gene expression and 
monoamine neurotransmitters were not raised in treated wild-type mice is probably 
due to the fact that dopamine is kept at a low level in ‘resting situations’, because of 
the chemical toxicity of this neurotransmitter (Mosharov et al., 2009, Calvo et al., 
2010). Furthermore, the addition of CIII stabilized the human hTH-p.R202H protein 
(equivalent to the mouse Th-p.R203H mutation) in vitro (Calvo et al., 2010). 
 
In the here presented study, it was investigated whether the pharmacological 
chaperons CIII and CIV restore TH activity, protein levels, gene expression, 
monoamine neurotransmitters and/or motor function in Th-ki/ki mice. As described in 
a previous study, adult mice were orally fed with 5 mg/kg/d CIII or CIV (Calvo et al., 
2010). BH4, the cofactor of TH, also showed chaperon activity on TH. Therefore, BH4 
was also included in this oral feeding study with relative high oral dosage of 100 
mg/kg/d, which allows to directly comparing between a natural and a synthetic 
chaperon effect (Thöny et al., 2008). In addition, adult mice were fed with 10/2.5 
mg/kg/d L-Dopa/carbidopa, serving as positive control for changes in the 
catecholamines. It has to be considered that the 12 days treatment in adult mice 
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have possible less impact then a three weeks treatment started after birth. Therefore, 
newborn mice were also fed for 3 weeks with CIII, which is so far the most promising 
pharmacological chaperon candidate to stabilize and improve brain TH concomitant 
with potentially improving motor or behavior dysfunction. 
 
Despite mTh gene expression, also mTph1/2 gene expressions were investigated, 
although no alterations in wild-type mice were detected when treated for 12 days with 
the pharmacological chaperons (Calvo et al., 2010). TPH1 is mainly present in the 
pineal gland, the serotonergic neurons in the raphe nuclei that project in all brain 
areas, the enterochromaffin cells, and the myenteric neurons in the gut (Cote et al., 
2003). TPH2 is predominantly found in the brainstem raphe nuclei (Walther and 
Bader, 2003, Patel et al., 2004).  
 
In chapter 2.1 it was shown that there is a strong decrease of TH in the striatium of 
Th-ki/ki mice, but not in the substantia nigra pars compacta or in the ventrolaterale 
thalamus, probably due to reduced projection into the striatum. The dopamine 
receptor D1 (DRD1) is highly abundant in the striatum, and belongs to the D1-
subtype of dopamine receptors, including also DRD5, and has a stimulatory effect on 
the cell. In addition, there is the D2-subtype including the DRD2, which is also highly 
abundant in the striatum, DRD3 and DRD4 receptors that have an inhibitory effect on 
the cell (Jaber et al., 1996). Therefore, it was investigated if there are alterations in 
the murine Drd1-5 (mDrd1-5) gene expressions and if the treatments with L-Dopa, 
BH4, or CIII/IV alter gene expression since it was shown in dopamine-depleted rats 
that L-Dopa administration resulted in the stimulation of D1 and D2 receptor systems 
(Trugman et al., 1991). 
 
Oral communication to Simon Heales indicated a possible increased AADC activity, 
encoded by the Ddc gene, in THD patients. Therefore, it was analyzed if the murine 
Ddc (mDdc) gene expression is increased in Th-ki/ki mice and if L-Dopa, BH4, or 
CIII/IV treatment has any altering effects on mDdc gene expression. 
 
Furthermore, Th-ki/ki mice have decreased body weight and size that is not caused 
by insulin-like growth factor-1 (IGF-1) deficiency (see chapter 2.1). Therefore, it was 
investigated further if murine Igf-1 gene (mIgf-1) expression is influenced in Th-ki/ki 
mouse brains when treated with L-Dopa, BH4, or CIII/IV. 
Th-ki Mouse Model - Oral Treatment Approaches 
 89
2.2.3 MATERIALS AND METHODS 
 
In the following, additional methods are described that are not present in chapter 2.1 
with the general description of the Th-ki mouse model (Korner et al, 2014, in 
preparation). 
 
 
2.2.3.1 Preparation of solutions 
 
BH4 solution: 1.5 g ascorbic acid, 750 mg N-acetyl-L-cystein and 1.945 g BH4 (Ref. 
no. 11.212, Schircks laboratories, Jona, Switzerland) were diluted in 15 ml degassed 
ddH2O and aliquots were stored at -80°C until use. Biopterin concentration was 
determined by HPLC, and mice were orally fed with 100 mg/kg body weight per day 
by using a Gilson pipette (with yellow tips).  
 
CIII or CIV solution: 400 mg dimethylsulfoxid (DMSO), 360 mg glucose and 20.05 mg 
of CIII or CIV were diluted in total 4 ml ddH2O and aliquots were stored at -80°C until 
use. Mice were orally fed with 5 mg/kg body weight per day of CIII or CIV by using a 
Gilson pipette (with yellow tips).  
 
As negative control, mice were fed with the equally amount of ddH2O or 
DMSO/glucose solution. 
 
 
2.2.3.2 Gene (mRNA) expression studies 
 
Murine Drd1a-5, Ddc- and Igf-1-mRNA expression levels were performed using 
commercially available ABI assays (Mm.02620146 for mDrd 1a-mRNA, NCBI RefSeq 
NM_010076.2; Mm00438545_m1 for mDrd2-mRNA, NCBI RefSeq NM_010077.2; 
Mm00432887_m1 for mDrd3-mRNA, NCBI RefSeq NM_007877.1; Mm00432893_m1 
for mDrd4-mRNA, NCBI RefSeq NM_007878.2;  Mm00658653_s1 for mDrd5-mRNA, 
NCBI RefSeq NM_013503.1; Mm00516688_m1 for mDdc-mRNA, NCBI RefSeq NM_ 
001190448.1 and Mm00439560_m1 for mIgf-1-mRNA, NCBI RefSeq 
NM_001111274.1). The murine glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) mRNA (ABI assay ID: Mm99999915_g1; NCBI RefSeq NM_008084.2) was 
used to normalize the relative mRNA levels. Values were calculated as described in a 
published method (Livak and Schmittgen, 2001).  
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2.2.4 RESULTS 
 
2.2.4.1 Adult mice fed for 12 days with L-Dopa, BH4 and pharmacological 
chaperons CIII/IV 
 
11 weeks old Th-ki/ki mice were fed for 12 days either with 10.0/2.5 mg/kg/d L-
Dopa/carbidopa, or 100 mg/kg/d BH4, or 5 mg/kg/d pharmacological chaperons CIII 
or CIV. As controls, age matched Th-ki/ki and Th-wt/wt animals were loaded with 3 
ml/kg/d ddH2O. It was expected that at least CIII would stabilize and thus increase 
the TH activity or protein amount since it was shown that CIII stabilizes the human 
TH mutant R202H in vitro and led to an increase in TH activity and protein amount in 
wild-type mice (Calvo et al., 2010). Unfortunately, brain TH activity was difficult to 
measure probably due to the large content of catecholamines found in the wild-type 
mouse brains, which seems to inhibit the TH activity. In our preliminary TH activity 
determination approach, only CIV treated mice had significantly reduced brain TH 
activity in comparisons to wild-type animals (Fig. 9 A). Unexpected, none of the oral 
feeding compounds led to the increase of brain TH protein (Fig. 9 B). Only treatment 
with L-Dopa/carbidopa led to the improvement of norepinephrine (63 % of wt), HVA 
(110% of wt) and 5-HTP (54% of wt), as well as a strong increase in 3-O-methyldopa 
(3-OMD, 16,068% of wt), which is the indicator for a successful L-Dopa/carbidopa 
treatment (Fig. 9 C). In comparison to the 3 weeks L-Dopa treatment of Th-ki/ki mice, 
which were treated after birth (see chapter 2.1), the 12 days L-Dopa treatment in 
adult Th-ki/ki mice led to less restoration of the brain monoamine neurotransmitters 
and metabolites (Fig. 9 C). 
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Figure 9: Biochemical analysis of brain tissue from adult mice fed for 12 days with 10.0/2.5 mg/kg/d L-
Dopa/Carbidopa, 100 mg/kg/d BH4, 5 mg/kg/d pharmacological chaperons CIII or CIV, or 3 ml/kg/d 
ddH2O. (A) TH activity (pmol/min/mg protein). (B) TH protein (TH/GAPDH). (C) Monoamine 
neurotransmitters and metabolites (pmol/mg protein). Th-wt/wt treated with ddH2O shown in black; Th-
ki/ki treated with ddH2O shown in white; Th-ki/ki treated with L-Dopa/carbodopa shown in yellow; Th-
ki/ki treated with BH4 shown in green; Th-ki/ki treated with CIII shown in red; Th-ki/ki treated with CIV 
shown in blue. Significant difference from the corresponding wild-type values is indicated by asterisks: 
* p < 0.05, ** p <0.01, *** 0.001 (two-tailed Student’s t-test). 
 
The amount of biopterin in the brain was measured to confirm that the BH4 crosses 
the BBB in BH4 fed Th-ki/ki mice. Only Th-ki/ki mice fed with BH4 had significantly 
more (1.5 times) BH4 then wild-type control mice (Fig. 10). So far, there is no 
analytical method to detect pharmacological chaperon concentrations in brain or 
other tissues. 
 
 
 
 
 
 
 
 
 
Figure 10: Biopterin measurements in brain of 12 days fed mice with 10.0/2.5 mg/kg/d L-
Dopa/carbidopa, 100 mg/kg/d BH4, or 5 mg/kg/d pharmacological chaperons CIII, CIV or 3 ml/kg/d 
ddH2O (pmol/mg protein). Th-wt/wt treated with ddH2O shown in black; Th-ki/ki treated with ddH2O 
shown in white; Th-ki/ki treated with L-Dopa/carbodopa shown in yellow; Th-ki/ki fed with BH4 shown 
in green; Th-ki/ki treated with CIII shown in red; Th-ki/ki treated with CIV shown in blue. Significant 
difference from the corresponding wild-type values is indicated by asterisks: ***p < 0.001 (two-tailed 
Student’s t-test). 
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In the following, the influence of L-Dopa, BH4, CIII or CIV on gene expression was 
analyzed. Despite testing the BH4 cofactor depending genes mTh, mTph1 and 
mTph2, the mDrd1a (homolog to human Drd1), mDrd2-5, the mIgf-1 and mDdc were 
analyzed in brain tissue. A summary of the gene expression is summarized in table 1. 
 
Table 1: Gene expression (mRNA) in brain from Th-ki/ki and Th-wt/wt mice fed for 12 days with L-
Dopa, BH4, CIII and CIV. 
Treatment mTh-mRNA mTph1-mRNA mTph2-mRNA mIgf-1-mRNA mDdc-mRNA 
Th-ki/ki H20 (n=5) 1.00 (0.58-1.74) 1.00 (0.70-1.43) 1.00 (0.40-2.51) 1.00 (0.89-1.13) 1.00 (0.66-1.52) 
Th-wt/wt H20 (n=5) 0.74 (0.48-1.16) 1.15 (0.93-1.42) 1.96 (0.95-4.08) 0.90 (0.81-0.99) 0.93 (0.61-1.41) 
Th-ki/ki L-Dopa (n=5) 1.48 (0.89-2.46) 1.63 (0.84-3.17) 2.39 (1.06-5.41) 0.97 (0.89-1.08) 1.31 (0.83-2.01) 
Th-ki/ki BH4 (n=5) 1.11 (0.64-1.93) 0.97 (0.83-1.13) 3.74 (1.32-10.65)a 0.87 (0.82-0.92)b 1.13 (0.66-1.93) 
Th-ki/ki CIII (n=5) 1.27 (0.82-1.96) 0.98 (0.89-1.09) 6.36 (3.46-11.71)c 0.88 (0.79-0.98) 1.43 (1.14-1.80) 
Th-ki/ki CIV (n=5) 1.36 (0.72-2.56) 1.35 (0.86-2.14) 3.21 (1.11-9.28)a 0.95 (0.83-1.08) 1.31 (0.79-2.19) 
 
Treatment mDrd1a-mRNA mDrd2-mRNA mDrd3-mRNA mDrd4-mRNA mDrd5-mRNA 
Th-ki/ki H20 (n=5) 1.00 (0.94-1.06) 1.00 (0.87-1.14) 1.00 (0.87-1.15) 1.00 (0.73-1.37) 1.00 (0.81-1.23) 
Th-wt/wt H20 (n=5) 0.89 (0.73-1.09) 0.81 (0.60-1.09) 0.84 (0.62-1.16) 1.25 (0.82-1.90) 1.10 (0.87-1.41) 
Th-ki/ki L-Dopa (n=5) 0.66( 0.38-1.15) 1.11 (0.61-2.00) 0.94 (0.52-1.69) 0.86 (0.58-1.27) 0.64 (0.41-1.00)a 
Th-ki/ki BH4 (n=5) 0.47 (0.35-0.62)d 0.81 (0.61-1.08) 0.58 (0.31-1.11) 1.21 (0.89-1.66) 0.60 (0.45-0.79)c 
Th-ki/ki CIII (n=5) 0.59 (0.41-0.86)b 1.20 (0.80-1.81) 0.79 (0.37-1.72) 1.27 (0.82-1.96) 0.53 (0.45-0.61)d 
Th-ki/ki CIV (n=5) 0.66 (0.55-0.79) c 1.22 (0.99-1.51) 0.91 (0.64-1.30) 1.00 (0.65-1.55) 0.48 (0.41-0.56)d 
 
 
Th-ki/ki fed with ddH2O was set to 1. Significant difference from the corresponding Th-ki/ki control 
values: ap < 0.1, bp < 0.05, cp < 0.01, dp < 0.001 (two-tailed Student’s t-test).  
 
None of the oral treatments led to gene expression alteration of the mTh, mTph1 and 
mDdc. Contradictory to the published data, the BH4, CIII and CIV treatment let to 
increased mTph2 expression (Calvo et al., 2010). Furthermore, the BH4, CIII, CIV 
and L-Dopa treatment led to decreased mDrd1a and/or mDrd5 gene expression 
whereas the mDrd2-4 were not altered. Generally, mIgf-1 gene expression is not 
different in Th-ki/ki mouse brains but the BH4 treatment led to lower mIgf-1 gene 
expression.  
 
To investigate if there is any improvement in motor function when treated with 
10.0/2.5 mg/kg/d L-Dopa/carbidopa or 5 mg/kg/d CIII (BH4 and CIV were not 
investigated), mice were tested for catalepsy by the bar test and their motor 
coordination by the rotarod test (Fig.11 A-D). Th-wt/wt and Th-ki/ki mice were fed at 
the age of 6 weeks with either L-Dopa or CIII. As control wild-type and Th-ki/ki mice 
were fed either with ddH2O (L-Dopa control group) or DMSO/glucose solution (CIII 
control group). 
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Figure 11: Catalepsy (bar test) and motor coordination (rotarod test) of adult mice fed for 12 days with 
10.0/2.5 mg/kg/d L-Dopa or 3 ml/kg/d ddH2O, and 5 mg/kg/d CIII or 1 ml/kg/d DMSO/glucose solution 
(control solution). (A) Bar test treated with L-Dopa or ddH2O (sec). (B) Rotarod test treated with L-
Dopa or ddH2O (sec). (C) Bar test treated with CIII or control solution (sec). (D) Rotarod test treated 
with CIII or control solution (sec). Th-wt/wt treated with ddH2O/control solution are shown in black; Th-
wt/wt treated with L-Dopa/CIII are shown in black-white stripes; Th-ki/ki treated with ddH2O/control 
solution are shown in gray; Th-ki/ki treated with L-Dopa/CIII are shown in gray-white stripes; ***p < 
0.001 (two-tailed Student’s t-test). 
 
Neither the L-Dopa nor CIII treatment improved the catalepsy symptom or enhanced 
the motor coordination in Th-ki/ki mice. In comparison to the Th-ki/ki mice, wild-type 
mice showed significant better performances in both tests independent from the 
treatment. 
 
In summary, only the L-Dopa treatment led to improvement in the brain monoamine 
neurotransmitters and none of the treatments had any positive effect on their motor 
function. Gene expression revealed alteration of mTph2, mDrd1a/5 and/or mIgf-1 
when treated with L-Dopa, BH4, CIII or CIV. 
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Neurotransmitters:  Newborns  fed for 3 weeks with CIII 
TH protein: Newborns fed for 3 weeks with CIII
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2.2.4.2 Newborn mice fed for 3 weeks with the pharmacological chaperon CIII  
 
As described in chapter 2.1, L-Dopa treatment over a period of 12 days of adult Th-
ki/ki mice showed less improvement in brain monoamine neurotransmitters in 
comparison to newborn mice treated for a period of 3 weeks. Furthermore, treatment 
with CIII over a period of 12 days showed also no effect on brain catecholamines. 
Similarly as for the L-Dopa treatment, newborn Th-ki/ki mice were fed in a next step 
for 3 weeks with CIII, in order to exclude that treatment duration or age of mice 
diminish a potential positive therapeutic effect of CIII. Again difficulties in TH activity 
measurements led to none reliable results showing no difference in brain TH activity 
between Th-ki/ki and wild-type mice, independent from the treatment (Fig. 12 A). 
There was no increase of brain TH protein for Th-ki/ki or wild-type mice treated with 
CIII (Fig. 12 B). In addition, there was no improvement in brain monoamine 
neurotransmitters for Th-ki/ki or wild-type mice treated with CIII (Fig. 12 C). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Biochemical analysis of brain from newborn mice fed for 3 weeks with 5 mg/g body weight 
of the pharmacological chaperons CIII. (A) TH activity (pmol/min/mg protein). (B) TH protein 
(TH/GAPDH). (C) Brain neurotransmitters (pmol/mg protein). Th-wt/wt mice treated with ddH2O are 
shown in black; Th-wt/wt mice treated with CIII are shown in black-white striped; Th-ki/ki mice treated 
with ddH2O are shown in gray; Th-ki/ki mice treated with CIII are shown in gray-white striped. 
Significant difference from the corresponding wild-type values is indicated by asterisks: * p < 0.05, ** p 
<0.01, *** 0.001 (two-tailed Student’s t-test). 
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Although, there was no significant improve in brain neurotransmitters the mice were 
tested for their catalepsy behavior and motor coordination (Fig. 13 A-B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Catalepsy (bar test) and motor coordination (rotarod test) of newborn mice fed for 3 weeks 
with CIII. (A) Bar test (sec). (B) Rotarod test (sec). Th-wt/wt mice treated with control solution are 
shown in black; Th-wt/wt mice treated with CIII are shown in black-white stripes; Th-ki/ki mice treated 
with control solution are shown in gray; Th-ki/ki mice treated with CIII are shown in gray-white stripes; 
***p < 0.001 (two-tailed Student’s t-test). 
 
The early and longer treatment with CIII did not lead to any improvement in the 
catalepsy symptom or the motor coordination in Th-ki/ki mice. In comparison to the 
Th-ki/ki mice, normal wild-type mice showed significant better performances in both 
tests independent from the treatment. 
 
Adult mice fed for 12 days with CIII showed increased mThp2 and decreased 
mDrd1a and mDrd5 mRNA-expression in the brain. Therefore, it was investigated if 
prolonged and earlier initiated CIII treatment in newborns would also lead to similar 
mRNA-expression alterations.  Results are shown in table 2. 
 
Table 2: Gene expression (mRNA) in brain from Th-ki/ki and wild-type mice fed for 3 weeks with CIII.   
 
Treatment mTh-mRNA mTph1-mRNA mTph2-mRNA mIgf-1-mRNA 
Th-ki/ki control (n=5) 1.00 (0.46-2.16) 1.00 (0.70-1.42) 1.00 (0.49-2.03) 1.00 (0.82-1.22) 
Th-ki/ki CIII (n=5) 1.03 (0.54-1.96) 1.22 (0.92-1.63) 0.14 (0.03-0.71)
a 1.04 (0.77-1.42) 
Th-wt/wt control (n=5) 1.34 (0.78-2.32) 1.57 (1.32-1.85)
b 0.81 (0.24-2.70) 0.71 (0.63-0.79)c 
Th-wt/wt CIII (n=5) 0.94 (0.76-1.15) 1.23 (0.90-1.68) 0.31 (0.13-0.76)
a 0.75 (0.66-0.84)b 
 
Treatment mDrd1a-mRNA mDrd2-mRNA mDrd3-mRNA mDrd4-mRNA mDrd5-mRNA 
Th-ki/ki control (n=5) 1.00 (0.77-1.31) 1.00 (0.62-1.62) 1.00 (0.78-1.28) 1.00 (0.74-1.36) 1.00 (0.82-1.22) 
Th-ki/ki CIII (n=5) 1.13 (0.76-1.68) 1.33 (0.82-2.18) 1.01 (074-1.38) 0.83 (0.56-1.22) 0.90 (0.58-1.41) 
Th-wt/wt control (n=5) 1.02 (0.69-1.52) 1.27 (0.74-2.20) 1.07 (0.41-2.79) 0.52 (0.35-0.78)
b 1.26 (0.94-1.69) 
Th-wt/wt CIII (n=5) 1.03 (0.77-1.38) 1.51 (1.00-2.28) 1.06 (0.63-1.81) 1.05 (0.76-1.39) 0.76 (0.58-0.98)a 
 
Th-ki/ki fed with control solution was set to 1. Significant difference from the corresponding Th-ki/ki 
control values: ap < 0.1, bp < 0.05, cp < 0.01, (two-tailed Student’s t-test).  
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The prolonged CIII treatment did not alter the mTh-mRNA expression in the Th-ki/ki 
and wild-type mice. Surprisingly, the three weeks treated mice did not mirror the 
same mRNA-expression alterations seen in adult mice treated for 12 days. Th-ki/ki 
and wild-type mice fed for three weeks with CIII showed reduced mTph2-mRNA 
expression levels whereas the 12 days treatment in adult Th-ki/ki mice showed 
increased mTph2-mRNA expression. Furthermore, Th-wt/wt mice fed with CIII had 
significant increased mTph1-mRNA expression. The prolonged CIII treatment did not 
alter the mDrd1a-3 mRNA-expression. Wild-type but not Th-ki/ki mice fed with CIII 
presented significant reduced mDrd5-mRNA expression levels as seen before in 12 
days CIII treated adult Th-ki/ki mice. Furthermore, there is the indication that 3 weeks 
old Th-ki/ki mice might have higher Drd4-mRNA expression then corresponding wild-
type animals. Unexpected, Th-ki/ki mice showed independent from the oral feeding 
increased mIgf-1 gene expression in comparison to wild-type mice. These results are 
contradictory to the results found in adult mice were brain mIgf-1 gene expression 
was not different from wild-type mice. 
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2.2.5 DISCUSSION 
 
Overall, it was shown that the 12 days oral treatment with potential TH chaperons 
BH4, or CIII/IV had no effect on brain mTh gene expression and translation, TH 
activity, monoamine neurotransmitter restoration or motor function in Th-ki/ki mice 
independent from their age or feeding duration. Only the L-Dopa/carbidopa treatment 
showed again some improvement in the catecholamines, although it was less 
efficient then the 3 weeks treatment started after birth. It is unknown, if a prolonged 
treatment in adult mice would lead to similar improvement or if the effect of L-Dopa is 
also age dependent. So far, it could have been validated that the additional applied 
BH4 reached the mouse brain. Although BH4 passed the BBB and thus reached the 
brain, there was no improvement in the catecholamines. Unfortunately there was no 
method available to quantify the amount of CIII or CIV in the brain to show that these 
compounds can cross the BBB reaching the TH. The Th-p.R203H mutation leads to 
highly destabilization of the TH protein. So far, it is unknown if a chaperon can 
stabilize this fragile mutant protein or if higher concentrations would improve the TH 
stability leading to more activity. It is highly likely that the mutant TH is too severe 
affected that stabilization would be possible.  
 
No alterations in the brain mTh, mTph1/2, mDrd1a-5, or mDdc gene expression was 
found in Th-ki/ki mice in comparison to wild-type animals. Surprisingly, treatment with 
BH4, CIII or CIV increased brain mTph2 (321-636% of wt) gene expression in adult 
Th-ki/ki mice fed for 12 days but not in 3 weeks treated animals. Brain mTph1-RNA 
expression was only significant increased in wild-type animals when fed for 3 weeks 
with CIII. The through CIII or IV altered mTph1/2 gene expression stays in contrary to 
the published data about CIII/CIV, where no alteration in mTph1/2 gene expression 
was reported (Calvo et al., 2010). It was already described that supplementation of 
BH4 leads to increased mTPH2 activity in vitro (Yang and Kaufman, 1994). Therefore, 
it would be interesting to measure mTPH2 activity in BH4, CIII or CIV treated Th-ki/ki 
mice. Elevated expression of mTph2 mRNA at the neuronal level was associated 
with increased anxiety-like behavior in mice and depressed suicides in humans (Hiroi 
et al., 2006, Bach-Mizrachi et al., 2008, Lowry et al., 2008). In contrast, 
polymorphisms in mTph2 were associated with the attention-deficit hyperactivity 
disorder. So far, it has been reported that there are no side effects caused by long-
term administration of BH4 (Cerone et al., 2004, Hennermann et al., 2005). Still the 
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question arises if through BH4, CIII or CIV treatment induced increased expression of 
mTph2 would lead to an anxiety-like or depressive behavior in the Th-ki/ki mice. 
 
L-Dopa, BH4, CIII or CIV treatments led to decreased gene expression of brain 
mDrd1a (47-66% of wt), mDrd5 (48-64% of wt) and/or mIgf-1 (87% of wt) in 12 weeks 
old Th-ki/ki mice. It is unknown why the oral feeding of the substances led to this 
gene expression alterations. It was shown that D1A-/- mutant mice are growth 
retarded and die shortly after weaning unless their diet was supplemented with 
hydrated food, but they exhibit normal coordination and locomotion (Drago et al., 
1994). In contrast, D5-/- mutant mice had a normal development but increased 
sympathetic tone and were hypertensive (Hollon et al., 2002). Further studies are 
needed to be done to elucidate the question if dopamine receptors are equally 
influenced in wild-type mice by the BH4 or CIII/IV treatment as seen in Th-ki/ki mice. 
 
The investigated mIgf-1 gene expression revealed that 3 weeks old Th-ki/ki mice 
seems to have increased mIgf-1 gene expression in comparison to wild-type mice, 
which was not the case in 12 weeks old Th-ki/ki mice, which also had normal serum 
IGF-1 levels (see chapter 2.1). The anabolic IGF-1 is synthesized in almost all 
tissues, dominantly in the liver which is the main contributor to serum IGF-1. IGF-1 is 
an important mediator for cell growth, differentiation, and transformation 
(Delafontaine et al., 2004). Studies with growth hormone (GH) depleted Ghr−/− mice 
showed that serum IGF-1 was as low as approximately 0.2% of the normal level. 
Therefore, serum IGF-1 levels are GH-dependent, excluding all tissues in which Igf-1 
expression is GH-independent, such as the skeletal system, brain, lung, heart, 
spleen, testis, and uterus (Stratikopoulos et al., 2008). Therefore, the brain mIgf-1 
gene expression does not influence serum IGF-1 levels. It was demonstrated that 
IGF-I plays has a highly distinctive pattern of gene expression during brain 
development and is essential for both fetal and postnatal CNS growth and 
development (Bondy, 1991, Netchine et al., 2009). In vitro and in vivo studies have 
demonstrated that IGF-1 stimulates mitosis in sympathetic neuroblasts, promotes 
embryonic neuronal survival and neurite outgrowth in cultured sensory, sympathetic, 
cortical, and motor neurons, induce oligodendrocyte differentiation, and is involved in 
dendritic maturation, synaptogenesis, and myelinization (Bondy, 1991). One of the 
many effects of IGF-1 in the CNS is promoting neuronal survival through activation of 
the PI3K/Akt pathway. It was shown that astrocyte-specific overexpression of IGF-1 
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protects hippocampal neurons and reduces behavioral deficits following traumatic 
brain injury in mice (Madathil et al., 2013). Transgenic mice that overexpress IGF-I 
exhibit marked brain overgrowth postnatally, whereas transgenic mice with ablated 
IGF-I gene expression have brain growth retardation (Calikoglu et al., 2001). 
Furthermore, studies of transgenic mice that overexpress IGF-I exclusively in the 
CNS, showed an increase in cerebellar granule cell number that appeared to be 
attributable predominantly to enhanced survival (Chrysis et al., 2001). It can be 
hypothesized that young Th-ki/ki mice might have overexpressed IGF-1 in brain to 
compensate the potential negative influence on brain development due to the TH 
deficiency. Further analysis of gene expression of unmature and developing mice 
should be done to further study Igf-1 expression in brain and peripheral tissues and 
IGF-I levels should be determined in the plasma. Furthermore, BH4 treated Th-ki/ki 
mice had slightly compromised mIgf-1 gene expression (87% of wt). There are no 
studies describing any correlation of BH4 on mIgf-1 gene expression, and therefore it 
is suggested to increase the cohort of mice to verify these results. 
 
Overall, gene expression was not altered equally in two CIII treatment studies. Adult 
Th-ki/ki mice with 12 days treatment had more expression alterations in the 
investigated genes then juvenile mice fed for 3 weeks. It is highly likely that gene 
expression in the young mice cohort is more variable since the 3 weeks mice are still 
developing to become mature. Therefore, there are higher variations in the gene 
expressions, which may impede to find differences in small cohorts. It is also 
debatable if mRNA-expression is only short-term altered and stabilizes after time. 
Since it is not possible yet to measure the amount of CIII in the brain, it makes it 
more difficult to interpret the current data. More studies could be done to investigate 
further this phenomenon.  
 
Still a huge challenge for the severe from of THD is in fact that although there is an 
improvement in brain monoamine neurotransmitters by L-Dopa/carbidopa treatment, 
there is no change in motor function probably due to prenatal developed lack of 
projection into the striatum, which plays an important role in planning and modulation 
of movement pathways (Voytek and Knight, 2010). Further oral treatment studies 
could investigate if projection into the striatum in Th-ki/ki mice increases and 
therefore, also their motor functions, when Th-ki/ki mice are already treated with L-
Dopa/carbidopa, BH4, or CIII/IV prenatal. 
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2.3 INVESTIGATION OF A GENE THERAPEUTIC APPROACH 
TARGETING THE LIVER USING AAV TO RESTORE THE BRAIN 
CATECHOLAMINE IN TH-KI/KI MICE 
 
 2.3.1 ABSTRACT 
 
The standardized treatment of 10 mg/kg/d L-Dopa in combination with 25% 
carbidopa could restore the lowered brain monoamine neurotransmitter concentration 
in Th-ki/ki mice but it did not improve the motor behavior. In this chapter it was 
attempted to correct the altered motor function in Th-ki/ki mice by a different 
approach, i.e. hepatic rAAV2/8 gene transfer of the mTh-cDNA expressed from the 
(artificial) liver specific promoter P3. The transgenic TH enzyme, expressed from the 
rAAV2/8 transduced hepatic cells, was expected to lead to the conversion of L-Tyr to 
L-Dopa in the periphery, i.e. liver. To prevent peripheral degradation of L-Dopa, the 
AADC inhibitor carbidopa was added to the drinking water during an experimental 
period of three weeks. After this treatment, mice were investigated for their motor 
function by bar and rotarod tests showing no improvement. Whole brain monoamine 
neurotransmitters revealed no restoration. Evaluation of the vector copy number in 
the hepatic cells revealed efficient transduction of the rAAV2/8 and mTh-mRNA 
expression was confirmed. TH activity in brain was unchanged. The protein amount 
in liver and brain is still under investigation. 
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2.3.2 INTRODUCTION 
 
The severe form of THD is difficult to treat and side effects can occur like 
dyskinesias, gastrointestinal side effects or hypersensitivity of the L-Dopa therapy as 
well as from other dopaminergic agonists (Furukawa, 2003, Hoffmann et al., 2003). 
Th-ki/ki mouse studies showed that oral application of L-Dopa for a limited period of 
12 days or 3 weeks improved or normalized the brain catecholamines but did not 
corrected their motor function (described in chapter 2.1 and 2.2). As an alternative to 
oral loading, experimental gene therapy to potentially correct THD was attempted 
next then AAV mediated gene expression in brain is a widely used approach in 
preclinical studies (Fig. 14). 6-OHDA lesioned rats (PD model) applicated with AAV 
vectors expressing hTH in the brain had long-term recovery of striatal expression of 
mRNA, TH enzyme activity, extracellular dopamine concentration and behaviour 
(Chakrabarty et al., 2013, During et al., 1994). Although this approach was 
successful, the use of AAV as a vector for gene therapy to targeting the brain is quite 
invasive approach with unknown risks. Therefore, it was investigated whether 
targeting of the Th-ki/ki mouse liver with a rAAV2 serotype 8 vector expressing mTh 
from a liver-specific synthetic promoter P3, lead to the production of L-Dopa 
synthesis in the periphery (Fig. 14) (Viecelli et al., 2014). Analog to oral L-Dopa 
treatment for patients, carbidopa needs to be given in addition to prevent peripheral 
conversion, i.e. degradation to dopamine by the enzymatic reaction of AADC (Fig. 
14). It is assumed that the in liver produced L-Dopa lead to the restoration of the 
brain catecholamines and the motor function in the Th-ki/ki mice. 
 
 
 
 
 
 
 
 
 
 
Figure 14: Schematic representation of viral gene therapeutic approach for Th-ki/ki mice. L-Tyr, L-
tyrosine; mTh, tyrosine hydroxylase cDNA. 
mTh 
Experimental liver gene transfer to Th-ki/ki mice: 
  
Conventional treatment of patients with THD:  
Oral application:
-L-Dopa
(+ carbidopa) 
L-Tyrà L-Dopa
(+ carbidopa)
L-Dopa
L -Dopa à Dopamine
L -Dopa à Dopamine
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2.3.3 MATERIALS AND METHODS 
 
In the following, additional methods are described that are not present in chapter 2.1 
or 2.2 with the general description of the Th-ki mouse model (Korner et al, in 
preparation). 
 
 
2.3.3.1 Generation of the AAV vector  
 
The mTh cDNA (transcript ID: ENSMUST105929) was synthesized by GeneArt® Life 
technology (Regensburg, Germany). This synthesized mTh cDNA sequence was 
used to generate the viral vector AAV2-Th. 
 
 
2.3.3.2 Production of rAAV 
 
rAAV was produced in collaboration with Cary O. Harding and Shelley Winn from 
Oregon Health & Science University (Oregon, Portland, USA) (Grieger et al., 2006). 
 
 
2.3.3.3 Application of rAAV2/8 and carbidopa 
 
Three weeks old Th-ki/ki or wild-type mice were i.p. injected with 2 x 1012 vector 
particles (vp) AAV2/8-Th or saline using a U-100 insulin syringe with a 28G needle. 
One tablet of 25 mg carbidopa (Lodosyn®; ATON Pharma Inc., New York, USA) was 
diluted in 125 ml drinking water (200 mg/l) and applied to the mice ad libitum. 
 
 
2.3.3.4 Copy number assay 
 
The copy number per diploid genome was measured as described in the published 
methods (Lu et al., 2012, Viecelli et al., 2014). The primers used in the quantitative 
PCR analysis correspond to the WPRE and are published (Ding et al., 2006). 
 
 
2.3.3.5 Gene (Th-mRNA) expression study 
 
Mouse Th-mRNA expression levels were performed using commercially available 
ABI assay (Mm00447553_g1; NCBI RefSeq NM_009377.1). Values were calculated 
as described in chapter 2.1 or 2.2. 
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2.3.4 RESULTS 
 
For the liver specific gene therapy for the Th deficient mice, the following AAV2 
vector expressing mTh was generated (AAV2-Th), which is schematically 
represented in Fig. 15. The transgene cassette was expressed by the liver specific 
P3 promoter (minimal transthyretin promoter, TTRmin, coupled to a de novo designed 
hepatocyte-specific cis-regulatory module 8, HS-CRM 8) (Viecelli et al., 2014). The 
woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was added 
downstream of the mTh sequence to enhance the transgene transcription. 
 
 
   
Figure 15: Schematic representation of the AAV2-Th vector. P3, minimal TTRmin coupled to a de novo 
designed HS-CRM 8; mTh, murine tyrosine hydroxylase cDNA; WPRE, woodchuck hepatitis virus 
posttranscriptional regulatory element; pA, poly A tail; I, inverted terminal repeats. 
 
Th-ki/ki or wild-type mice were i.p. injected with either 2 x 1012 vp of the recombinant 
AAV2/8-Th (rAAV2/8-Th) or saline. Mice were kept for three weeks under 200 mg/l 
carbidopa in the drinking water ad libitum. Brain lysate was analyzed for their TH 
activity and brain monoamine neurotransmitters (Fig. 16 A-C). As expected, Th-ki/ki 
mice had significant lower TH activity in the brain than wild-type animals independent 
from the treatment (Fig. 16 A). In general, the rAAV-Th treated mice did not have 
higher TH activity in liver (Fig. 16 B). In contrast, saline treated Th-ki/ki mice had 
significant higher TH activity than the wild-type mice for unknown reasons (Fig. 16 B). 
There was no improvement in brain monoamine neurotransmitters in the rAAV2/8-Th 
injected Th-ki/ki mice although it seems that saline treated Th-ki/ki mice had 
significant lower 3-OMD levels in comparison to the other groups (Fig. 16 C). 
Alterations of 3-OMD in Th-ki/ki mice was not described yet.  
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Figure 16: Biochemical analysis of rAAV2/8-Th or saline treated Th-ki/ki or Th-wt/wt mice. (A) Brain 
TH activity (pmol/min/mg protein). (B) Liver TH activity (pmol/min/mg protein). (C) Brain 
neurotransmitters (pmol/mg protein). Th-wt/wt mice injected with saline are represented in black; Th-
wt/wt mice injected with rAAV2/8-Th are represented in black-white stripes; Th-ki/ki mice injected with 
saline are represented in gray; Th-ki/ki mice injected with rAAV2/8-Th are represented in gray-white 
stripes. Significant difference from the corresponding wild-type values is indicated by asterisks: * p < 
0.05, ** p <0.01, *** 0.001 (two-tailed Student’s t-test). 
 
Gene therapy treated mice also showed no improvement in there motor behavior 
(Fig. 17 A-B). 
 
 
 
 
 
 
 
 
Figure 17: Catalepsy (bar test) and motor coordination (rotarod test) of gene therapy treated mice. (A) 
Bar test (sec). (B) Rotarod test (sec). Th-wt/wt mice injected with saline are represented in black; Th-
wt/wt mice injected with AAV2/8-Th are represented in black-white stripes; Th-ki/ki mice injected with 
saline are represented in gray; Th-ki/ki mice injected with AAV2/8-Th are represented in gray-white 
stripes; ***p < 0.001 (two-tailed Student’s t-test). 
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To determine if the AAV2/8-Th vector was present in the liver, the average number of 
vector genomes per diploid hepatocyte and the Th-mRNA expression in all liver cells 
was calculated (table 3) (Livak and Schmittgen, 2001, Lu et al., 2012, Viecelli et al., 
2014).  
 
Table 3: DNA copy number per diploid genome and mTh-mRNA transgene expression of rAAV2/8-Th 
treated mice. 
Genotype Treatment DNA copy number/diploid genome mTh-mRNA* 
    
Th-wt/wt (n=4) saline n.a. 1.0 (0.8-1.3) 
    
Th-wt/wt (n=3) rAAV2/8-Th 6.8 ± 5.6 7,383.0 (2,635.0-20,685.0) a 
    
Th-ki/ki (n=4) saline n.a. 1.1 (0.8-1.5) 
    
Th-ki/ki (n=4) rAAV2/8-Th 8.8 ± 2.8 24,902.5 (21,288.7-29,129.6)a 
 
n.a., not applicable; * mTh-mRNA gene expression was normalized to Gapdh and Th-wt/wt treated 
with saline was set to 1. Significant difference from the corresponding wild-type values: ap< 0.001 (two-
tailed Student’s t-test). 
 
Both, rAAV2/8-Th treated wild-type and Th-ki/ki mice had detectable amount of 
vector-DNA in the liver. There was no significant difference in the DNA copy number 
per diploid genome between AAV2/8-Th treated wild-type and Th-ki/ki mice. As 
shown in table 3, between 6-9 copies per hepatocyte were detected 21 days after 
rAAV2/8-Th injection. The liver mTh-mRNA gene expression analysis showed 
between 7,000-25,000 folds increase in mTh-mRNA expression in rAAV2/8-Th 
injected mice. Th-ki/ki mice treated with rAAV2/8-Th had significant higher liver mTh-
mRNA expression then rAAV2/8-Th applicated wild-type mice (p<0.05). Furthermore, 
rAAV2/8-Th treated Th-ki/ki and Th-wt/wt mice had in average almost 57 (p<0.001) 
and 17 (p<0.001) times more mTh-mRNA expression (quantitative measurement), 
respectively, in comparison to mTh-mRNA expression levels found in untreated wild-
type mouse brains.  
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2.3.5 DISCUSSION 
 
The rAAV2/8-Th treated wild-type and Th-ki/ki mice showed significantly increased 
liver mTh-mRNA expression, which was between 17-57 times relative higher than 
mTh expression found in wild-type mouse brains. Changes in TH protein amount in 
liver still needed to be analyzed. Although mTh was very high expressed in the liver, 
there was no increase in the hepatic TH activity and therefore, there was no improve 
of brain monoamine neurotransmitter deficiency in Th-ki/ki mice. Higher viral dosages 
or different application methods could be tested. It was reported that intravenous virus 
application through the tail vein led to higher transgene expression in liver in 
comparison to i.p. injection (Dane et al., 2013). In the here presented study, the AAV-
Th vector was delivered via i.p. injections, which might explain the relative low 
hepatic copy number of vector genomes. It is also possible that, although mRNA is 
expressed, the transcript was not translated into a protein sequence. Further 
analyses, including for instance Western blot, are necessary to rule out a potential 
translation problem and to proof that the lack of hepatic TH protein activity is 
responsible for the absence of increased brain L-DOPA following liver directed gene 
therapy. Low mRNA expression might be caused inefficient transport from the 
nucleus into the cytoplasm for translation. In this context, it has been shown that 
insertion of intronic sequence into a transgene cassette increases mRNA expression 
by supporting the delocalization of mRNA from the nucleus into the cytoplasm for 
translation (Buchman and Berg, 1988, Palmiter et al., 1991). Therefore, insert of an 
intron into the TH vector sequence might be beneficial to improve transgene 
expression. Furthermore, the ad libitum application method of adding carbidopa in 
the drinking water had the advantage that the mice receive carbidopa constantly but 
has the disadvantage that it was difficult to monitor their exact intake.  It is also 
unknown how stable diluted carbidopa is over time. To avoid this unsteady 
administration of carbidopa, future rAAV gene therapeutic approaches should be 
directly applied to the brain. The successful delivery of rAAV into the mouse brain 
was described by either direct brain targeting of by peripheral injection through 
intracardiac administration route or by the intravenously by the superficial temporal 
vein (Rahim et al., 2011, Iwata et al., 2013, von Jonquieres et al., 2013). 
Furthermore, intravenously injection of rAAV2/9 into fetal mice via vitelline vessels to 
target the CNS was described (Rahim et al., 2011). The advantage of the 
intracardiac method is that the whole brain can be reached and not only restricted 
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brain areas (Iwata et al., 2013). The application method also depends on the age of 
the mice. Injections of neonates can be so far only performed by direct injection into 
the brain (Kim et al., 2013). Intracerebroventricular injection with rAAV2/1 on 
neonatal day P0 results in widespread CNS expression, whereas the biodistribution 
is limited if injected beyond neonatal day P1 (Chakrabarty et al., 2013). Also the 
choice of the AAV capsid serotype can influence the distribution if the rAAV in the 
brain: it was demonstrated that rAAV2/8 and 2/9 resulted in the most widespread 
biodistribution in the brain (Chakrabarty et al., 2013). In contrast, rAAV2/5 showed 
very limited brain transduction after neonatal injection (Passini et al., 2003). 
Furthermore, the biodistribution of most serotypes varying depending on the day of 
injection, like e.g. injection on neonatal day P0 resulted in mostly neuronal 
transduction, whereas administration between 24-84 hours postnatal resulted in more 
non-neuronal transduction (Chakrabarty et al., 2013). It was shown that a single 
rAAV2/1 intraventricular injection led to live long treatment in a β-glucuronidase-
deficient mouse model (mucopolysaccharidosis type VII) (Passini et al., 2003). 
Furthermore, it was described that rAAV2/8 achieved higher level of gene transfer to 
the central CNS upon intraventricular injection in neonatal mice compared to rAAV2/1 
and rAAV2/2 (Broekman, 2005). Another application for targeted gene delivery is the 
in vivo electroporation of CNS, which can also be used to apply non-viral vectors 
(Saito, 2006, De Vry et al., 2010). Still AAV injection into the neonatal mouse brain 
accesses more regions of the brain including the cerebellum and brainstem that have 
been difficult to target by electroporation (Kim et al., 2013). Nevertheless, new AAV 
are described that have smaller and optimized AAV expression cassettes, which 
showed improved packaging capacity and transgene expression in neurons and 
would therefore, also increase rAAV efficacy (Choi et al., 2014). A phase 1 study of 
intrastriatal infusion of AAV encoding human AADC in subjects with PD was already 
tested (ClinicalTrials.gov, number: NCT00229736). Another phase 1 PD study 
showed the safety and tolerability of gene therapy with a rAAV expressing the 
glutamic acid decarboxylase (GAD) gene (ClinicalTrials.gov, number: NCT00195143). 
Multicistronic vector-mediated striatal gene transfer of TH, AADC, and GTPCH 
resulted in more effective dopamine production and more remarkable behavioural 
recovery in 6-OHDA lesioned Parkinsonian rats compared with the expression of TH 
alone (Fan et al., 1998). Furthermore, non-viral gene therapy of 6-OHDA lesioned 
Parkinsonian rats using a TH expression plasmid encapsulated inside a pegylated 
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immunoliposome led to increased TH enzyme activity and TH immunocytochemistry 
showed that the entire striatum was immunoreactive for TH after the intravenous 
gene therapy (Zhang et al., 2003).  
 
Taken together, rAAV gene treatment by targeting the brain of neonatal Th-ki/ki mice 
would be a considerable approach to treat the monoamine neurotransmitter 
deficiency and the motor deficiency, and therefore, it would be a potential treatment 
for THD patients. 
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ABSTRACT 
 
OBJECTIVE: Tetrahydrobiopterin (BH4) is an essential cofactor for the aromatic 
amino acid hydroxylases, alkylglycerol monooxygenase and nitric oxide synthases 
(NOS). Inborn errors of BH4 metabolism lead to severe insufficiency of brain 
monoamine neurotransmitters while augmentation of BH4 by supplementation or 
stimulation of its biosynthesis is thought to ameliorate endothelial NOS (eNOS) 
dysfunction, to protect from (cardio-) vascular disease and/or prevent obesity and 
development of the metabolic syndrome. We have previously reported that 
homozygous knock-out mice for the 6-pyruvolytetrahydropterin synthase (PTPS; Pts-
ko/ko) mice with no BH4 biosynthesis die after birth.  
RESEARCH DESIGN: Here we generated a Pts-knock-in (Pts-ki) allele expressing 
the murine PTPS-p.Arg15Cys with low residual activity (15% of wild-type in vitro) and 
investigated heterozygous (Pts-ki/wt), homozygous (Pts-ki/ki) and compound 
heterozygous (Pts-ki/ko) mutants.  
RESULTS: Mice were viable and, depending on the severity of the Pts alleles, 
exhibited up to 90% reduction of PTPS activity in liver and brain. Although (brain and 
liver) neopterin was significantly elevated, BH4, blood L-phenylalanine and brain 
monoamine neurotransmitters dopamine were apparently unaffected. Yet, Pts-ko/wt 
and Pts-ki/ki mice exhibited increased body weight and elevated intra-abdominal fat 
tissue. Comprehensive phenotyping of Pts-ki/ki mice revealed alterations in energy 
metabolism, higher fat content, lower lean mass, and increased blood glucose and 
cholesterol. Transcriptome analysis indicated changes in glucose and lipid 
metabolism. Furthermore, differentially expressed genes associated with obesity, 
weight loss, hepatic steatosis and insulin sensitivity were consistent with the 
observed phenotypic alterations. 
CONCLUSION: We conclude that reduced PTPS and potentially mildly compromised 
BH4-biosynthetic activity in mice leads to abnormal body fat distribution and 
abdominal obesity. This study associates a novel single gene mutation with 
monogenic forms of obesity. 
 
Key words: Tetrahydrobiopterin, endothelial dysfunction, eNOS/NOS3, neopterin, 
metabolic syndrome, monogenic obesity 
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INTRODUCTION 
 
Tetrahydrobiopterin (BH4) is synthesized de novo from guanosine triphosphate (GTP) 
by the three enzymes GTP cyclohydrolase I (GTPCH), 6-pyruvoyltetrahydropterin 
synthase (PTPS) and sepiapterin reductase (SR)1. BH4 is an essential cofactor for 
the aromatic amino acid monooxygenases, i.e. the phenylalanine hydroxylase (PAH), 
the tyrosine hydroxylase (TH) and the two tryptophan hydroxylases (TPH1, TPH2). 
Besides providing L-tyrosine (L-Tyr) for protein and catecholamine biosynthesis, the 
major role of the hepatic PAH is the prevention from systemic L-phenylalanine (L-
Phe) accumulation, which is toxic in the brain. TH and TPH1/2 are the key enzymes 
in the biosynthesis of L-3,4-dihydroxyphenylalanine (L-Dopa) and 5-hydroxy-L-
tryptophan (5-HTP), respectively. BH4 is also a cofactor for the three nitric-oxide 
synthases (NOS) isoenzymes neuronal NOS (nNOS/NOS1), cytokine-inducible NOS 
(iNOS/NOS2) and endothelial NOS (eNOS/NOS3) for nitric oxide production as well 
as for the alkylglycerol monooxygenase (AGMO) which catalyzes the hydroxylation of 
alkylglycerols or ether lipids1. 
 
BH4 deficiency is a heterogeneous group of rare disorders associated with a 
spectrum of phenotypes ranging from mild, peripheral symptoms including 
hyperphenylalaninemia (HPA) due to lowered hepatic PAH activity to severe 
morbidity due to compromised monoamine neurotransmitter synthesis by dysfunction 
of TH and TPH in the brain2. Oral supplementation with BH4 - in combination with 
neurotransmitter precursors - has been successfully employed to treat patients. 
Besides cofactor for the aromatic amino acid hydroxylases, BH4 is an intracellular 
antioxidant and a key regulator of cellular redox signaling, and conditions of low BH4 
for NOS lead to NOS uncoupling and production of superoxide rather than NO1, 3. 
Since NO is required to maintain vascular function, limited bioavailability of the NOS 
cofactor BH4 is associated not only to cell toxicity but also to vascular dysfunction3. 
Thus, perturbed homeostasis of BH4 does not only lead to oxidative stress but is 
thought to be associated with pathogenesis of cardiovascular and neurodegenerative 
diseases.  
 
Over the last years, numerous experiments with rodents or human patients were 
performed under conditions of increased BH4 by augmentation of cofactor through 
pharmacological supplementation, stimulation of biosynthesis or protection from 
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oxidation, and they basically all confirmed correction of eNOS dysfunction to protect 
from (cardio-) vascular disease4, 5. Furthermore, the bioavailability of endothelial BH4 
for eNOS was found also to be important, besides probably many other dietary 
factors6, for the control of glucose and lipid homeostasis7, 8, and various experiments 
in animal models and patients suggest a role in, or progression to, type 2 diabetes 
mellitus (T2DM)9-14. Oral supplementation of BH4 over several weeks in rats 
prevented endothelial dysfunction and restored adiponectin levels, a hormone 
secreted from adipose tissue and regulating glucose and fatty acid catabolism15. It 
was speculated based on such experiments with animals and in patients with T2DM 
that BH4 might be a candidate for the treatment of the metabolic syndrome. Increase 
of abdominal obesity is known to contribute to insulin resistance and metabolic 
abnormality which is linked to development of T2DM and cardiovascular disease16-18. 
However, the underlying mechanisms for the relation between arterial hypertension, 
insulin resistance, and the metabolic syndrome are unclear18.  
 
Various transgenic animal models are available to study pathophysiology and 
disease mechanism of BH4 cofactor deficiency1. We and others have reported on the 
perinatal lethal phenotype of a homozygous Pts-knock-out mouse (Pts-ko/ko)19, 20. 
This mouse mutant exhibited complete absence of PTPS biosynthesis activity 
accompanied by systemic HPA, severe brain monoamine neurotransmitter 
deficiency, IGF-1 depletion and dwarfism, while whole brain NOS activity was normal. 
Due to its severe morbidity and perinatal mortality, this mouse model turned out to be 
difficult for further and detailed studies on the natural history and development of 
pathophysiology for classical BH4 deficiency. We thus aimed at generating a mouse 
model with a milder form of BH4 deficiency. Here we report on the generation and 
characterization of a Pts-knock-in (Pts-ki) mouse with reduced PTPS activity and 
found in homozygous Pts-ki/ki and in heterozygous Pts-ko/wt mutant animals, both 
with severely compromised but residual PTPS activity, abnormal body fat distribution 
and abdominal obesity.  
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MATERIALS, METHODS AND ANIMAL HUSBANDRY 
 
Pts gene targeting 
A genomic clone containing the murine Pts gene was as described previously, 
isolated from a 129/Sv-λ phage library21. For targeting vector (pMSY211) 
construction, a 1.3 kb fragment of the Pts gene spanning exon 1 was used as short 
arm of homology (see Supplementary Figure S1B). A phosphoglycerate kinase 
promoter (Pgk)-diphtheria toxin (DT) gene cassette, essential for the negative 
selection of the embryonic stem (ES) cells, was added 5’ to the short arm of 
homology. The long arm of homology was a 5.1 kb fragment containing exons 2, 3 
and 4 of the Pts gene, and as a positive selective marker, the “floxed” Pgk-neomycin 
resistance gene (neo) cassette that was introduced between the short and the long 
arm of homology. After successful construction, the pMSY211 targeting vector was 
linearized and electoporated into ES cells derived from 129S6/SvEvTac strain. ES 
cell clones with correct homologous recombination were confirmed by nested PCR 
under standard amplification conditions with 40 cycles with primers MSY220: 5’-
GCACCCCAAGGTAGCCAAGAATTTG-3’ and MSY221: 5’-TTCTTCGCCCACCCCG 
AAATTGATG-3’, followed by 25 cycles with primers MSY226: 5’-ACCGGGCTGGAG 
AACATCTGATAAG-3’ and MSY228: 5’-TCAGCAGCCTCTGTTCCACATACAC-3’. 
For further confirmation of correctly targeted ES cell clones, Southern blot analysis 
was performed (not shown). One correctly targeted ES cell clone was chosen for 
blastocyst injection. Blastocyst injection (FVB/N host embryos) led to generation of 
one 50% chimeric male that, when sexually mature, was mated with FVB females. 
The chimera revealed germline transmission resulting in the generation of 
heterozygous Pts-R15C knock-in (Pts-ki) targeted mice. Correct genotype was 
confirmed on genomic DNA from tail or ear biopsies by Pts-ki or Pts-ko genotyping 
PCR (for genotyping, see Supplementary Fig. S1C and S1D plus supplementary 
information).  
 
Mouse husbandry 
Animal experiments were carried out in accordance with the guidelines and policies 
of the State Veterinary Office of Zurich and Swiss law on animal protection, the Swiss 
Federal Act on Animal Protection (1978), and the Swiss Animal Protection Ordinance 
(1981). Animal studies presented here received approval from by the Cantonal 
Veterinary Office, Zurich, and the Cantonal Committee for Animal Experiments, 
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Zurich, Switzerland. All mice, including the wild-type controls, are based on C57/Bl6-
background. The high fat diet was from Research Diets D12331 (with 58% kcal% fat 
w/sucrose Surwit Diet) for up to 10 weeks of feeding mice ad libitium. At the GMC 
mice were maintained in IVC cages with water and standard mouse chow (Altromin 
1314, Altromin, Lage, Germany) according to the GMC housing conditions and 
German laws. All tests performed at the GMC were approved by the responsible 
authority of the district government of Upper Bavaria, Germany. 
 
Preparation of mouse tissues 
Mice were sacrificed, and brains and livers were removed and snap-frozen in liquid 
nitrogen.  Whole mice brains and livers were ground down to powder. To each 
sample, 500 µl of homogenization buffer (50 mM Tris-HCl, pH 7.5, 100 mMKCl/1 mM 
EDTA, 1 mM DTT in H2O, 0.2mM PMSF in isopropanol (10 mg/ml), 1 μM leupeptin in 
H2O (5 mg/ml) and 1 μM pepstatin in methanol (1 mg/ml)) was added. The 
TissueLyserII (Qiagen; cat. no. 85300) was used for lysate extraction. A 5 mm 
stainless steel bead (Qiagen; cat. no. 69989) was added to each sample. The 
samples were placed into the tissue lyser adapters and were shake at a frequency of 
20/s for 90 sec. The lysate was clarified by centrifugation at 13,000 rpm for 20 min 
and supernatant was used for lysate measurements.  
 
Determination of brain neurotransmitter metabolites, and neopterin and 
biopterin in mouse tissues and body fluids  
Biopterin, neopterin in liver and brain, and monoamine neurotransmitter metabolites 
in brain were determined according to a published method19. For pterin 
measurements in mouse mother milk, milk was collected according to a published 
method22. After birth, pups were removed from the mothers. Six hours later, mothers 
were anesthetized by isoflurane, followed by a inter peritoneal injection of 2 U of 
oxytocin (Sigma-Aldrich, Buchs, Switzerland), and, after 1 min, mice were milked23. 
The few micro liters of collected milk was immediately diluted in ddH2O and stored at 
-80°C before determination of pterins.   
 
Determination of L-Phe and L-Tyr concentration in whole blood samples 
Before blood collection, adult mice were starved between 4-6 hours to avoid 
fluctuation in plasma amino acid levels. Blood was collected from tail veins and 
directly spotted onto Guthrie cards. Concentrations of L-Phe and L-Tyr were 
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measured by electrospray ionization tandem mass spectrometry as described (ESI-
MS/MS) 24.  
 
Determination of PTPS enzyme activity 
PTPS activity of mouse brain and liver lysates was determined according to a 
described method with minor modifications19. In a first step, an incubation mixture of 
60 µl/sample was prepared, containing  22.6 µl of 100 mM Tris-HCl buffer pH7.4, 5.5 
µl of 200 mM MgCl2, 5.5 µl of 20 mM NADP, 5.5 µl of 20 mM NADPH, 13.2 µl of 0.6 
mM NH2P3  and 2.3 µl of 0.39 U/ml SR. Contrary to our previously published method, 
no DHPR was added to the mixture (as we found that PTPS enzyme activity showed 
no significant differences in the presence or absence of DHPR; unpublished 
observation). To 60 µl of incubation mixture, either 50 µl of brain lysate or 25 µl liver 
lysate plus 25 µl homogenization buffer was added. The final volume of 110 l 
containing liver or brain extracts were incubated at 37°C in the dark for 30 min (liver) 
or 1 hour (brain). For the “blank reaction”, 50 µl of 100 mM Tris-HCl buffer pH 7.4 
were added to 60 µl of incubation mixture and incubated for 30 min (liver) or 1 hour 
(brain) at 37°C in the dark. For “blanks with no incubation”, 60 µl of 100 mM Tris-HCl 
buffer pH 7.4 were added to 50 µl of brain lysate or 25 µl of liver lysate plus 25 µl of 
homogenization buffer. To stop the reactions, 33 µl of 30% trichloroacetic acid were 
added to all samples, including blanks, followed by 10 min incubation at 4°C. 
Samples were centrifuged at 13,000 rpm for 5 min. The pellets were discarded, and 
20 µl of a 1% iodine solution (0.1 g I2 and 0.2 g KI in 10 ml 1M HCl) was added to a 
supernatant of 100 µl, followed by incubation at room temperature in the dark for one 
hour. Finally, 30 µl of 1% w/v ascorbic acid solution was added before samples were 
centrifuged in AmiconR Ultra-0.5 Centrifugal Filter (Millipore, cat. no: UFC501096) for 
10 min at 13,000 rpm. The total amount of biopterin was detected by reversed-phase 
high-performance liquid chromatography (HPLC). PTPS activity was expressed in 
μU/mg of total protein. Total protein was determined by using an M-TP Mikroprotein 
kit from Beckman Coulter Synchron LX-System (Beckman Coulter Inc, Brea, CA; kit-
no. 445860). 
 
Quantification of mRNA expression 
RNA was extracted from mouse tissue (liver and brain) by the Qiagen DNeasy blood 
and tissue kit (Ref. 69504; Hombrechtikon, Switzerland) and cDNA was made by the 
Promega reverse transcription system (Ref. nr. A3500; Dübendorf, Switzerland). 
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Mouse Pts, eNos/Nos3 adiponectin and Il6 mRNA expression levels were quantified 
using commercially available ABI assays (Mm.35856 for Pts mRNA, NCBI RefSeq 
NM_011220.2; Mm00435217_m1 for eNos/Nos3 mRNA, NCBI RefSeq 
NM_008713.4; Mm00456425-m1 for adiponectin mRNA, NCBI RefSeq 
NM_009605.4; Mm59064-m1 for IL6 mRNA, NCBI RefSeq NM_031168.1). The 
murine glyceraldehyde-3-phosphate dehydrogenase (Gapdh) mRNA (ABI assay ID: 
Mm99999915_g1; NCBI RefSeq NM_008084.2) was used to normalize relative Pts, 
adiponectin and IL-6 mRNA levels. Values were calculated as described in a 
published method25.  
 
Determination of various metabolic parameters 
Abdominal fat was resected from mice followed by determination of its weight. 
Triglyceride in liver and plasma, cholesterol in plasma, and HDL in plasma was 
measured according to standard methods in our routine Clinical Chemistry unit in a 
Beckman Coulter UniCel® DxC 600 (Nyon, Switzerland) following the manufacturers 
procedures26. For determining “fasted glucose”, mice underwent overnight food 
withdrawal.  
 
Western blot  
PTPS protein was analyzed from liver extracts by Western blot. Protein-extracts (100 
mg/ml) were blotted onto a nuPAGE® 4-12% Bis-Tris Gel (Life technologies, Zug 
Switzerland) incubated with the affinity-purified anti-human PTPS polyclonal antibody 
SZ28 (1:200 diluted)27, followed by incubation with a secondary antibody, Anti-Rabbit 
IgG, Horseradish Peroxidase-Linked whole antibody Na-934V (1:10’000 diluted; GE 
Healthcare, Glattbrugg, Switzerland), and visualization with the AmershamTM ECLTM 
Western Blotting Detection Reagents (GE Healthcare, Glattbrugg, Switzerland). Blots 
were striped with Restore Western Blot Stripping Buffer (Fisher Scientific AG, 
Wohlen, Switzerland) before staining with β-actin where blots were incubated with 
the primary monoclonal anti-β-actin antibody clone AC-74 produced in mouse 
(diluted 1:10’000; Sigma-Aldrich, Buchs, Switzerland), followed by incubation with the 
secondary antibody, ECLTM anti-mouse IgG horseradish peroxidase-linked whole 
antibody NA931V produced in sheep (diluted 1:10’000; GE Healthcare, Glattbrugg, 
Switzerland). The bands were acquired using Gel Logic 6000 PRO system (Bio 
Carestream Health, Centre “Les Tuillieres“, Switzerland) and the band intensity was 
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quantified by the Carestream Molecular Imaging Software, Version 5.0 (Carestream 
Health). 
For Western analysis of TH, brain tissues were homogenized with 50 mM sodium-
phosphate buffer (pH 7.4) containing 100 mM NaCl, 1 mM dithiothreitol, 2 μg/ml 
leupeptin, 1 μg/ml pepstatin and 0.5 mM phenylmethylsulfonyl fluoride. The 
homogenates were subjected to 12% SDS-polyacrylamide gel electrophoresis, 
blotted onto apolyvinylidenedifluoride membrane (Bio-Rad, Hercules, CA), blocked 
with 5% skim milk, incubated with anti-TH antibody (1:5’000; AB152, Millipore, 
Billerica, MA), or anti-β-actin antibody (1:30’000; A5441, Sigma-Aldrich, St. Louis, 
MO) and then incubated with horseradish peroxidase-conjugated anti-rabbit IgG 
(NA9310, GE Healthcare, Pittsburgh, PA) or anti-mouse IgG (NA9340, GE 
Healthcare). The immunoreactivity was detected using Immobilon Western 
Chemiluminescent HRPSubstrate (Millipore). 
 
Systemic phenotype analysis by the German Mouse Clinic 
Comprehensive phenotypical and behavioral characterization of Pts-ki/ki mice was 
done in collaboration with the German Mouse Clinic (GMC) in Munich, Germany28, 29. 
Over a period of 10 weeks a total of 78 mice (20 Pts-ki/ki males, 20 Pts-ki/ki females, 
20 wild-type males and 18 wild-type females) were subdivided into two pipelines and 
subjected to the various non-invasive tests including measurements of approximately 
550 parameters within 14 different areas. The body composition was analyzed by 
non-invasive qNMR (Bruker MiniSpec LF50, Bruker, Ettlingen, Germany). Food 
uptake, energy expenditure and metabolic fuel utilization were assessed by indirect 
calorimetry (SM-MARS 8 Channel Metabolic System, Sable Systems Ltd., Las 
Vegas, USA). Parameters were monitored over 21 hours beginning 5 hours prior to 
lights-off (6 p.m. CET) and ended 4 hours after lights-on the next morning. Data were 
recorded every 10 min resulting in 126 data points for oxygen consumption (VO2), 
carbon dioxide production (VCO2), respiratory exchange ratio (RER=VCO2/VO2), 
cumulative physical activity, and total food uptake. Lipid and carbohydrate oxidation 
rates were calculated from gas exchange data30. Blood samples for clinical chemistry 
analyses were collected in Li-heparin coated tubes after overnight food withdrawal 
and from ad libitum fed mice. Plasma samples were analyzed using an AU400 
autoanalyzer (Olympus, Germany) and adapted reagent kits provided by Beckman-
Coulter, Wako Chemicals GmbH or Randox according to GMC standard 
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procedures31. Immunoglobulins in blood serum were detected by immunology and 
allergy screening. 
 
Transcriptome analysis 
Total RNA of brain and liver from of 17 weeks old male animals (Pts-ki/ki n = 4, wild-
type n = 4) was extracted according a standardized protocol (RNAeasy mini kit, 
Qiagen). For gene expression profiling Illumina Mouse Ref8 v2.0 Expression 
BeadChips were performed as previously described32, 33 Illumina Genomestudio 
2011.1 was applied for data normalization (cubic spline) and background corrections. 
Statistical analysis32, 34, 35 identified differential gene expression between mutant and 
wild-type tissues comparing single mutant values with the mean of four wild-types 
(FDR < 10% in combination with mean fold change > 1.9). Overrepresented 
functional annotations within the data set were provided as GO terms of the category 
‘Disease and Function Annotations’ (Ingenuity Pathway Analysis, IPA). Expression 
data were available at the public repository database GEO36 (GSE55148). 
 
GSE55148 for reviewers only: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token= 
srinessoffuxfcn&acc=GSE55148 
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RESULTS 
 
Generation of a Pts knock-in mouse (Pts-ki)  
To generate a viable mouse model for BH4 deficiency, we chose to knock-in a single 
point mutation in the murine Pts gene, c.43C>T leading to mPTPS-p.Arg15Cys. This 
mutation corresponds to the human mutation PTS-c.46C>T/hPTPS-p.Arg16Cys 
which was found in a patient with a mild phenotype with lowered BH4 biosynthesis in 
peripheral organs but normal BH4 and neurotransmitter levels in the CNS 
(Supplementary Fig. S1A)27, 37. Expression studies of recombinant hPTPS-
p.Arg16Cys and mPTPS-p.Arg15Cys in COS-1 cells revealed enzyme activity of 12% 
and 15%, respectively, compared to wild-type PTPS (not shown). Details for the 
targeting vector construct and strategy for knocking-in the mPTPS-p.Arg15Cys allele 
(Pts-ki), including mouse genotyping, are described in the section of materials and 
methods and are depicted in Supplementary Figures S1B - S1D.  
 
Homozygous Pts-ki/ki mice exhibit lowered PTPS activity and elevated 
neopterin, but normal plasma L-Phe and tissue BH4  
Upon breeding Pts-ki mice to homozygosity, we found the expected Mendelian ratio 
for a recessive allele with ~25% Pts-ki/ki mice, and no behavioral or visible 
abnormalities compared to their wild-type littermates. In the following, we bred all 
possible viable Pts genotypes, excluding homozygous knock-outs which are perinatal 
lethal and analyzed 10-12 weeks old adults for their PTPS expression and activity, 
pterin content in different organs, L-Phe and L-Tyr in blood, and for monoamine 
neurotransmitter biosynthesis in the brain.  
First, we quantified Pts gene expression in liver and brain, and found normal mRNA 
expression in Pts-ki/wt and Pts-ki/ki mice, and, as expected a roughly 50% reduction 
of gene expression in mice with one Pts-ko null allele (Table 1). We also quantified 
PTPS protein expression in liver and found a roughly 50% reduction in mice with one 
null (ko) allele compared to wild-type and Pts-ki/wt mice. An exception was the 
somewhat unprecedented elevation of PTPS expression in Pts-ki/ki mice, which 
might be due to a compensatory action due to low PTPS activity. Unfortunately, we 
could not quantify the PTPS protein in whole brain extracts, as expression levels 
were below detection limit.  
Next, we determined PTPS enzyme activity in liver and brain. As depicted in Fig. 1A, 
PTPS activity was only slightly but not significantly reduced in liver and brain of Pts-
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ki/wt and in brain of Pts-ko/wt compared to wild-type mice while Pts-ki/ki, Pts-ko/wt 
and Pts-ki/ko mice showed a strong reduction of activity in brain and/or liver. Taken 
together, progressive reduction of PTPS activity in mice with different Pts alleles is as 
follows: ko/wt > ki/ki > ki/ko > ko/ko (for Pts-ko/ko see19).  
Systemic accumulation of neopterin, the oxidized and dephosphorylated substrate of 
the PTPS enzyme, is one of the diagnostic hallmarks of PTPS deficiency1. In 
accordance with the observation of lowered PTPS activity, we found slightly elevated 
neopterin in Pts-ki/ki mice at least in liver (but not in brain), but significantly elevated 
neopterin in liver and brain of Pts-ki/ko mice (Fig. 1B). In contrast, biopterin levels in 
liver, brain and mother milk did not differ in the different Pts backgrounds at least in 
our adult mice (Fig. 1C). From previous studies with Pts-ko/wt mice, we observed a 
roughly 50% reduction of BH4 in the liver of newborns which was compensated later 
during development19, 38. Mother milk was analyzed because the mammary gland 
was reported to be the tissue with probably the highest concentration of biopterin 
biosynthesis, and a potential reduction of biopterin in milk might have an effect on the 
development of offsprings39, 40. There was no difference in mouse mother milk 
between Pts-wt/wt, Pts-ki/wt, Pts-ko/wt and Pts-ki/ki (Fig. 1D). Furthermore, we found 
no indication for (systemic) elevation of L-Phe or L-Tyr analyzed in peripheral blood 
(Fig. 1E). Plasma L-Phe remained also unchanged when Pts-ki/ki mice were exposed 
to high levels of L-Phe (300 mg/l) for 5 days in the drinking water (not shown).  
 
Brain monoamine neurotransmitter levels and TH expression are not altered in 
Pts mice with lowered PTPS activity  
Similarly to BH4, monoamine neurotransmitter metabolites in the brain of adult mutant 
mice did also not differ in the different Pts backgrounds (Fig. 1F). Nevertheless, at 
least compound heterozygous Pts-ki/ko and homozygous Pts-ki/ki mice were 
severely compromised regarding PTPS activity as we found elevated neopterin (Figs. 
2A and B). We thus further analyzed brain TH expression in these mice because TH 
expression and/or stability were reported to be reduced under conditions of BH4 
and/or PAH deficiency20, 41, 42. However, we found no difference in TH expression in 
adult brains between Pts-ki/ko mice compared to their Pts-wt/wt, Pts-ki/wt and Pts-
ko/wt controls (Supplementary Fig. S2). In conclusion, we found no neurological 
abnormalities in our homozygous Pts-ki/ki or compound heterozygous Pts-ki/ko mice 
regarding the brain TH expression and/or monoamine neurotransmitter biosynthesis.  
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Heterozygous Pts mutant mice exhibit abnormal body weight and intra-
abdominal fat content 
Since Pts-ko/wt mutant synthesized potentially less BH4 as we found a ~50% 
reduction at least after birth but compensation at later ages 19, 38, we initially 
hypothesized that these animals might be prone to cofactor limitation under for 
instance acute hyperglycemia. Yet, in standard oral glucose tolerance loading tests 
we could not see any difference in glucose clearance between groups of wild-type 
and Pts-ko/wt mice (not shown). At the same time, we found that Pts-ko/wt mice tend 
to have a slightly higher relative increase in body weight and in intra-abdominal fat 
than their wild-type litter mates. This phenomenon seemed to be more pronounced in 
male mice than in females, and we therefore limited the following analyses to male 
mutants. By serendipity, we further observed in the same male mice during autopsies 
an increase in intra-abdominal fat content. A representative quantification of such an 
early observation is summarized in Table 2: upon feeding limited number of male 
mice (n = 4) over a period of several weeks with high fat diet (58 kcal% fat with 
sucrose compared to normal diet with 11 kcal% fat with corn starch), we saw a two-
fold increase in intra-abdominal adipose tissue compartments in Pts-ko/wt mice 
compared to an only 1.6-fold increase in wild-type control mice. For these first 
observations, we decided to dissect and weigh the sum of epididymal (or 
perigonadal) fat tissues, termed ‘intra-abdominal fat’, as a marker for fat increase. An 
in vivo determination of whole-body fat in mice using time-domain magnetic 
resonance analysis (TD-NMR) was only performed later to confirm these 
observations in Pts-ki/ki mouse mutants (see below). Next we extended our studies 
with male Pts-ko/wt male mice by further analyzing various metabolic parameters in a 
larger cohort of mice fed with high fat diet (see Supplementary Table S1). This study 
corroborated the previously observed increase in intra-abdominal fat in Pts-ko/wt 
mice (p < 0.05), while metabolic, inflammatory and oxidative stress parameters were 
either unchanged or only slightly and statistically not significantly increased in Pts-
ko/wt mice compared to wild-type controls. As shown in Supplementary Table S1, 
these parameters included triglycerides in liver and plasma, plasma cholesterol and 
HDL, blood glucose, and adiponectin and Il6 gene expression in fat tissue. The 
observation of body weight increase in mildly compromised Pts males, i.e. Pts-ko/wt 
compared to wt, was also seen in a parallel study including Pts-ki/ki males (see Table 
3). Here we found differences in body weight (but not in plasma glucose) when mice 
PTPS Deficient Mouse Models – Manuscript (submitted) 
 123
were kept over several weeks under standard chow or under high fat diet. From 
these observations we concluded that a lowered PTPS activity that is not necessarily 
connected to detectable reductions of BH4 in tissues such as liver or brain is a 
potential risk factor for weight increase with a tendency for abdominal obesity at least 
in male mice. For further analysis, we undertook a comprehensive and standardized 
analysis towards a potential metabolic phenotype with our Pts-ki/ki mutant mice.  
 
Comprehensive phenotyping of Pts-ki/ki mice revealed a reduced body mass 
with higher fat content and lower lean mass, and an increase in fasting plasma 
glucose, plasma cholesterol and triglycerides  
Pts-ki/ki mice were systematically characterized in the primary screen of the German 
Mouse Clinic43, 44. 78 mice (40 mutants and 38 wild-type littermates) were analyzed in 
the screens dysmorphology, behavior, neurology, eye, nociception, energy 
metabolism, clinical chemistry, immunology, allergy steroid metabolism, 
cardiovascular function, lung function, and pathology. In addition, liver and brain 
tissue samples were used for microarray based analysis of differential gene 
expression. Pts-ki/ki mice showed phenotypic alterations indicating a mild metabolic 
phenotype. Despite a slight reduction in body mass in 13 weeks old mutants 
compared to wild-type controls, fat mass was increased especially in male mutants 
whereas lean mass was reduced (Fig. 2A-C and Table 4). The monitoring of daily 
energy expenditure and substrate utilization by indirect calorimetry in male control 
and mutant mice revealed no differences between genotypes (see Supplementary 
Table S2). Clinical chemistry analyses of plasma samples revealed for both sexes a 
mild increase of fasting glucose levels in Pts-ki/ki mice and significantly higher 
cholesterol and triglyceride concentrations in plasma of ad libitum fed mutant mice as 
compared to corresponding controls. Additionally, alkaline phosphatase activity in 
plasma of mutant mice was slightly increased compared to controls, pointing towards 
a potential liver dysfunction (Supplementary Table S3). The remaining parameters 
analyzed did not show significant genotype-related differences. 
 
Brain and liver transcriptome profiles of Pts-ki/ki mice 
To potentially identify differential gene regulation in Pts-ki/ki mice with reduced PTPS 
enzyme activity and elevated neopterin in brain and liver, transcriptome profiles of 
these organs were performed (see Supplementary Tables S4 for liver and S5 for 
brain). Slightly increased expression levels of Pts were detected in both organs 
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comparing Pts-ki/ki with Pts-wild-type mice (fold change: brain 1.45 ± 0.48; liver 1.66 
± 0.33) which is similar to what we found by RT-qPCR (see Table 1) and which might 
be a compensatory effect due to reduced PTPS enzyme activity. Statistical analysis 
revealed 36 significantly regulated genes in brain and 347 in liver of Pts-ki/ki mice 
(see Suppl. Table S4 and S5). An overlap of 22 differentially down-regulated genes 
was found between the analyzed organs: Alg, Atm, Cd14, Cd207, Ch25h, Hp, Hspb1, 
Lcn2, Lrg1, Mkks, Ms4a6d, Miacr1, Osmr, Retnlg, S100a8, S100a9, Serpina3f, 
Serpina3g, Socs3, Srpr, Tmem25, and Zfp235. Several of these common genes were 
associated with cytokine activity (Mkks, Osmr, Serpina3f, Serpina3g, and Socs3), 
immune processes (Atm, Cd14, Cd207, Lrg2, S100a8 and Tmem25) and metabolism 
(Ch25h, Lcn2, Osmr, S100a8 and Socs3). Further overlap was detected among the 
over-represented functional annotations of the regulated genes: proliferation and 
differentiation of cells, cell death, leukocyte migration and vascular disease 
(Supplementary Table S6) which might be an indication for inflammatory processes. 
Exclusively, genes annotated with glucose (e.g. Cxcl14, Dusp1, Fabp5, Myd88, Nnmt, 
Nos3, Pilrb, Ptpn1, Retnlb, Serpina3, Stat3, Timp1, Tlr2, Vcam1, Xbp1) and lipid 
metabolism (e.g. Abcb1b, Adora1, Adrb2, Apoa4, Atf3, Cebpb, Fabp5, Fas, Lbp, 
Lcn2, Lgals3, Ptpn1, Saa1, Stat3, Xbp1), protein synthesis (e.g.  Arntl, Bag3, Casp4, 
Gdf9, Hdc, Hmox1, Lgmn, Mkks, Mt1e, Mt1h, Myd88, Rcan1, S100a9, Sgms1, 
Slc39a14, Thbd, Tlr2), obesity (e.g. Adora1, Adrb2, Atf3, Cebpb, Fabp5, Gas6, Hhex, 
Icam1, Lbp, Mfsd2a, Mkks, Mt1e, Mt1h, Ppargc1b, Socs3, Stat3), weight loss (e.g. 
Adh7, Apcs, Arntl, Atf3, Bag3, Cdkn1a, Ikbke, Mt1e, Mt1h, Nfkb2, Tlr2, Tpmt), 
hepatic steatosis (e.g. Adora1, Atf4, Cyp4a11,, Fabp5, Igfbp1, Il18, Il1b, Lbp, Mfsd2a, 
Retnlb, Ripk2, Stat3, Steap4, Tlr2) and insulin sensitivity (e.g. Arntl,  Cebpb, Ptpn1, 
Socs3, Spp1, Stat3, Tgm2, Tlr2, Xbp1) were over-represented in liver. These gene 
ontology (GO) terms might be of particular interest with regard to reduced body mass 
and elevated blood glucose and cholesterol levels in Pts-ki/ki mice. It has to be 
emphasized that we found reduced gene expression levels for Nos3 only in hepatic 
transcriptome profiling analysis which would give evidence towards a mildly 
compromised eNOS/NOS3 function, whereas a “validation” by RT-qPCR did not 
necessarily confirm this in the various Pts-mice tested (see Supplementary Table S7). 
The potential association between the reduced BH4-biosynthetic activity, abnormal 
body fat distribution and abdominal obesity, and the reduced gene expression levels 
of eNos/Nos3 found in liver will be discussed below. 
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DISCUSSION 
 
The here presented Pts-ki mouse was initially thought to represent a hypomorphic 
model that mimics human BH4 deficiency due to severely reduced PTPS activity 
which, if untreated, may be lethal in patients but not at birth as it is observed in Pts-
ko/ko mice. We found that a reduction of up to 90% of PTPS activity (in Pts-ki/ko 
mice) does not lead to systemic hyperphenylalaninemia concomitant with brain 
monoamine neurotransmitter abnormality. Unexpectedly, such mice turned out to 
exhibit compromised or limited cofactor availability without classical sings of BH4 
deficiency but rather with abnormal body fat distribution and abdominal obesity. An 
indirect measure of BH4 limitation due to low PTPS activity is the elevated neopterin 
that is clearly detectable in liver and less striking in brain in at least Pts-ki/ko mice. As 
described in the introduction, it was found that conditions of increased BH4 may 
protect from cardiovascular diseases, endothelial dysfunction and potentially also 
from progression to T2DM through endothelial BH4 for eNOS (for references see 
Introduction). Yet, whereas the role of increased BH4 in abdominal obesity or the 
metabolic syndrome has been investigated, the opposite condition i.e. decreased 
BH4 – but not classical BH4 deficiency – in these processes has not been studied to 
our knowledge under in vivo conditions. By serendipity, we found in our first mouse 
model with potentially limited BH4, i.e. in the heterozygous Pts-ko/wt mice, abnormal 
fat distribution which was later confirmed also in homozygous Pts-ki/ki mice.  
 
A following up study by a comprehensive and standard systemic and phenotype 
analysis of Pts-ki/ki mice revealed slight alterations in energy metabolism with higher 
fat content, lower lean mass, and mildly increased fasting blood glucose as well as 
cholesterol and triglyceride levels in these mutant animals. Transcriptome analysis of 
liver indicated changes in glucose and lipid metabolism, including genes such as 
Adora1, Adrb2, Apoa, Atf3, Atf4, Cebpb, Cxcl14, Dusp1, F13a1, Fabp5, Map3k14, 
Nos3, Ppargc1a, Rgs16, Socs3, Stat3, Steap4 and Zc3h12a. Furthermore, several of 
the differentially regulated genes in liver are associated with obesity, weight loss, 
hepatic steatosis and insulin sensitivity, which are consistent with the phenotypic 
alterations found in Pts-ki/ki mice. Genes as Adrb2, Apoa4, Adora, Atm and Ripk2 
play roles in lipid accumulation in liver and hepatosteatosis. Deficiency of Ripk2, also 
down-regulated in our study, exacerbates hepatosteatosis45. However, Adrb2 and 
Atm, recently linked with activation of fatty liver-induced steatoapoptosis and 
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fibrosis46, 47, were down-regulated in liver of Pts-ki/ki mice. Additionally, over-
expression of Apoa4 and Adora, both genes associated with reduction of lipid 
accumulation48, 49, give evidence for protection of liver dysfunction. Several genes 
associated with insulin sensitivity showed decreased expression in Pts-ki/ki mutants. 
While Atf3 has antidiabetic effects50, Tgm2 null mice were glucose intolerant51 and 
Fabp5 was described to modulate systemic glucose metabolism and insulin 
sensitivity52. Reduced body mass correlated also to the down-regulation of genes 
annotated with obesity, e.g. the adipocyte specific transcription factor Cebpb53, 
Dusp1, expressed in visceral adipose tissue of several obese man54 and Nik, a gene 
that protect against hyperglycemia and glucose intolerance in obese mice55. 
 
A potential direct link between reduced BH4 biosynthetic activity to abnormal body fat 
distribution and abdominal obesity can potentially be through a mildly compromised 
eNOS/NOS3 function as suggested at least by the hepatic transcriptome profiling 
analysis with reduced expression of eNos/Nos3 in liver. It was reported that 
increased NO signaling inhibits insulin induced gluconeogenesis in hepatocytes56, 
therefore reduced NO signaling might increase hepatic gluconeogenesis and fasting 
glucose levels. Furthermore, expression and stability of eNOS-mRNA are influenced 
by many epigenetic and external factors that could also account for differences seen 
in the degree of reduction in gene expression57. Since we have not found yet a 
molecular mechanism, we can only speculate about an influence of potential BH4-
cofactor limitation in e.g. endothelial tissues that is propagated in the organism 
through a (mildly) compromised eNOS/NOS3. An alternative link between the mildly 
reduced biopterin biosynthesis and the observed obesity could be accumulation of 
the by-product neopterin which was detectable at least in liver tissue from Pts-ki/ko 
and Pts-ki/ki mice while Pts-ko/wt mice had only an insignificant neopterin increase 
after birth19. Neopterin was proposed to reflect oxidative stress induced by immune 
system activation in general, and was found to be elevated in patients with 
inflammation and atherosclerosis58. Recently, neopterin was also shown to negatively 
effect expression of various transporters involved in cellular cholesterol efflux and 
foam cell formation and thus to have an aggravating effect on atherosclerosis59. 
Clearly, more studies are required to confirm a connection to eNOS/NOS3 and/or 
neopterin. Nevertheless, our study associates a single gene mutation with monogenic 
forms of obesity, a well know phenomenon related to the so-called leptin-
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melanocortin pathway, that regulates energy balance and food intake, and, if 
compromised, may lead to obesity (for an review see60). In conclusion, a reduction in 
BH4-biosynthetic activity caused by a single heterozygous gene mutation leads in 
mice to abnormal body fat distribution and abdominal obesity. Whether such an effect 
is also visible in humans that are carriers of a mutation in the PTS gene (or in other 
BH4-cofactor metabolizing genes) need to be verified by additional studies.  
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Figure 1. Biochemical analysis of blood, milk, liver and brain tissues from mice carrying the 
various Pts alleles Pts-wt/wt, Pts-ki/wt, Pts-ki/ki, Pts-ko/wt and Pts-ki/ko. (A) PTPS enzyme 
activity (µU/mg protein) in liver and brain, (B) neopterin (pmol/mg protein) in liver and brain, (C) 
biopterin (pmol/mg protein) in liver and brain, (D) biopterin and neopterin in mother milk (nmol/l), (E) 
blood L-Phe and L-Tyr concentrations (µmol/l), and (F) brain monoamine neurotransmitter metabolites 
dopamine, norepinephrine, epinephrine and serotonin (pmol/mg protein). Five10-12 weeks old mice 
were in every group (3 mice in D). Genotypes are indicated by bar color: Pts-wt/wt (white), Pts-ki/wt 
(gray-white striped), Pts-ki/ki (gray), Pts-ko/wt (black & white striped) and Pts-ki/ko (gray & black 
striped). Significant difference from the corresponding wild-type value is indicated by asterisks: *, p < 
0.05; **, p <0.01; ***, 0.001 (Student’s two tailed t-test). 
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Figure 2. Body composition analysis by non-invasive NMR. (A) Body mass (in g). (B) Non-
invasive NMR scans to determine the lean mass (in g), and (C) fat mass (in g). Open circles, Pts-wt/wt 
females (n = 9); grey circles, Pts-ki/ki females (n = 10); open squares, Pts-wt/wt males (n = 10); grey 
squares, Pts-ki/ki males (n = 10). Significant difference from the corresponding wild-type value is 
indicated by asterisks: *, p < 0.05; **, p <0.01; ***, 0.001 (Student’s two tailed t-test). 
 
Table 1: Pts-gene expression and PTPS protein in liver and brain. 
a Normalized relative to GAPDH mRNA; bp < 0.001; cp < 0.01; dp < 0.05 with value of Pts-wt/wt mice 
(Student’s two tailed t-test), GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PTPS, 6-
pyruvoyltetrahydropterin synthase. 
 
Genotype Liver Brain Liver 
 Pts-mRNAa Pts-mRNAa PTPS protein (PTPS/β-Actin) 
Pts-wt/wt (n=5) 1.00 (0.75-1.33) 1.00 (0.89-1.13) 0.12 ± 0.03 
Pts-ki/wt (n=5) 1.27 (0.93-1.73) 1.12 (1.01-1.24) 0.18 ± 0.03 
Pts-ki/ki (n=5) 1.15 (0.97-1.39) 1.21 (1.09-1.35)d 0.28 ± 0.07d 
Pts-ko/wt (n=5) 0.55 (0.45-0.68)c 0.51 (0.45-0.58)b 0.06 ± 0.04 
Pts-ki/ko (n=5) 0.46 (0.40-0.53)b 0.64 (0.57-0.72)b 0.04 ± 0.02d 
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Table 2: Body weight and intra-abdominal fat tissue in male Pts-ko/wt versus Pts-wt/wt mice 
fed with standard chow or high fat diet (ad libitum). 
_________________________________________________________________________________________________________________ 
Mouse (males; n = 4) Diet Body weight in g (increase in %) Intra-abdominal fat in mg (increase in %) 
_____________________________________________________________________________________________________ 
Pts-wt/wt standard chow      4.7 ± 0.9  (100%)  342.5 ± 142.7  (100%) 
Pts-wt/wt high fat    11.2 ± 2.2  (238%)  542.3 ± 170.1  (158%) 
 
Pts-ko/wt standard chow      3.6 ± 1.2  (100%)  421.3 ± 121.2  (100%) 
Pts-ko/wt high fat    10.0 ± 1.2  (275%)  845.5 ± 169.7  (201%) 
_________________________________________________________________________________________________________________ 
 
Table 3: Body weight increase in various Pts mutant mice.  
Body weight increase in Pts-mutant mice, i.e. heterozygous Pts-ko/wt and homozygous Pts-ki/ki, after 
10 weeks feeding with standard chow or high fat diet (ad libitum). 
 
  Standard chow: High Fat diet: High fat diet: 
  Difference in body weight Difference in body weight Blood glucose  
  (grams)  (grams)  (mM)  
  4 weeks 10 weeks 4 weeks 10 weeks 4 weeks 10 weeks 
          
Pts-wt/wt (n = 10) 0.86 2.59 3.93 7.84 6.23 6.04 
Pts-ko/wt (n = 10) 3.49 a 6.17 a 4.61 10.62
c 6.01 6.45 
Pts-ki/ki (n = 10) 2.43b 5.35b 9.42a 16.28a 6.46 6.22 
ap < 0.001; bp < 0.01; cp < 0.1 with value of Pts-wt/wt mice 
 
Table 4: Body composition analysis of Pts-ki/ki mice by qNMR (g, mean ± sd). 
Statistics: body mass was analyzed by 2-WAY ANOVA for genotype, sex, and genotype x sex 
interaction. Fat mass and lean mass were analyzed by linear regression modeling for genotype, sex, 
and genotype x sex interaction (body mass as covariate). Superscripts at p-value of main effect of 
genotype indicate significance level of the genotype x sex interaction. Genotype effects were tested 
separately within males and females only when a significant genotype x sex interaction could be 
detected. Further explanations: n/a not analyzed; n.s. not significant, * p £ 0.05, ** p £ 0.01. 
 
  Female  Pts-wt/wt 
Female  
Pts-ki/ki 
Male 
Pts-wt/wt 
Male  
Pts-ki/ki 
Main effect 
genotype 
(superscript genotype X 
sex interaction) 
within 
females 
within 
males 
  (n = 9) (n = 10) (n = 10) (n = 10) p-values 
Body mass (g)  22.3 ± 1.2 21.8 ± 1.3 30.4 ± 2.0 29.0 ± 0.8 0.0176n.s. n/a n/a 
Fat mass (g) 5.4 ± 0.4 5.5 ± 0.5 6.4 ± 0.4 7.2 ± 0.9 0.5791** 0.3700 0.0035 
Lean mass (g)  13.6 ± 0.8 13.4 ± 0.8 19.7 ± 1.5 18.2 ± 0.5 0.7468* 0.7197 0.0214 
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 Supplementary Figure S1. Generation of the murine Pts-ki allele. (A) Primary amino acid sequence 
alignment of human and mouse PTPS, which share 82.1% sequence identity. The human mutation 
PTS-p.Arg16Cys (hR16C) and the corresponding mouse mutation Pts-p.Arg15Cys (mR15C), both 
located in exon 1, are marked with arrows. (B) Schematic representation of genomic structure of the 
murine Pts wild-type allele (top), the targeting vector pMSY211 including the mR15C mutation (E1’), 
the p.L16L mutation to destroy the BssSI restriction site, a Pgk-DT-gene-cassette (DT) for negative 
selection, and a “floxed” Pgk-neo-gene-cassette (PGK neo) for positive selection (middle), and the 
resulting targeted mutant allele (bottom). (C) Schematic representation of the genotyping concepts for 
the Pts-wt, Pts-ki and Pts-ko alleles with genomic DNA and the primer pairs a/b (Pts-ki PCR) and c/d/e 
(Pts-ko PCR). Pts-ki PCR: primers a and b are located upstream and downstream from exon 1 (E1), 
respectively. They generate a 730 bp for the wild-type/knock-out alleles and a 751 bp PCR fragment 
for the knock-in allele (due to additional targeting vector sequence; see C). Digestion with restriction 
enzyme BssSI, 3 bp downstream of the mR15C-c.43C>T mutation, leads to a 444 bp and a 286 bp 
fragment for the wild-type/knock-out PCR products. The PCR fragment derived from the Pts-ki allele 
can not be digested with BssSI because the silent p.L16L/c.48C>G mutation destroys the BssS1-
recognition site. The Pts-wt and the Pts-ko alleles can not be distinguished by the Pts-ki genotyping 
using primer pair a/b. Pts-ko PCR: genotyping according to our previously published method19. Primer 
c is upstream of exon 2 (E2), primer d is specific for exon 2 and primer e is specific for the lacZ gene. 
The primer pair c/d results in a wild-type fragment of 287 bp and a knock-in fragment of 316 bp 
whereas primer pair c/e generates mutant fragment of 355 bp (due to the difference in the Pts-intron 1 
sequence between the 129/Ola and C57BL/6J mice strains; see C). (D) Conventional 2% agarose gel 
representative PCR-genotyping for the Pts-ki allele (top; after BssSI digestion) and Pts-ko allele 
(bottom).  
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Supplementary Figure S2. TH protein expression in brain of Pts-ki/ko mice. Western blot analysis 
and densitometric quantification of TH in brains from (A) newborn mice (n = 3 Pts-wt/wt, 5 Pts-ko/wt, 
24 Pts-ki/wt, and 19 Pts-ki/ko) and (B) young adult animals (n = 3 Pts-wt/wt, 7 Pts-ko/wt, 12 Pts-ki/wt, 
and 13 Pts-ki/ko). For details see also Materials and Methods.  
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Supplementary Table S1: Metabolic parameters in male Pts-ko/wt versus Pts-wt mice. 
 
Parameter 
 
 
Pts-ko/wt 
(n = 10-15) 
 
Pts-wt/wt  
(n = 10-14) 
 
p-value 
 
Body weight (g) 
 
28.0 ± 2.2 
 
28.0 ± 1.3 
 
0.956 
 
Intra-abdominal fat (mg) 
 
817 ± 244 
 
652  ± 181 
 
0.049* 
 
Total Biopterin  
(pmol/mg protein) 
 
 
92.6 ± 8.2 
 
93.2 ± 9.6 
 
0.889 
 
PTPS activity in liver 
(µU/mg protein) 
 
 
13.7 ± 1.2 
 
28.6 ± 6.7 
 
2.218 x 10e-6** 
 
Triglycerides in liver 
(µmol/mg protein) 
 
 
0.07 ± 0.02 
 
0.05 ± 0.03 
 
0.330 
 
Plasma cholesterol 
 (mmol/L) 
 
3.30 ± 0.28 
 
2.95 ± 0.71 
 
0.302 
 
Plasma triglycerides (mmol/L) 
 
 
0.96 ± 0.20 
 
0.85 ± 0.45 
 
0.612 
 
Plasma HDL 
(mmol/L) 
 
 
3.52 ± 0.46 
 
2.92 ± 1.06 
 
0.251 
 
Adiponectin in fat tissue  
(RT-qPCR gene expression  
in % of Gapdh) 
 
 
62.6 ± 17.1 
 
72.5 ± 19.4 
 
0.229 
 
IL-6 in fat tissue 
(RT-qPCR gene expression  
in % of Gapdh) 
 
 
38.3 ± 18.8 
 
42.9 ± 27.5 
 
0.667 
 
 
* p < 0.05;  ** p < 0.000005 
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Supplementary Table S2: Indirect calorimetry of Pts-ki/ki male mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistics: body mass, body temperature, mean RER, mean activity, lipid oxidation, carbohydrate 
oxidation: 1-WAY ANOVA (genotype); mean, min and max VO2, food intake: linear regression model 
(genotype, body mass as covariate); mean ± sd. 
 
 
 
 
 
 
 
 
 
 
 
Parameter Male p-values 
 Pts-wt/wt Pts-ki/ki   
 (n=7) (n=7) Genotype Body mass 
Body mass (g) 30.1 ± 1.8 28.6 ± 0.8 0.071 n/a 
Body temperature (°C) 36.00 ± 0.4 36.30 ± 0.3 0.134 n/a 
Food intake (g) 5.2 ± 0.5 6.7 ± 3.5 0.556 0.514 
Mean VO2 
(ml h-1) 95.6 ± 5.1 89.2 ± 3.1 0.105 0.058 
Min VO2 (ml h-1) 55.4 ± 5.1 53.3 ± 4.4 0.761 0.045 
Max VO2 (ml h-1) 144.2 ± 10.3 137.4 ± 9.4 0.838 0.051 
Mean RER (VCO2/VO2) 0.89 ± 0.02 0.89 ± 0.03 0.822 n/a 
Lipid oxidation (g/min) 0.00027 ± 0.00006 0.00024 ± 0.00006 0.3818 n/a 
Carbohydrate oxidation 
(g/min) 0.00142 ± 0.00012 
0.00136 ± 
0.00017 0.4212 n/a 
Mean activity (counts) 0.081 ± 0.07 0.070 ± 0.06 0.749 n/a 
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Supplementary Table S3. Plasma clinical chemistry of Pts-ki/ki mice and Pts-wt/wt controls. 
 
 Female 
Pts-wt/wt 
Female 
Pts-ki/ki 
Male 
Pts-wt/wt 
Male 
Pts-ki/ki 
p-values 
 
 (n = 9) (n = 10) (n = 10) (n = 10) genotype sex genotype x sex 
Fasting Glucose [mmol/l] 7.84 ± 1.35 8.92 ± 1.94 9.23 ± 2.11 11.02 ± 2.23 0.028 0.009 0.578 
Fasting Cholesterol 
[mmol/l] 2.117 ± 0.386 2.216 ± 0.431 2.6 ± 0.345 2.879 ± 0.321 0.122 < 0.001 0.457 
Fasting HDL-cholesterol 
[mmol/l] 1.609 ± 0.351 1.7 ± 0.363 2.027 ± 0.263 2.259 ± 0.257 0.114 < 0.001 0.483 
Fasting non-HDL 
Cholesterol [mmol/l] 0.507 ± 0.05 0.516 ± 0.086 0.573 ± 0.092 0.62 ± 0.084 0.292 0.002 0.465 
Fasting Triglycerides 
[mmol/l] 0.813 ± 0.211 0.901 ± 0.156 0.971 ± 0.125 1.062 ± 0.297 0.186 0.022 0.979 
Fasting NEFA [mmol/l] 0.99 ± 0.26 0.85 ± 0.27 0.72 ± 0.13 0.64 ± 0.13 0.106 0.001 0.686 
Sodium [mmol/l] 144.89 ± 2.3 142 ± 4.3 146.4 ± 2.8 148.4 ± 2.1 0.648 < 0.001 0.016 
Potassium [mmol/l] 3.76 ± 0.2 3.98 ± 0.5 3.92 ± 0.3 3.8 ± 0.3 0.644 0.945 0.133 
Chloride [mmol/l] 111.07 ± 1.9 107.6 ± 3.1 108.96 ± 2.7 111.16 ± 1.8 0.426 0.362 0.001 
Total protein [g/l] 48.22 ± 1.9 47.8 ± 2 50 ± 1.6 49.6 ± 2.6 0.539 0.011 0.987 
Albumin [g/l] 28 ± 1.4 27.8 ± 1.5 28.6 ± 1.3 27.4 ± 1.6 0.148 0.834 0.298 
Creatinine [µmol/l] 8.86 ± 0.7 8.19 ± 0.9 7.05 ± 1.1 6.97 ± 0.8 0.176 < 0.001 0.295 
Urea [mmol/l] 10.62 ± 1.9 11.67 ± 1.7 12.03 ± 1.7 11.75 ± 2.1 0.521 0.215 0.274 
Cholesterol [mmol/l] 1.8 ± 0.3 2.27 ± 0.3 2.78 ± 0.5 3.01 ± 0.8 0.038 < 0.001 0.459 
Triglycerides [mmol/l] 1.07 ± 0.3 1.56 ± 0.4 2.23 ± 0.6 2.7 ± 1 0.028 < 0.001 0.983 
ALAT/GPT [U/l] 26.44 ± 7.3 21.8 ± 6.1 37.6 ± 35.2 33.4 ± 22.9 0.531 0.112 0.975 
ASAT/GOT [U/l] 59.33 ± 13.6 72.4 ± 29.9 49.8 ± 21 57.4 ± 19 0.15 0.089 0.699 
alpha-Amylase [U/l] 734.86 ± 60.1 845.01 ± 333.1 907.93 ± 187.6 821.71 ± 163.6 0.862 0.28 0.159 
Glucose [mmol/l] 12.35 ± 2.2 11.09 ± 1.7 10.97 ± 1.4 11.87 ± 1.8 0.753 0.604 0.066 
Lactate-dehydrogenase 
[U/l] 220.77 ± 59.8 226.58 ± 61.4 211.31 ± 89.4 201.28 ± 51.7 0.923 0.426 0.716 
Calcium [mmol/l] 2.24 ± 0.1 2.21 ± 0.1 2.29 ± 0.1 2.28 ± 0.1 0.405 0.011 0.458 
Inorganic phosphate 
[mmol/l] 1.27 ± 0.2 1.16 ± 0.2 1.6 ± 0.4 1.52 ± 0.3 0.348 0.001 0.893 
Iron [µmol/l] 24.26 ± 1.9 24.8 ± 4.1 21.57 ± 2.2 19.84 ± 2.7 0.524 < 0.001 0.225 
Alkaline phosphatase 
[U/l] 138.89 ± 17.9 144.6 ± 15.4 83 ± 9.4 96 ± 16.5 0.061 < 0.001 0.456 
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Supplementary Table S4: Heat map liver. 
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Supplementary Table S5: Heat map brain. 
 
 
            
            
            
      
 
 
 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
             
Heat map of regulated genes in liver (Table S4) and brain (Table S5) of Pts-ki/ki mice compared 
to wild type animals. Fold changes were calculated as ratios of signal intensities of single mutant 
samples and the mean of the respective wild type controls. Log2 fold changes were color coded 
according the scale bar at the bottom of the heat maps. Blue represents the down-regulation and 
yellow the up-regulation in the mutant tissue. 
PTPS Deficient Mouse Models – Manuscript (submitted) 
 144
Supplementary Table S6: Over-represented gene ontology categories for genes regulated in 
brain and liver of Pts-ki/ki mice. *The p-values (right-tailed Fisher Exact Test) for a given process 
annotation is calculated by considering the number of genes that participate in that process and the 
total number of genes known to be associated with that process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S7: eNos/Nos3-gene expression and PTPS protein in liver and brain. 
aNormalized relative to Gapdh-mRNA, Gapdh, glyceraldehyde 3-phosphate dehydrogenase; 
eNos/Nos3, Endothelial nitric oxide synthase/ nitric oxide synthase 3 
 
A) Brain 
Functions annotation p-value*   # genes 
leukocyte migration 2.11E-09 14 
vascular disease 3.80E-06 11 
differentiation of cells 6.60E-04 12 
proliferation of cells 9.70E-03 15 
B) Liver 
Functions annotation p-value   # genes 
leukocyte migration 1.25E-23 71 
vascular disease 2.43E-21 70 
quantity of immunoglobulin 8.53E-21 37 
morphology of body cavity 1.77E-16 66 
lipid metabolism 3.19E-15 57 
cell death 1.13E-14 133 
protein synthesis 1.08E-13 39 
glucose metabolism 9.29E-13 61 
differentiation of cells 2.09E-12 86 
weight loss 8.02E-12 24 
inflammatory response 2.48E-10 11 
hepatic steatosis 8.82E-09 21 
metabolism of reactive oxygen species 2.70E-08 34 
morphology of liver 3.65E-08 18 
hypertrophy 4.09E-08 29 
obesity 5.32E-08 27 
insulin sensitivity 1.10E-07 13 
i-kappab kinase/nf-kappab cascade 6.98E-07 13 
Genotype Liver Brain 
 eNos/Nos3-mRNAa eNos/Nos3-mRNAa 
   
Pts-wt/wt (n=5) 1.00 (0.78-1.28) 1.00 (0.71-1.41) 
Pts-ki/wt (n=4-5) 1.04 (0.85-1.27) 1.18 (0.86-1.64) 
Pts-ki/ki (n=5) 0.85 (0.67-1.06) 1.24 (0.93-1.64) 
Pts-ko/wt (n=4-5) 1.41 (0.88-2.23) 1.23 (0.77-1.96) 
Pts-ki/ko (n=5) 0.67 (0.43-1.03) 1.19 (1.00-1.41) 
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3.2 CHALLENGING THE OBSERVATION OF “UNAFFECTED” AND 
“AFFECTED” PTS-KI/KO MICE FROM DIFFERENT BREEDING 
COMBINATIONS OF PTS-KI AND PTS-KO PARENTS 
 
3.2.1 ABSTRACT 
 
Dea Adamsen reported in her PhD thesis the existence of two different phenotypes in 
compound heterozygous Pts-ki/ko mice derived from homozygous Pts-ki/ki mothers: 
a severely “affected” group that died around 3-4 days after birth, and a second 
“unaffected” group with normal survival (described in chapter 3.1). The analyzed liver 
and brain tissue in the “affected” group showed low PTPS enzyme activity, reduced 
biopterin and increased neopterin levels (only in liver). Furthermore, they showed 
mild HPA and non detectable amounts of brain monoamine neurotransmitters. It 
should be emphasized that D. Adamsen also reported that Pts-ki/wt or Pts-ko/wt 
mothers did not generate “affected” Pts-ki/ko mice, indicating that genotype of the 
parents, especially of the mother, lead to phenotypical variations in the offspring. 
Therefore, it was the objectives to validate and eventually understand the cause for 
these two phenotypes and to deeper investigate potential difference in Pts-ki/ko mice 
derived from different breeding combinations, i.e. Pts-ki/ko offspring from Pts-ki/wt, 
Pts-ko/wt or Pts-ki/ki parents. In a first step, newborn mice, especially Pts-ki/ko 
newborns, derived from different breeding combinations of homozygous and 
heterozygous Pts-ki with heterozygous Pts-ko mice were investigated for potential 
differences. These analyses included potential mild variations in PTPS enzyme 
activity (liver and brain), biopterin (liver and brain), neopterin (liver) and serotonin 
(brain) levels. To confirm the appearance of the “affected” versus “unaffected” Pts-
ki/ko phenotype, Pts-ki/ko mice from homozygous Pts-ki/ki mouse mothers were 
investigated for up to 4 days after birth, which was the described time span when the 
“affected” phenotype was noticed by D. Adamsen. At the age of 4 days, the pups 
were sacrificed and biochemically analyzed. Furthermore, D. Adamsen suggested in 
her PhD thesis that “litter size” may enhance the appearance of the “affected” Pts-
ki/ko phenotype. Therefore, it was examined whether there are more “affected” Pts-
ki/ko offsprings in big litters with 8-9 pups compared to small litters with 3-4 pups 4 
days after birth. Surprisingly, the appearance of the “affected” Pts-ki/ko mouse 
phenotype could not be confirmed.  
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3.2.2 INTRODUCTION 
 
To generate a severe and central phenotype of BH4 deficiency in a mouse model 
without having newborn lethality, the Pts-ko mouse strain (Sumi-Ichinose et al., 2001, 
Elzaouk et al., 2003) was crossed to the Pts-ki mouse strain (R. Scavelli, 2006, 
Univerity of Zurich, Thöny et al., 1994, Oppliger et al., 1995), generating the 
compound heterozygous Pts-ki/ko mouse model. Homozygous Pts-ko/ko showed a 
severe and central phenotype with newborn lethality, whereas the homozygous Pts-
ki/ki mice had a mild and peripheral phenotype. The first 
phenotypical analysis of the compound heterozygous Pts-
ki/ko mice was performed by D. Adamsen in 2011 (Adamsen, 
2011). She reported in her dissertation that Pts-ki/ko mice 
from Pts-ki/ki mouse mothers showed two distinguishable 
phenotypes: the “unaffected” Pts-ki/ko mice with a slightly 
more severe BH4 deficiency phenotype then Pts-ki/ki mice, 
and the “affected” Pts-ki/ko mice, which showed a severe 
and central form of BH4 deficiency with visible abnormalities 
at the age of 3-4 days, including reduced body size, altered 
milk-intake (no white belly), and behaviour and movement 
disorders (Fig. 18) (Adamsen, 2011). At birth, all Pts-ki/ko 
showed reduced PTPS activity in liver and brain, as well as elevated neopterin in 
liver. The “affected” group worsened the following 3-4 days by having further reduced 
PTPS activity and low biopterin levels in liver and brain, increased neopterin levels in 
liver, mild HPA and non detectable amounts of brain monoamine neurotransmitters, 
and finally died or had to be sacrificed. In contrast, the so called “unaffected” group 
showed also reduced PTPS activity but normal levels of biopterin and neopterin in 
liver and brain, normal blood L-Phe and brain monoamine neurotransmitters. 
“Unaffected” Pts-ki/ko mice survived and had a normal lifespan. Heterozygous Pts-
ki/wt or Pts-ko/wt mothers did not produced “affected” Pts-ki/ko offsprings. A 
summary of D. Adamsen’s data is represented in table 4. 
 
 
 
 
 
 
 
Figure 18: Pictures from 
D. Adamsen dissertation. 
A: 3-4 days after birth 
‟affected” Pts-ki/ko (right) 
mice stood out from their 
“un-affected” Pts-ki/ko 
(left) littermates.  
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Table 4: Summary of D. Adamsen’s data (University of Zurich, 2011). 
  ♀Pts-ki/ki x ♂Pts-ko/wt ♀Pts-ko/wt x ♂Pts-ki/ki or ♂Pts-ki/wt 
   newborns 3-4 days 3 weeks 
 Parameter Tissue   "affected" "unaffected" "unaffected" 
PTPS activity Liver 32 % of wt 10 % of wt 36 % of wt no data 
 Brain 25 % of wt 3 % of wt 53 % of wt no data 
 L-Phe Blood normal ~900 µmol/l normal normal 
Biopterin Liver normal 3 % of wt normal normal 
 Brain 11 % of wt 4 % of wt normal normal 
Neopterin Liver ~2,300 % of wt 30,900 % of wt normal 750 % of wt 
 Brain normal normal normal normal 
Neurotransmitters Brain normal n.d. normal normal 
 
Wt, wild-type; n.d., non detectable.  
Overall, it was proposed that “affected” Pts-ki/ko mice had the potential to be a 
suitable mouse model to study BH4 deficiency as they mimic the biochemical 
hallmarks of the severe and central human BH4 deficiency (Adamsen, 2011). It was 
discussed that this preliminary observation of two phenotypes could be explained by 
a “mother effect” (Pts-ki/ki mothers) in combination with “allelic effect” (homozygosity) 
(Adamsen, 2011). Furthermore, D. Adamasen’s hypothesized that differences in 
biopterin amounts in mother milk and/or that the “mother effect” (Pts-ki/ki females) in 
combination with “allelic effect” (homozygosity) led to these two diverse phenotypes 
(D. Adamsen, 2011, Haberman, 1974).  
The objective in this study was focused on the validation of D. Adamsen’s preliminary 
observation of the two described phenotypes and the investigation on the possible 
causes. D. Adamsen’s first hypothesis that different amounts of biopterin in mother 
milk could lead to the appearance of the two phenotypes could be excluded (see 
chapter 3.1). It was previously described in a creatine deficiency knock-out mouse 
model for guanidinoacetate N-methyltransferase (GAMT) that intercrosses of 
heterozygous mutant mice resulted in a deviation from the Mendelian inheritance 
pattern probably caused by newborn lethality (Schmidt et al., 2004). Heterozygous 
Pts-ki/wt or Pts-ko/wt mice are generated by breeding heterozygous Pts-ki/wt or Pts-
ko/wt males with wild-type females, whereas homozygous Pts-ki/ki mice can only be 
produced by intercrosses. Therefore, a “mother effect” (Pts-ki/ki mothers) in 
combination with “allelic effect” (homozygosity) would be more likely to explain D. 
Adamsen’s summarized observation that only Pts-ki/ki females produced “affected” 
Pts-ki/ko offsprings.  
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To examine this thesis, Pts-ki/ko newborns and their siblings from all possible 
breeding combinations of Pts-ki/wt, Pts-ko/wt and Pts-ki/ki parents were compared 
for alterations in their PTPS activity, biopterin, neopterin, L-Phe, L-Tyr and 
monoamine neurotransmitter levels. In a next step, the “affected” phenotype was 
reproduced by breeding homozygous Pts-ki/ki females to heterozygous Pts-ko/wt 
males and the offsprings are closely investigated the following 4 days to detect 
“affected” animals. Furthermore, it was investigated if there are more “affected” pups 
in big litters (8-9 pups) than in small litters (3-4 pups) due to decreased availability of 
mother milk (rich source of BH4) in big litters due to increased competitions between 
the pups (Weinmann et al., 2011). All material and methods used in this study were 
described in chapter 3.1. 
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3.2.3 RESULTS 
 
3.2.3.1 Characterisation of newborn mice from different breeding combinations 
of Pts-ki/wt, Pts-ko/wt and Pts-ki/ki parents 
 
In a first step, the characterisation of Pts-ki/ko newborns was extended by breeding 
homozygous or heterozygous Pts-ki mice with heterozygous Pts-ko mice in all 
possible combination (Fig. 19), and newborns were collected for biochemical 
analysis. Breeding combinations with a Pts-ki/ki parent is abbreviated as 
“homozygous” breeding, whereas breeding combinations with a Pts-ki/wt parent is 
abbreviated as “heterozygous” breeding (Fig. 19). Fig. 19 also summarizes the 
percentage of all pups born from each breeding combination showing that the pups 
were born at the expected Mendelian frequency.  
 
 
 
 
 
Figure 19: Schematic representation of all possible breeding combinations of Pts-ki/wt, Pts-ko/wt and 
Pts-ki/ki: “Homozygous” Pts-ki/ki breedings pairs generate Pts-ki/wt and Pts-ki/ko offsprings; 
“heterozygous” Pts-ki/wt breedings pairs generate Pts-wt/wt, Pts-ki/wt, Pts-ko/wt and Pts-ki/ko 
offsprings. Females are indicated by circles; males are indicated by squares; unknown sex is indicated 
by triangle; Pts-wt allele is indicated in white; Pts-ki allele is indicated in gray; Pts-ko allele is indicated 
in black.  
 
A summary of the biochemical analysis of all offsprings from each breeding 
combination is listed in table 5.  All newborn mice were investigated for their liver and 
brain PTPS activity, biopterin and neopterin, blood L-Phe and L-Tyr, and brain 
monoamine neurotransmitters (table 5).  
 
 
 
 
F1 
“Homozygous” breeding “Heterozygous” breeding 
P 
Pts-wt allele 
Pts-ki allele 
Pts-ko allele 
54% 46% 30% 22% 22% 26% 50% 50% 22% 22% 26% 30% 
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Newborns were counted as “affected”, when detected with mild HPA (L-Phe 360-600 
µmol), low biopterin (< 5 pmol/mg protein) and/or low monoamine neurotransmitters, 
which are hallmarks for the described “affected” animals. None of the analyzed Pts-
ki/ko newborns fulfilled these criteria. Overall, PTPS activity in liver from Pts-ki/wt, 
Pts-ko/wt and Pts-ki/ko newborns from all breeding combinations was significantly 
lower than in both Pts-wt/wt offspring groups. On average, Pts-ki/ko mice had 9% (p 
< 0.001), Pts-ki/wt mice had 54% (p < 0.05), and Pts-ko/wt mice 45% (p < 0.05) of 
PTPS activity in comparison to Pts-wt/wt animals (table 5). PTPS activity in brain, 
was significantly different from Pts-wt/wt offsprings in all Pts-ki/ko mouse groups 
(average: 7% of wt; p < 0.001), in Pts-ki/wt pups (46% of wt; p < 0.01) derived Pts-
ki/ki mothers, and Pts-ko/wt offsprings (33% of wt; p < 0.01) animals derived from 
Pts-ko/wt mothers (table 5). Biopterin levels in liver from Pts-ki/ko (67% of wt; 
p<0.05) and Pts-ki/wt (74% of wt; p<0.05) derived from Pts-ki/ki mothers were 
significantly lower in comparison to the Pts-wt/wt mouse groups (table 5). In contrast, 
there was no difference in biopterin amounts in brain in any of the newborn groups 
(table 5). All Pts-ki/ko newborns had significantly increased neopterin levels in liver 
(average: 14 times higher; p<001), but not in brain (table 5). Blood L-Phe levels of 
Pts-ki/ko offsprings from Pts-ki/ki mothers (66% of wt; p<0.05) or fathers (69% of wt; 
p<0.05) were significantly lower in comparison to the Pts-wt/wt mouse groups (table 
5). Blood L-Tyr levels from Pts-ki/ko (66% of wt; p<0.05) and Pts-ki/wt (71% of wt; 
p<0.05) derived from Pts-ki/ki mothers were significantly lower in comparison to the 
Pts-wt/wt mouse groups (table 5). In the measurement of brain monoamine 
neurotransmitters dopamine, norepinephrine, epinephrine and serotonin, no 
significant difference between Pts-ki/ko, Pts-ki/wt and Pts-ko/wt newborns to Pts-
wt/wt offsprings was detected (table 5). 
 
In summary, Pts-ki/ko mice had significantly lower liver and brain PTPS activity, 
increased neopterin levels in liver, and mainly normal biopterin levels, except for Pts-
ki/ko and Pts-ki/wt newborns derived from Pts-ki/ki mothers, which showed 
significantly lower biopterin levels in their liver. None of the newborns had mild HPA 
or altered brain monoamine neurotransmitter levels. Therefore, no affected Pts-ki/ko 
newborn could be detected. 
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3.2.3.2 Direct comparison of newborn Pts-ki/ko mice derived from different 
breeding combinations of Pts-ki/wt, Pts-ko/wt and Pts-ki/ki parents 
 
Since we found slight differences in blood L-Phe and L-Tyr, and liver biopterin levels 
in-between same genotypes from different breeding combinations, Pts-ki/ko 
newborns from different breeding groups were directly compared (Fig. 20 A-E). 
 
 
 
 
 
 
Figure 20: Comparison between Pts-ki/ko mice from different breeding combinations of Pts-ki and 
Pts-ko parents by biochemical analysis of blood, liver and brain tissue. (A) PTPS enzyme activity in 
liver and brain (µU/mg protein). (B) Blood L-Phe and L-Tyr concentrations (µmol/l). (C) Biopterin levels 
in liver and brain (pmol/mg protein). (D) Neopterin levels in liver and brain (pmol/mg protein). (E) Brain 
monoamine neurotransmitters dopamine, norepinephrine, epinephrine and serotonin levels (pmol/mg 
protein). Breeding combination indicated by bar colour: “homozygous breeding” pairs: ♀ Pts-ki/ki x ♂ 
Pts-ko/wt (black), and ♀ Pts-ko/wt x ♂ Pts-ki/ki (white); “heterozygous breeding” pairs: ♀ Pts-ki/wt x ♂ 
Pts-ko/wt (dark gray), and ♀ Pts-ko/wt x ♂ Pts-ki/wt (light gray). Significant difference is indicated by 
asterisks: * p < 0.05, ** p <0.01 (two-tailed Student’s t-test). 
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In liver, Pts-ki/ko offspring from Pts-ki/ki (5% of wt) mothers or fathers (6% of wt) 
showed the lowest PTPS activity and were significantly different from Pts-ki/ko 
animals from Pts-ki/wt mothers (p < 0.05), which showed the highest PTPS activity 
(16% of wt) (Fig. 20 A). In brain, Pts-ki/ko mice from “heterozygous” breeding pairs 
had the highest PTPS activity (9% of wt), and especially Pts-ki/ko mice from Pts-ki/wt 
mothers had significantly higher PTPS activity then Pts-ki/ko mice derived Pts-ki/ki 
mothers (7% of wt; p < 0.05) or fathers (5% of wt; p < 0.05) (Fig. 20 A). Pts-ki/ko mice 
from Pts-ki/ki mothers (66% of wt) or fathers (69% of wt) had significantly lower L-
Phe levels than Pts-ki/ko mice derived from a “heterozygous” Pts parents (p < 0.01) 
(Fig. 20 B). In contrast, Pts-ki/ko offspring from Pts-ko/wt mothers and Pts-ki/wt 
fathers had the highest blood L-Tyr levels and significantly differed from other Pts-
ki/ko animal groups (p < 0.05) (Fig. 20 B). In liver, Pts-ki/ko mice from Pts-ki/ki 
mothers (67% of wt) or fathers (80% of wt) had significantly lower liver biopterin 
levels than Pts-ki/ko mice from Pts-ki/wt mothers (p < 0.05) (Fig. 20 C). In brain, Pts-
ki/ko mice from Pts-ki/wt mothers had the highest biopterin amount (105% of wt), and 
were significantly higher then Pts-ki/ko mice from Pts-ko/wt mothers (p < 0.05) (Fig. 
20 C).  In liver, Pts-ki/ko mice derived Pts-ki/wt mothers had the highest neopterin 
amount (22 times higher than wt), and were significantly higher than Pts-ki/ko mice 
from Pts-ko/wt mothers (Fig. 20 D). There was no difference for neopterin levels in 
brain between the different Pts-ki/ko mouse groups (Fig. 20 D). No differences were 
observed in brain catecholamines between the different Pts-ki/ko mouse groups (Fig. 
20 E), but Pts-ki/ko mice from Pts-ki/ki mothers (85% of wt) had significantly lower 
serotonins levels than Pts-ki/ko mice from other breeding combinations (p < 0.05; 
Fig. 20 E). In summary, Pts-ki/ko newborns from “homozygous” breedings, especially 
from Pts-ki/ki mothers, showed lower PTPS activity in liver and brain, blood L-Phe 
and L-Tyr, biopterin levels in liver, and serotonin levels in brain, in comparison to Pts-
ki/ko newborns from “heterozygous” breedings. 
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3.2.3.3 Breeding of “affected” Pts-ki/ko mice: Comparison of 3-4 days old Pts-
ki/ko mice derived from small and large litters  
 
To study, if “affected” animals are present in 3-4 days old animals, Pts-ki/ki females 
were bred with Pts-ko/wt males. Furthermore, it was investigated, if there are more 
“affected” animals in big litters with at least 8 pups then in small litters containing 
maximum 4 pups. It is hypothesized that newborns are depending on the BH4 
received from the mother milk to develop normal and prevent them to get “affected” 
(Adamsen, 2011). In a big litter there are more struggles between the siblings to get 
mother milk, which could lead to more “affected” animals. Animals were 
phenotypically defined as “affected” when they appeared smaller then other litter 
mice, located out side the nest, showed movement disorders and/or had no visible 
white belly from drinking mother milk. Biochemically, Pts-ki/ko mice were counted as 
affected when they had HPA (L-Phe >360 µmol/l), low biopterin in liver and brain 
and/or low brain neurotransmitters (Adamsen, 2011). Two big litters and five small 
litters were phenotypically investigated with totally 12 Pts-ki/ko and 24 Pts-ki/wt pups. 
A summary of all animals is listed in table 6. 
 
Table 6: Summary of 3-4 days old mice from small and large litters from Pts-ki/ki females bred with 
Pts-ko/wt males. 
Litter size Pts-ki/wt "unaffected" Pts-ki/ko "affected" Pts-ki/ko 
Total big litters 
(2 litters; 8-9 pups) 
11 6 0 
Total small litters 
(5 litters; 3-4 pups) 
13 6 0 
 
None of the total 12 Pts-ki/ko showed signs to have an “affected” phenotype. All 
animals were investigated for their PTPS activity in liver and brain (Fig. 21 A), blood 
L-Phe and L-Tyr (Fig. 21 B), biopterin in liver and brain (Fig. 21 C), neopterin in liver 
and brain (Fig. 21 D), and brain monoamine neurotransmitters dopamine, 
norepinephrine, epinephrine and serotonin (Fig. 21 E). Pts-ki/wt siblings were used 
as control comparison, where no differences were expected between small and large 
litters. 
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Figure 21: Comparison between Pts-ki/ko mice from big litters (8-9 pups) and small litters (3-
4 pups) of Pts-ki/ki mothers and Pts-ko/wt fathers by biochemical analysis of blood, liver and 
brain tissue. (A) Blood L-Phe and L-Tyr concentrations (µmol/l). (B) PTPS enzyme activity in 
liver and brain (µU/mg protein). (C) Biopterin levels in liver and brain (pmol/mg protein). (D) 
Neopterin levels in liver and brain (pmol/mg protein). (E) Brain monoamine neurotransmitters 
dopamine, norepinephrine, epinephrine and serotonin levels (pmol/mg protein). Genotypes 
are indicated by bar colour: Pts-ki/wt mice from small litters are shown in gray, Pts-ki/ko mice 
from small litters are shown in gray striped, Pts-ki/wt mice from large litters are shown in 
black, and Pts-ki/ko mice from large litters are shown in black striped. Significant difference is 
indicated by asterisks: * p < 0.05, ** p <0.01, *** p <0.001 (two-tailed Student’s t-test). 
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Pts-ki/ko mice from big litters had significantly reduced PTPS activity in liver in 
comparison to Pts-ki/ko mice from small litters (3.6 times less; p < 0.01; Fig. 21 A). 
There was no difference in liver PTPS activity in Pts-ki/wt siblings derived from 
different litter sizes. There was no significantly difference in brain PTPS activity for 
Pts-ki/ko (or Pts-ki/wt) derived from small or big litters (Fig. 21 A). Pts-ki/ko mice from 
small litters had the highest blood L-Phe levels and were significantly different from 
Pts-ki/wt from big litters (p < 0.05; Fig. 21 B). There was no significant difference in 
blood L-Tyr levels (Fig. 21 B) or biopterin amounts in liver and brain (Fig. 21 C) for 
Pts-ki/ko and Pts-ki/wt derived from small or big litters. In general, Pts-ki/ko mice had 
increased neopterin levels in liver and brain in comparison to Pts-ki/wt (p < 0.001), 
but there were no significant differences between Pts-ki/ko mice or Pts-ki/wt derived 
from small or big litters (Fig. 21 D). Pts-ki/wt mice from small litters had significant 
higher norepinephrine levels then Pts-ki/wt and Pts-ki/ko mice from big litters or Pts-
ki/ko from small litters (p < 0.05; Fig. 21 E). There was no difference for the brain 
catecholamines dopamine or epinephrine, or the brain monoamine neurotransmitter 
serotonin for Pts-ki/ko and Pts-ki/wt derived from small or big litters (Fig. 21 E). In 
summary, Pts-ki/ko mice from big litters had significantly reduced PTPS activity in 
liver in comparison to Pts-ki/ko mice from small litters, but not for the other 
parameters measured. Furthermore, none of the investigated Pts-ki/ko mice had an 
“affected” phenotype. 
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3.2.4 DISCUSSION 
 
The observation in the dissertation of D. Adamsen (2011) that Pts-ki/ki mothers 
produce “affected” Pts-ki/ko mice, which reflect the severe and central form of BH4 
deficiency, was not supported in the presented study. It is unknown what led to the 
description of “affected” Pts-ki/ko mouse phenotype. A possible explanation could be 
found in the different breeding conditions for D. Adamsen’s and the present study. In 
the present study, female mice were separated from other mice to raise their pups  in 
order to decrease stress and stress induced cannibalism of pups reported to 
frequently appear in C57BL/6 derived mouse strains, and to increase the chances of 
newborn survival (Burds Connor, 2007). In D. Adamsen breeding, several females 
were kept with a male mouse in a cage, which led to high litters when the mouse 
mothers gave birth and therefore, it increased the “struggle stress” for mother milk 
between the newborns, which also increased the newborn lethality rate. This effect of 
increased newborn “struggle stress” is even bigger when litters were born at different 
time points, given the younger and weaker mice decreased chances of getting 
mother care. Probably due to mixed aged litters and in consequence increased 
lethality rate in newborns, the wrong impression of “affected” and “unaffected” Pts-
ki/ko mice could have been raised. Indications for this assumption can be found on 
Fig. 18 shown in chapter 3.2.1, which shows a picture from D. Adamsen’s 
dissertation, showing a so called “unaffected” (left) and an “affected” (right) Pts-ki/ko 
mouse (Adamsen, 2011). Since genotyping of mice at this age was not possible, it 
would be not possible to distinguish Pts-ki/wt from Pts-ki/ko siblings, and therefore, it 
is unclear if the mouse pups on Fig. 18, actually shows Pts-ki/ko or Pts-ki/wt mice. 
Nevertheless, the right pup does not show unhealthy sings such as starvation or 
dehydration, which would lead to a shrunken and skinny body due to negligence from 
the mother as described in D. Adamsen’s dissertation to happen at day 3-4 after 
birth. In comparison, the skin color of the left animal on Fig. 18 looks rather gray due 
to changes of the skin color from pink to gray during day 3-4, whereas the skin colour 
of the right animal is still quite pink (Schertzer and Lynch, 2008; Burds Connor, 
2007). Therefore, Fig. 18 rather shows two pups with different ages, then a healthy 
and an under developed animal. Nevertheless, there is still the open question of the 
biochemical analysis of the so called “affected” Pts-ki/ko mice, which showed 
depletion of biopterin and brain monoamine neurotransmitters, and mild HPA. It can 
be only speculated that maybe dying or dead newborns were collected and 
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compared with 3-4 days old healthy mice, which could lead to not comparable and/or 
not reliable results. Nevertheless, in my own biochemical comparison I found in Pts-
ki/ko newborns from different breeding combination of homozygous or heterozygous 
Pts-ki bred with heterozygous Pts-ko mice slightly differences in PTPS activity (liver 
and brain), biopterin (liver and brain), neopterin (liver), blood L-Phe and L-Tyr, and 
brain serotonin levels. Therefore, it might be of interest in potential further and future 
studies to investigate whether such differences could also be found in adult mice. 
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4.1 EXPERIMENTAL STUDY ON A NON-VIRAL GENE THERAPY APPROACH BY 
INTRAMUSCULAR EXPRESSION OF A COMPLETE PHENYLALANINE 
HYDROXYLATING SYSTEM 
 
 
4.1.1 ABSTRACT 
 
Complete correction of cPKU with rAAV in the Pahenu2/2 mouse model system was 
shown by targeting skeletal muscle to express the complete L-Phe hydroxylating 
system by coordinate expression of the three murine genes Pah, Gch1 and Pts to 
produce PAH and its cofactor BH4 that are both naturally not present in muscle. 
Nevertheless, AAV gene therapy in human patients would need very high amount of 
virus, which is technically difficult and related with high costs. Furthermore, rAAV can 
trigger immunogenicity, inflammatory response, severe malignancy and eventually 
complete shutdown of transgene expression in humans. Recently, the first non-viral 
gene therapy was reported that corrected cPKU in Pahenu2/2 mice by liver-targeting 
with naked DNA vectors named MC (Viecelli et al., 2014). The goal of this study is to 
achieve a non-viral muscle-directed gene therapy to correct cPKU in the Pahenu2/2 
mouse model system. Besides applying the original triple-cystronic cassette used in 
the viral approach, various additional modifications to potentially enhance 
expression, including codon-optimization, insertion of intronic sequences, 
transcription or gene expression latency elements like WPRE and/or the 
scaffold/matrix attachment region (S/MAR) were generated, resulting in up to 12 
potential therapeutic MC vectors for in vivo testing. All vectors were validated under 
cell culture conditions for enzyme activity and biopterin biosynthesis. MCs were 
delivered to skeletal muscles of Pahenu2/2 mice by hydrodynamic limb vein (HLV) 
injection or electroporation. To assess extension and distribution of MCs in muscle 
tissue, a MC expressing the firefly luciferase (Luc) was electroporated into Pahenu2/2 
mice and analyzed thereafter by using an in vivo imaging system (IVIS) (Ding et al., 
2008, Lim et al., 2009). Although high concentrations of triple-cistronic MCs were 
applied, there was no correction of blood L-Phe levels in the Pahenu2/2 mice. 
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4.1.2 INTRODUCTION 
 
Although cPKU is a treatable metabolic disease by life-long restricted diet of the 
amino acid L-Phe, a permanent cure that would eliminate sole dependence upon 
dietary therapy would be a big improvement in life quality for all individuals with 
cPKU, their families, and health care providers. Therefore, gene therapy is an 
attractive approach to treat cPKU. Several experimental gene therapies reported the 
complete and life-long gender-independent correction of blood L-Phe levels in 
Pahenu2/2 mice, by targeting the liver using high viral doses of AAV2 pseudo-typed 
with serotypes 1, 2 or 8 expressing the mPah transgene (Ding et al., 2006, 
McDonnald, 2006, Rebuffat et al., 2010, Thöny, 2010). The pathophysiology of many 
inborn errors of metabolism like in e.g. cPKU is mediated by circulating toxic 
metabolites, rather than a local effect of enzyme deficiency in a specific tissue 
(Meyburg and Hoffmann, 2008, Alfadhel et al., 2013). Therefore, expression of a L-
Phe metabolizing system in tissues other than liver should also lead to correction of 
HPA and its attendant phenotypic features. The complete correction of cPKU in 
Pahenu2/2 mice by AAV2 serotype 1 mediated intramuscular expression of a complete 
L-Phe hydroxylating system, which required the coordinate expression of the three 
murine genes mPah-mGch1-mPts (vector AAV2-PKU3) in skeletal muscle was 
successfully achieved (see Fig. 22) (Ding et al., 2008). Skeletal muscle is an 
attractive target tissue because it is a not essential vital organ with readily 
accessibility through direct injection or intravascular delivery methods, it is supported 
by a vigorous blood supply, and it makes up as much as 20-30% of the human body 
weight and 35% of mouse body weight (Arora and Rochester, 1982, Stratikopoulos et 
al., 2008).   
 
Despite the worldwide success with AAV-based gene transfer in small and large 
animal disease models, AAV can trigger immunogenicity, inflammatory response, 
severe malignancy like e.g. that neonatal injection of an AAV vector led to 
hepatocellular carcinoma in mice, and eventually complete shutdown of transgene 
expression in humans (Donsante et al., 2007, Hasbrouck and High, 2008). 
Furthermore, it was reported that the transduction efficacy and transgene expression 
after liver-targeted delivery of AAV in female mice was significantly decreased in 
comparison to male mice, whereas sex did not have a significant effect on AAV gene 
transfer into non-hepatic tissues (Davidoff et al., 2003). In this context, non-viral 
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vectors for gene therapy have recently gained considerable momentum, and are 
becoming very attractive in combination with the MC technology (Viola et al., 
Donsante et al., 2001, Al-Dosari and Gao, 2009; see also chapter 1.3.6.2). Moreover, 
it was shown that MCs express their transgenes longer and at higher levels in the 
liver in comparison to their PP, which still includes the bacterial backbone, upon a 
single hydrodynamic tail vein injection (Hutchins, 2000, Gorecki, 2006, Viecelli et al., 
2014). Recently, complete correction of HPA in Pahenu2/2 mice was achieved by liver-
directed MC naked DNA gene therapy (Viecelli et al., 2014).  
 
The goal of this study was to evaluate a non-viral triple-cystronic expression of a 
complete L-Phe metabolizing system in skeletal muscle for the normalization of L-
Phe and correction of the cPKU phenotype in Pahenu2/2 mice, analog to the approved 
viral muscle gene therapy (see Fig. 22). Therefore, the triple-cistronic mPah-mGch1-
mPts expression cassette was used in a MC vector to target the skeletal muscles of 
Pahenu2/2 mice (Fig. 22).  
Figure 22: Schematic representation of viral and non-viral vector gene therapy. mPah, murine 
phenylalanine hydroxylase gene; mGch1, murine guanosine triphosphate cyclohydrolase 1 gene; 
mPts, murine 6-pyruvoyl-tetrahydropterin synthase gene; MC, minicircle; BH4, tetrahydrobiopterin; L-
Phe, L-phenylalanine, rAAV2/1-PKU3, recombinant AAV2 serotype 1-mediated vector expressing the 
genes mPah-mGch1-mPts. 
 
Since naked DNA has a low transfection efficacy and transient expression in vivo, the 
triple-cistronic vector was modified by codon optimization, and insertion of intronic 
sequence, woodchuck hepatitis WPRE and/or the scaffold/matrix attachment region 
(S/MAR) elements (Hagstrom et al., 2004). The codon optimization refers to the 20 
so-called biogenic amino acids, which are encoded by 61 codons (three nucleotides 
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encoding for a specific amino acid) and therefore many amino acids are encoded by 
more than one codon (“codon degeneration”). There can be preferences for one of 
the synonymous codons that encode for the same amino acid (codon usage bias), 
and this preference could influence e.g. gene expression level (Gustafsson et al., 
2004). There are several statistical methods to predict gene expression levels based 
on codon usage bias, which differs from organism to organism and can be even cell 
or tissue specific (Comeron and Aguade, 1998, Fox and Erill, 2010). Furthermore, 
codon optimization algorithms include avoidance of CpG islands, secondary 
structures, cryptic splice sites splice suppressors and restriction enzyme recognition 
sites (Satya et al., 2003, Gustafsson et al., 2004). Modifications of genes according 
to such statistical methods showed that these codon-optimized genes had positive 
effects at transcriptional, translational, and mRNA stability levels (Grosjean and Fiers, 
1982, Fath et al., 2011). Furthermore, it has been shown that the insertion of intronic 
sequence into a transgene increases expression in mice which can lead to 400-time 
more RNA, depending on the position of insertion (Buchman and Berg, 1988, 
Palmiter et al., 1991). Therefore, a minimized version of mPah intron 1 was inserted 
in some MC constructs. The minimized intron 1 version consists of only 819 bp out of 
6,222 bp of the total intron 1 sequence, including 299 bp downstream of exon 1 and 
520 bp upstream of exon 2. To further enhance gene expression, WPRE was 
inserted in some of the MC vectors (Klein et al., 2006). Furthermore, it was described 
that the addition of a S/MAR sequence in MC increases stability of expression and 
latency in vivo (Argyros et al., 2011). For a first validation of the different modified MC 
vectors, in vitro (cell culture) studies were used to elucidate the MCs with the highest 
enzyme activity and biopterin biosynthesis, which were then tested in a second step 
in vivo in Pahenu2/2 mice for therapeutic efficacy. Two in vivo application techniques to 
target skeletal muscle cells were used: HLV injection or electroporation (Schertzer 
and Lynch, 2008, Zhang et al., 2010).  Furthermore, to assess the extension of 
distribution of MC in the muscle in vivo, a MC expressing the Luc was used to 
perform IVIS (Ding et al., 2008, Lim et al., 2009).  
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4.1.3 MATERIALS AND METHODS 
 
4.1.3.1 Vector plasmids 
 
Sequencing analysis of AAV2-PKU3 plasmid revealed two missense mutations, one 
located in the mPah (c.1126G>A, p.E376K) and one in the mPts gene (c.230A>G; 
p.E77G) and the disruption of one of the two inverted terminal repeat (ITR) sites, 
necessary to generate rAAV. Therefore, the AAV2-PKU3.3 was cloned with the 
correction of the two mutations and the replacement of the disrupted ITR site (see 
chapter 5.1). The mPts and mGch1 cDNA were codon optimized and synthesized by 
GenScript USA Inc. (Piscataway, USA). The mPah were codon optimized and 
synthesized by GeneArt® Life technology (Regensburg, Germany). Detailed 
descriptions of all plasmids are listed in chapter 5.1. 
 
 
4.1.3.2 Transfection of COS-1 cells with PP or MC vectors 
 
MC or PP vectors were transfected in combination with a β-galactosidase-expressing 
plasmid in COS-1 cells as described in a published method (Heintz et al., 2012).  
 
 
4.1.3.3 Enzyme activity assays in vitro 
 
β-galactosidase expression assay was performed according to the protocol of the ß-
galactosidase enzyme assay system by Promega (Ref. nr. E2000, Dübendorf, 
Switzerland). The optical density (OD) at 420 nm was measured with an Ultrospec 
3100 Pro UV/visible spectrophotometer (linear range OD 0.2-0.8; Ref. nr. 80-2112-
31; Amersham Bioscience, Glattbrugg, Switzerland). The amount of biopterin and 
PAH, GTPCH and PTPS enzyme activities of the PP or MC transfected COS-1 cells 
were measured according to published methods (Bonafe et al., 2001, Blau, 2008b, 
Heintz et al., 2012). Enzyme activity and biopterin levels were normalized to the β-
galactosidase expression and the plasmid size using the AAV2-PKU3 plasmid as 
reference. 
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4.1.3.4 Hydrodynamic limb vein injection of MC into Pahenu2/2 mice 
 
Both hind limbs of Pahenu2/2 mice were used for hydrodynamic limb vein injection with 
total of 1 mg MC DNA per injection. This was done in a collaborative approach in the 
laboratory of C. O. Harding and S. Winn at the Department of Molecular and Medical 
Genetics at the Oregon Health & Science University (Portland, Oregon, USA) (Zhang 
et al., 2010). Pahenu2/2 mice are fed with standard mouse chow leading to high blood 
L-Phe levels in the Pahenu2/2 mice.  
 
 
4.1.3.5 Electroporation of MC into Pahenu2/2 mice 
 
120 µg MC DNA was electroporated into the musculus (m.) gastrocnemius (left leg) 
or m. vastus (right leg) of the hind limbs of Pahenu2/2 mice in collaboration with Lars 
Aagaard and Hanne Gissel Hyldkrog from the Department of Biomedicine  at the 
University of Aarhus (Denmark). All Pahenu2/2 mice were fed with L-Phe deficient diet 
with 1.5% tyrosine from Harlan Teklad custom research diets (https://www. 
harlan.com), and 0.625 mg/ml L-Phe is added in the drinking water. Under these 
housing conditions Pahenu2/2 mice show low L-Phe levels (<360 µmol/l). After 
electroporation, the drinking L-Phe levels were elevated to 2.5 mg/ml during the 
length of the experiment, which increases the blood L-Phe (>360 µmol/l) levels in 
PKU mice (Schertzer and Lynch, 2008).  
 
 
4.1.3.6 In vivo imaging system  
 
Mice were anaesthetized with 2-3% isoflurane and 150 mg/kg body weight D-luciferin 
(Ref. nr. LUCNA-1G; Gold Biotechnology, St. Louis, USA) was subcutaneously 
injected. After 10 min, mice were screened for Luc expression with the 
bioluminescence by the Xenogen IVIS Imaging 200 Series (Ref. nr. IVIS200; Perkin 
Elmer, Santa Clara, USA). Data are analyzed by using LIVINGIMAGE 3.20 software 
from Xenogen. Background levels of bioluminescence for mice should be around 3 x 
105 photons/sec (p/s).  
 
 
4.1.3.7 Blood L-Phe measurements  
 
Blood L-Phe was measured in dried blood spots by tandem MS/MS according to a 
published method (Guthrie and Susi, 1963; Rashed et al., 1995).  
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4.1.4 RESULTS 
 
4.1.4.1 MC vectors and in vitro expression  
 
Table 7 lists all MC vectors generated for this study. All MC vectors contained the 
human cytomegalovirus promoter (CMV) for coordinately expression in combination 
with internal ribosomal entry site (IRES) elements between the three genes mPah, 
mGch1 and mPts. In this study, control vector AAV2-PKU3.3 was used instead of the 
published triple-cystronic AAV2-PKU3 vector because of the found disruptions in the 
AAV2-PKU3 vector described in chapter 4.1.3.1 and 5.1. Analogous to the 
therapeutic viral vector AAV2-PKU3.3, the MC vector MC.PKU104 was generated. In 
a next step, the viral element WPRE was excluded from the MC vector to avoid 
potential immune reaction against the WPRE, generating the MC.PKU105 vector. To 
increase stability of expression and latency in vivo, S/MAR was added to the triple-
cystronic vector, named MC.PKU106. Furthermore, the Luc was added for potential 
IVIS recording (MC.PKU102). In a next step, the MC vectors were stepwise codon 
optimized. First, mPah was converted to murine codon optimized (mco) Pah with 
(MC.PKU108) or without (MC.PKU109) WPRE. The mcoPah has all exons codon 
optimized except of exon 1, which remained wild-type. A shorted version of mPah 
intron 1 (819 bp) was introduced in the mcoPah with (pMC.PKU114) or without 
(MC.PKU115) WPRE. In a second step, all three genes were codon optimized, again 
with (MC.PKU116) or without (MC.PKU117) WPRE. In a last step, MC vectors with 
mcoPah containing the short intron 1, mcoGch1 and mcoPts genes were generated 
with (MC.PKU118) or without (MC.PKU119) WPRE. For IVIS studies, MC.PKU121 
was generated containing only Luc. 
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Table 7. List of MC vectors. 
Vector Vector type Promoter mPah mGch1 mPts Luc 
Enhancing 
elements 
PP size 
(bp) 
MC size 
(bp) 
AAV2-PKU3.3 viral CMV wt wt wt - WPRE 9,376 - 
MC.PKU104 non-viral CMV wt wt wt - WPRE 9,382 5,382 
MC.PKU105 non-viral CMV wt wt wt - - 8,798 4,798 
MC.PKU106 non-viral CMV wt wt wt - S/MAR 11,040 7,040 
MC.PKU102 non-viral CMV wt wt wt wt S/MAR 13,065 9,065 
MC.PKU108 non-viral CMV mco wt wt - WPRE 9,434 5,434 
MC.PKU109 non-viral CMV mco wt wt - - 8,850 4,850 
MC.PKU114 non-viral CMV mco + intron wt wt - WPRE 10,092 6,092 
MC.PKU115 non-viral CMV mco + intron wt wt - - 9,508 5,508 
MC.PKU116 non-viral CMV mco mco mco - WPRE 9,443 5,443 
MC.PKU117 non-viral CMV mco mco mco -  8,859 4,859 
MC.PKU118 non-viral CMV mco + intron mco mco - WPRE 10,101 6,101 
MC.PKU119 non-viral CMV mco + intron mco mco - - 9,517 5,517 
MC.PKU121 non-viral CMV - - - wt - 7,390 3,390 
 
 
CMV, human cytomegalovirus promoter; mPah, murine phenylalanine hydroxylase gene; mGch1, 
murine GTP cyclohydroxylase 1 gene; mPts, murine 6-pyruvoyl-tetrahydropterin synthase gene; Luc, 
firefly luciferase gene; WPRE, woodchuck hepatitis post-transcriptional regulatory element; S/MAR, 
scaffold/matrix attachment region; wt, wild-type; mco, mouse codon optimized; PP, parental plasmid; 
MC, minicircle. 
 
To compare the enzyme activity of the non-viral vectors, the MC and PP vectors were 
tested in transiently transduced COS-1 cells for their biopterin biosynthesis and for 
their PAH, PTPS and GTPCH enzyme activity (summarized in Fig. 23 A-D).  
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PAH enzyme activity in vitro
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Figure 23: Biopterin amount or enzyme activities (PAH, GTPCH and PTPS) of PP and MC vectors. 
(A) Biopterin levels (pmol/mg protein). (B) PAH activity (mU/mg protein). (C) GTPCH activity (µU/mg 
protein). (D) PTPS activity (µU/mg protein). PPs are shown by filled out bars; MCs are shown by striped 
bars; insertion of WPRE is indicated with a gray plus; insertion of S/MAR is indicated with a black plus.  
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All tested PP and MC vectors showed enzyme activity and biopterin biosynthesis in 
vitro. MC vectors showed not much more enzyme activity or higher biopterin levels 
then PP plasmids in vitro. Furthermore, codon optimization and/or the insertion of an 
intron did not lead to much higher enzyme activity or increased biopterin levels in 
vitro. MC vectors containing the WPRE showed in general slightly elevated enzyme 
activity and/or biopterin levels in comparison to equivalent vectors without WPRE. 
 
 
4.1.4.2 In vivo application of MCs by HLV injection 
 
To investigate the therapeutic efficacy in vivo of the triple-cystronic MCs, namely 
MC.PKU102, 104, 105, 108, 109, 117, 118 or 119, 1 mg DNA of each of the MC 
vectors was HLV-injected into both hind legs of Pahenu2/2 mice. An overview of the 
type and amount of HLV injected MCs is summarized in table 8. 
 
Table 8:  List of HLV injected MCs into the hind limbs of Pahenu2/2 mice. 
 
Vector Size Amount (µg) Amount (pmol) Vector particles (vp) 
MC.PKU102 9065 1000 167.1 1.0 x1014 
MC.PKU104 5382 1000 281.5 1.7 x1014 
MC.PKU105 4798 1000 315.7 1.9 x1014 
MC.PKU108 5434 1000 278.8 1.7 x1014 
MC.PKU109 4850 1000 312.4 1.9 x1014 
MC.PKU117 4859 1000 311.8 1.9 x1014 
MC.PKU118 6101 1000 (x4) 248.3 (x4) 1.5 x1014 (x4) 
MC.PKU119 5517 1000 (x4) 274.6 (x4) 1.7 x1014 (x4) 
 
Injection efficacy was between 30-60% (personal communication with S. Winn). To 
calculate the injection efficacy, the amount of muscle expansion was observed during 
the HLV injection as well as the leakage of the injection fluid.  In an optimal injection 
procedure,  the m. gastrocnemius expanded 2x-3x with less than 10% fluid "leakage" 
or loss leading to approximately 70% of the muscle cells to take-up and express the 
genetic material (shown by GFP expression system; personal communication with S. 
Winn). Blood L-Phe was measured at different time points as depicted in Fig. 24. 
Pahenu2/2 mice injected with MC.PKU118 or 119 were re-injected at day 18, 45 and 60 
with 1 mg of MC DNA.  
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L-Phe: HLV injected Pahenu2/2 mice  
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Figure 24: Blood L-Phe levels of MC HLV injected Pahenu2/2 mice (µmol/l). Arrows are indicating 
(re)injection; MC.PKU102 is shown in yellow; MC.PKU104 is shown in red; MC.PKU105 is shown in 
light green; MC.PKU108 is shown in turquoise; MC.PKU109 is shown in purple; MC.PKU117 is shown 
in blue; MC.PKU118 is shown in dark green; MC.PKU119 is shown in violet. Therapeutic range is 
indicated below 360 µmol/l L-Phe.  
 
Unfortunately, none of the MC injected into Pahenu2/2 mice showed normalization L-
Phe levels (<360 µmol/l). Further measurements are needed to elucidate the vector 
copy number, PAH, GTPCH and PTPS activities, and/or BH4 content in the MC 
treated muscle tissue. 
 
4.1.4.3 In vivo application of MCs by electroporation 
 
The HLV injection method showed high variation in transfection efficacy. Therefore, a 
potentially more precise application method, namely electroporation, was used to 
transfer the MCs into muscle cells in a next approach. For the electroporation, MCs 
with the wild-type versions of three genes with (MC.PKU104) or without 
(MC.PKU105) WPRE or mcoPah including an intron in combination with the wild-type 
mGch1 and mPts genes with WPRE (MC.PKU114) were chosen. MC.PKU105 was 
chosen to exclude the probability that any immune reaction against WPRE would 
eliminate the MC DNA in vivo.  MC.PKU121, which expresses the Luc gene, was 
used to visualize the expression and distribution of the electroporated MCs in vivo by 
using IVIS. 120 µg DNA was electroporated for each vector into either m. vastus 
(right hind leg) or m. gastrocnemius (left hind leg) of Pahenu2/2 mice (total 240 µg) by 
H. G. Hyldkrog (see table 9).  
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Table 9: List of electroporated MCs into the hind limbs of Pahenu2/2 mice. 
Vector Size Amount (µg) Amount (pmol) Vector particles (vp) 
MC.PKU104 5382 240 67.6 4.1 x1013 
MC.PKU105 4798 240 75.8 4.6 x1013 
pMC.PKU114 6092 240 59.7 3.6 x1013 
pMC.PKU121 3390 240 107.3 6.5 x1013 
 
The Pahenu2/2 mice were housed on a low L-Phe diet leading to low blood L-Phe 
levels (<360 µmol/l). After electroporation, their diet was supplemented with an 
increased dose of L-Phe, which leads to HPA in untreated PAH deficient mice. 
Theoretically, the MC.PKU 104, 105 or 114 treatments should prevent Pahenu2/2 mice 
to develop HPA when supplied with high dose of L-Phe. The L-Phe increased diet 
was continued until mice were sacrificed at day 56. PKU mice electroporated with 
vector MC.PKU121 (expressing only the Luc gene) were used as negative control. 
For positive control, a Pahenu2/2 mouse was hydrodynamic tail vein (HTV) injected with 
a liver directed lentivirus expressing mPah. Luc expression was investigated by IVIS 
at day 3, 6, 14, and 29 (Fig. 25 A-B) as well as blood L-Phe until day 56 (Fig. 25 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
PKU Mouse Model – Non-Viral Gene Therapy Approaches 
 176
IVIS Data: Electroporation (MC.PKU121)
1.0E+05
1.0E+06
1.0E+07
1.0E+08
1.0E+09
0 7 14 21 28
Days after injection
To
ta
l F
lu
x [
p/
s]
Gastrocnemius (n=3-5)
Vastus (n=3-5)
0
360
720
1080
1440
1800
2160
2520
2880
0 7 14 21 28 35 42 49 56 63
µm
ol
/l
Days after injection
MC.PKU104 (n = 5)
MC.PKU105 (n = 5)
MC.PKU114 (n = 5)
MC.PKU121 (n = 3)
Lentivirus (n = 1)
L-Phe: Electroporated Pahenu2 /2 mice
IVIS data: Electroporation (MC.PKU121) 
L-Phe: Electr porated PKU mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: IVIS and blood L-Phe levels of MC electroporated Pahenu2/2 mice. (A) IVIS pictures of 
MC.PKU121 application. (B) IVIS data of MC.PKU121 application (p/s). (C) Blood L-Phe levels 
(µmol/l). MC.PKU104 shown in red; MC.PKU105 shown in light green; MC.PKU114 shown in pink; 
MC.PKU121 shown in light blue; lentivirus black; therapeutic range is indicated below 360 µmol/l L-
Phe. 
 
Pahenu2/2 mice electroporated with MC.PKU121 showed stable Luc expression up to 
29 days (Fig. 25 A-B). None of the MCs electroporated Pahenu2/2 mice showed low L-
Phe levels (< 360 µmol/l) until day 56 (Fig. 25 C). It seems that at day 6 the blood L-
Phe levels of the PKU mice electroplated with MC.PKU104, 105 or 114 had slightly 
lower L-Phe levels than Pahenu2/2 mice electroplated with the negative control vector, 
although it was not a significant different (p > 0.053). At day 6 the positive control 
Pahenu2/2 mouse, which was HTV injected with the lentivirus, showed low blood L-Phe 
levels (< 360 µmol/l). Surprisingly, at day 14 the blood L-Phe level of this mouse was 
high and dropped again at day 21 and stayed low until day 56. In general, there were 
high fluctuations in blood L-Phe levels because the Pahenu2/2 mice were not starved. 
Again, further analyses need to be done with muscle tissue of MCs treated mice to reveal the 
vector copy number, PAH, GTPCH and PTPS activities, and/or BH4 content. 
B 
C 
m. gastrocnemius (n=3-5) 
m. vastus (n=3-5) 
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4.1.5 DISCUSSION 
 
In this study, 12 potential therapeutic MC vectors were generated, and in a first step, 
the different vectors with various modifications (codon-optimization, insertion of 
intron, WPRE and S/MAR) were compared in vitro: PAH, GTPCH and PTPS enzyme 
activity as well as the biosynthesis of biopterin was quantified in comparison the 
control vector AAV2-PKU3.3. All PP and MC constructs showed PAH, GTPCH and 
PTPS enzyme activity, despite that the GTPCH enzyme activity was rather low and 
all transfected cells showed detectable levels of biopterin. The results of enzyme 
activity and biopterin production from cells transfected with PP compared to MC 
showed that transgene expression from MC vectors was not advantageous over the 
PP. The in vivo study of PP versus MC treated Pahenu2/2 mice showed that Pahenu2/2 
mice injected with the same amount of PP and MC had indeed similar relative mPah-
mRNA gene expressions and DNA copy numbers per diploid genome, but PP 
injected Pahenu2/2 mice had only little to no PAH enzyme activity and therefore, no 
therapeutic efficacy, whereas MC treaded Pahenu2/2 mice lowered blood L-Phe levels 
for a period of up to 180 days (Viecelli et al., 2014). It was hypothesized that PP were 
either transcriptionally blocked or very rapidly suppressed due to the phenomenon of 
plasmid-derived transcription blocking or silencing in liver and other organs due to the 
bacterial backbone (Viecelli et al., 2014). Vectors (PPs or MCs) carrying the WPRE 
had somewhat higher enzyme expression and produced more biopterin in vitro.  
 
Although all vectors were shown to  be functional in vitro, none of the MCs vectors 
lead to lower blood  L-Phe levels in Pahenu2/2 mice independent whether they were 
infused by HLV injection or electroporation, even at very high doses of up to 4 mg of 
MC DNA (total 6-6.8 x 1014 vp). For HLV injected Pahenu2/2 mice, the transfection 
varied from 30-60% efficacy. In liver, 3 x 1012 vp (7.7 µg) of MC DNA still showed 
blood L-Phe lowering to less than 600 µmol/l up to 180 days. Personal 
communication with Hiu Man Viecelli (Division of Metabolism, University Children’s 
Hospital Zurich, Switzerland) revealed that MC expressing the mcoPah version used 
in this study did not let to therapeutic efficacy when HTL injected into the liver for 
unknown reasons. In contrast, MC vector expressing the mcoPah including the short 
version of intron 1 (same as used in this study) showed up to 10 times better efficacy 
then MC containing the wild-type Pah cDNA version. Therefore, it would be not 
surprising if MCs carrying a codon optimized version of mPah or even mGch1 and 
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mPts are inefficient in vivo, which concerns the vectors MC.PKU108, 109 and 116-
119. This would also theoretically explain why multiple injection of MC.PKU118 or 
119 did not lead to blood L-Phe lowering in the Pahenu2/2 mice.  
 
The HLV injection method showed apparently high variations based on the amount of 
muscle expansion during the HLV injection as well as the leakage of the injection 
fluid (was between 30-60%; personal communication by S. Winn, see chapter 
4.1.4.2). Analysis of treated mice still needs to be done to validate the efficacy of the 
HVL technique. Validation includes measuring vector genome copy numbers or 
immunohistology to show the number of PAH expressing transduced myocytes. In 
parallel, another established method, namely electroporation, was used to transfer 
MC DNA into skeletal muscle tissue. Electroporation has the advantage that different 
muscle parties can be targeted independent from each other. In this study, Pahenu2/2 
mice were electroporated into the m. vastus and m. gastrocnemius. For 
electroporation, MCs only carrying a wild-type mPah or a mcoPah including an intron 
were chosen. Studies with MC.PKU121 expressing Luc showed relative stable 
transcription in the m. gastrocnemius and m. vastus. In general, the electroporated 
m. gastrocnemius showed slightly higher Luc expression than m. vastus, although 
there was no significant difference between the two muscles (Student’s t-test). 
Unfortunately, also the electroporated PKU mice had not lowered blood L-Phe levels 
when treated with MCs. In this study approach, Pahenu2/2 mice were fed with a L-Phe 
poor diet and L-Phe is added in the drinking water. Before blood collection, mice 
were not starved which might lead to higher variations in blood L-Phe levels. On day 
6, the Pahenu2/2 mice electroporated with the theoretically expected best treatment 
vector MC.PKU114 had almost significant lower blood L-Phe levels then the negative 
control group injected with MC.PKU121. Very unusual is the behavior of the blood L-
Phe levels of positive control mouse that was HTV injected with the lentivirus 
expressing mPah in liver. As expected, this mouse showed low blood L-Phe levels at 
day 7, but surprisingly and for unknown reasons high levels at day 14, which declined 
again at day 21 and stayed low the rest of the experiment.  
 
Overall, it is unknown, why none of the injected/electroporated MCs showed not even 
transient therapeutic efficacy. As mentioned, one parameter could be that codon 
optimized genes are not therapeutic, although the reason for this phenomenon is 
unknown. Furthermore, it was shown that liver targeting MCs including S/MAR or Luc 
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had no therapeutic efficacy in Pahenu2/2 mice (personal communication H. M. Viecelli). 
Also in this study, MCs including Luc and/or S/MAR showed generally lower enzyme 
activities and biopterin production in vitro. It is not known if these elements alter the 
gene expression of mPah or if the increased size of these MCs has a reduced 
injection and/or cell integration efficacy. Although there is theoretically no size 
limitation in MCs, it has been shown for electroporated muscle cells that smaller DNA 
molecules have a higher transfection efficacy (Molnar et al., 2004). Even the smallest 
therapeutic MC for muscle gene therapy is more then double the size of the used 
therapeutic MC for liver non-viral gene therapy (Viecelli et al., 2014). Therefore, it 
would be interesting to test if larger MCs also lead to therapeutic efficacy in liver, to 
exclude that larger vectors reduce therapeutic efficacy.  There is also the probability 
of too low injected/electroporated dose of MCs. It was shown in MC liver gene 
therapy for PKU mice that 3 x 1012 vp were still sufficient for blood L-Phe lowering 
(Viecelli et al., 2014). In this study, doses between 4.1 – 68 x 1013 vp were used still 
leading to no therapeutic efficacy. Open questions like silencing/methylation of the 
MCs or degradation could be answered by further analysis of the 
injected/electroporated tissue. 
 
In the future, it should be focused on the application of non-viral vector analogous to 
the therapeutic vectors AAV-PKU3.3, i.e. MC.PKU105 or MC.PKU104. Also MCs 
including an intron in the mcoPah transgene but no codon-optimization like 
MC.PKU114 and 115 are very promising vectors for muscle gene therapy. Since HLV 
injection showed high variations in transfection efficiency, electroporation is the 
preferable method for MC delivery. Furthermore, it is necessary to figure out if 
therapeutic efficacy of MCs that can be altered by vector size, which could lead to a 
reduced cell transfection rate. Future analysis for enzyme activity and transgene 
expression studies for the injected/electroporated muscle tissues need to be done. 
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4.2 ATTEMPT TO GENERATE A PKU MOUSE MODEL 
SYNTHESISING BH4 IN MUSCLE BY EXPRESSING THE GCH1 AND 
PTS GENES USING AAV 
 
4.2.1 ABSTRACT 
 
As reported in the precedent chapter, attempts to correct cPKU by coordinate 
expression of three genes in skeletal muscle from a non-viral MC vector were not 
successful. Although the reason for this was not clear, it was speculated that a PKU 
mouse with stable expression of mGch1 and mPts and thus biosynthesis of BH4 in 
skeletal muscle might be a helpful tool for further studies. With such a PKU mouse, 
MC delivery and testing for muscle gene expression would be limited to one gene 
vector, i.e. Pah, instead of three genes, to eventually correct cPKU in muscle of the 
Pahenu2/2 mice. Stable expression of mGch1 and mPts in PKU mice was attempted by 
using an AAV2 serotype 1 vector. Therefore, in a first step, it was tested if mPah can 
be separated from mGch1 and mPts and still has therapeutic efficiency when co-
expressed. Furthermore, to assess the required expression level and extension of 
distribution of PAH in muscle for therapeutic efficacy in vivo, an AAV2/1-vector 
expressing Luc downstream of the mPah transgene was used to perform IVIS. 
Although, therapeutic doses of the all rAAV2/1’s were applied, not even the published 
viral therapeutic control vector AAV2/1-PKU5 showed cPKU correction in the 
Pahenu2/2 mice for unknown reasons. 
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4.2.2 INTRODUCTION 
 
So far, a triple-cystronic gene therapy approach to treat cPKU in muscle of Pahenu2/2 
mice by using non-viral vectors was negative (described in chapter 4.1). In general, a 
triple-cystronic gene therapy approach is challenging to establish because too low 
expression of one out of three genes can be the reason for no efficacy. In 
comparison to viral vectors, non-viral vectors have generally low transfection efficacy, 
which worsens with increasing vector size (Molnar et al., 2004). A transgenic mouse 
model (Tg/Pahenu2), which expressed mPah and mGch1 in skeletal muscle was 
already reported (Ding et al., 2008). This mouse showed transient lowering of L-Phe 
levels in blood after a single intraperitoneal (i.p.) injection of BH4. Unfortunately, this 
mouse model is not longer available (personal communication with C. Harding). 
However, the laboratory of C. Harding attempted to generate a new transgenic PKU 
mouse, which expresses hGch1 and hPts for BH4 production in skeletal muscle. With 
such a mouse model, a non-viral gene therapy could be attempted by injecting a MC 
vector that expresses only one gene (mPah). It is speculated that optimization of MC 
delivery and PAH expression in skeletal muscle would be easier than a triple-
cystronic approach. Unfortunately, such a PKU mouse that expresses the BH4-
biosynthetic genes and produces the cofactor in skeletal muscle tissue was not 
available because after two series of embryo injections, no founder mice could be 
isolated due to unknown reasons (C. Harding, personal communication). Thus an 
alternative possibility was investigated by transducing skeletal muscles of PKU mice 
with an AAV2/1 vector that expresses mGch1 and mPts. Thus an alternative 
possibility was investigated by transducing skeletal muscles of PKU mice with an 
AAV2/1 vector that expresses mGch1 and mPts. Such a virally pre-injected PKU 
mouse could be used to test for HLV injection of a MC vector that expresses the 
mPah gene in order to test for correction of HPA (Fig. 26).  
 
 
To validate the potential benefit of such a variant PKU mouse model, it first had to be 
investigated if the separation of the triple-cystronic viral vector AAV2-PKU3 into a 
vector expressing mPah and a second vector expressing mGch1 and mPts for 
cofactor production still lead to therapeutic efficiency when co-injected (Fig. 26). To 
test this, AAV2/1 vectors were used as they showed stable and long-term expression 
in mice. The triple-cistronic expression cassette from vector AAV2-PKU3.3 was 
separated into two viral vectors, AAV2-PKU16 expressing mPah and AAV2-PKU12 
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expressing mGch1 and mPts. Furthermore, it was planned to assess the distribution 
and therapeutic expression of PAH in muscle by adding the Luc downstream of the 
mPah transgene (AAV2-PKU11.2) for IVIS application. With this gain of knowledge, 
therapeutic doses of MC vector can be easier assessed by generating an MC vector, 
which also expresses Luc downstream of the mPah transgene.  
 
In summary, it was investigated if the separation of the therapeutic triple-cystronic 
setting is still therapeutic (needed to generated the BH4 muscle expressing PKU 
mouse model) and if so, how much AAV2/1 mPah expression leads to therapeutic 
efficacy in vivo (needed to determine the dose for the non-viral one gene MC 
approach).  Therefore, PKU mice were rAAV injected into the m. gastrocnemius, the 
same method used in the therapeutic triple-cystronic AAV-PKU3 setting (Ding et al, 
2009). 
Figure 26: Schematic representation of generating a BH4 muscle expressing PKU mouse model for 
non-viral one gene therapy. mGch1, murine guanosine triphosphate cyclohydrolase 1 gene; mPts, 
murine 6-pyruvoyl-tetrahydropterin synthase gene; Luc, firefly luciferase gene; BH4, 
tetrahydrobiopterin; L-Phe, L-phenylalanine; MC, minicircle. 
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4.2.3 MATERIALS AND METHODS 
 
4.2.3.1 Viral vector plasmids 
 
In chapter 4.1.3.1 the correction of the two missense mutations in mPah (c.1126G>A, 
p.E376K) and mPts (c.230A>G; p.E77G) in the AAV2-PKU3 plasmid as well as the 
correction of the disrupted ITR site was described. Furthermore, the published vector 
AAV2-PKU5 showed also the mPah p.E376K mutation, which was corrected and the 
AAV2-PKU56 plasmid was generated (received from H. M. Viecelli). Therefore, 
instead of AAV2-PKU3 and AAV2-PKU5, AAV2-PKU3.3 and AAV2-PKU56 were 
used as positive controls, respectively. Detailed summary of all viral plasmids is listed 
in chapter 5.1. 
 
 
4.2.3.2 rAAV production 
 
4.2.3.2.1 Transfection, purification and titer determination 
 
Confluent 293T cells in a 15 cm plate were split into 1:3, and incubated over night at 
37°C and 5% CO2. The next day, cells had a confluence of 50-60%, and the 
Dulbecco's modified eagle medium (Thermo Scientific, Reinach, Basel, Switzerland) 
with 1% L-glutamine (Thermo Scientific) was changed. A transfection mixture for one 
plate containing 25 µg of viral plasmid, 37.5 µg helper plasmid and 20 µg of the 
AAV1-capsid plasmid were mixed in up to 1100 µl ddH2O. 150 µl of 2.5 M CaCl2     
pH 7.13 (ref. nr. 21097, Fluka Chemie GmBH) followed by 1250 µl 2x HeBS pH 7, 
including 0.28 M NaCl, 0.05 M HEPES and 1.5 mM Na2HPO4, were added, mixed 
and incubated at room temperature for 5 min. The transfection reaction was added 
drop wise to the cells (total 20 plates per virus). The cells were incubated for 72 h at 
37°C and 5% CO2. Cells were collected, washed with 1x phosphate buffered saline, 
shock frozen with liquid nitrogen and stored at -80°C. rAAV purification and titer 
determination were performed as described in the published methods (Haberman 
RP, 1999, Ding et al., 2006).  
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4.2.3.2.2 Enzyme activity 
 
To confirm that the generated rAAV are vital and infectious, 50-60% confluent 293T 
cells on a 15 cm plate were transduced with 25 µl AAV2/1-PKU3.3, 11.2, 12 or 16 for   
48 h at 37°C and 5 % CO2. PAH or PTPS activity was measured as described in 
chapter 4.1.3.3. 
 
 
4.2.3.2.3 Application of AAV vectors to Pahenu2/2 mice 
 
Pahenu2/2 mice were anaesthetized with 2-3% isoflurane. Hind limbs were shaved and 
disinfected with 70% ethanol. Both hind limbs were injected with a maximum volume 
of 100 µl rAAV2/1 per hind limb. Injection was done directly into m. gastrocnemius 
using a U-100 insulin syringe with a 28 G needle. 
 
 
4.2.3.3 In vivo imaging system 
 
Was performed as described in chapter 4.1.3.6 but D-luciferin was i.p. injected.  
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4.2.4 RESULTS 
 
4.2.4.1 AAV vectors and in vitro expression  
 
In a first step, the published triple-cystronic expression cassette from vector AAV2-
PKU3, containing the genes mPah, mGch1 and mPts expressed from the human 
CMV promoter, was separated into one vector expressing mPah with Luc for 
analyzing expression level and distribution in vivo (AAV2-PKU11.2) and one 
expressing mGch1 and mPts (AAV2-PKU12) (Ding et al., 2006). In addition, an AAV 
expressing only mPah (AAV2-PKU16) was generated. Theoretically, the co-injection 
of AAV2/1-PKU12 and AAV2/1-PKU11.2 or 16 into the m. gastrocnemius muscle 
should clear the high L-Phe levels in Pahenu2/2 mice. The already published vectors 
AAV2-PKU3 and AAV2-PKU5, which is liver directed gene therapy vectors 
expressing mPah under the liver expressing chicken β-actin (CBA) promoter, was 
planned to use as positive control (Rebuffat et al., 2010). Due to sequence alteration 
found in control AAV2-PKU3 and AAV2-PKU5 vectors described in chapter 4.2.3.1, 
AAV2-PKU3.3 and AAV2-PKU56 were used as positive controls, respectively. All 
rAAV vectors were generated with serotype 1 capsid that had tropism for skeletal 
muscle. A summary of all viral plasmids is listed in table 10. 
 
Table 10: Viral plasmid list. 
Vector Promoter mPah mGch1 mPts Luc Enhancing elements Vector size (bp) 
Vector size    
ITR to ITR (bp) 
AAV2-PKU3.3 CMV wt wt wt - WPRE 9,361 5,628 
AAV2-PKU11.2 CMV wt - - wt WPRE 9,320 5,587 
AAV2-PKU16 CMV wt - - - WPRE 7,227 3,494 
AAV2-PKU12 CMV - wt wt - WPRE 7,419 3,777 
AAV2-PKU56 CBA wt - - - WPRE 7,973 4,292 
 
CMV, human cytomegalovirus promoter; CBA, chicken β-actin promoter; mPah, murine phenylalanine 
hydroxylase gene; mGch1, murine GTP cyclohydrolase 1 gene; mPts, murine 6-pyruvoyl-
tetrahydropterin synthase gene; Luc, firefly luciferase; WPRE, woodchuck hepatitis post-transcriptional 
regulatory element; wt, wild-type. 
 
To validate that AAV2/1-PKU3.3, AAV2/1-PKU11.2, AAV2/1-PKU12 and AAV2/1-
PKU16 are infectious, 293T cells were transduced with 25 µl of the AAV2/1 for 48h 
and enzyme activity was analyzed. PAH enzyme activity was measured for AAV2/1-
PKU3.3, AAV2/1-PKU11.2 and AAV2/1-PKU16. PTPS activity was evaluated for 
AAV2/1-PKU12 (Fig. 27). 
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Figure 27: PAH or PTPS activity of AAV2/1-PKU3.3, AAV2/1-PKU11.2 and AAV2/1-PKU16 or 
AAV2/1-PKU12 transduced 293T cells, respectively (mU/mg protein). 
 
In general, viral plasmid inserts with more than 5,500 bp (AAV2-PKU3.3 and AAV2-
PKU11.2) had relative low titers. Unfortunately, the titer of viral vector AAV2/1-
PKU3.3 was too low to reach therapeutic efficacy in mice (therapeutic dose of 
AAV2/1-PKU3: 3.5 × 1012 vp), and therefore, it could not be used as positive control 
(Ding et al., 2008). Because of the low titer of AAV2/1-PKU11.2, the viral vector was 
used to investigate the distribution in muscle but not to evaluate the therapeutic dose. 
Overall, all rAAV2/1 vectors showed PAH or PTPS enzyme activity, although viral 
rAAV2/1 with relative low titers, like e.g. AAV2/1-PKU3.3 and AAV2/1-PKU11.2, 
showed very low enzyme activity (Fig. 27).  
 
 
4.2.4.2 In vivo evaluation of potential therapeutic efficacy of the separated 
rAAV2/1 triple-cystronic vector  
 
Next, it was to evaluate if co-expression in muscle of AAV2/1-PKU12 expressing 
mGch1-mPts and rAAV2/1-PKU16 expressing mPah would lead to L-Phe clearance 
in Pahenu2/2 mice. 1.5 x 1013 vp (low dose) or 6.0 x 1013 vp (high dose) of vector 
AAV2/1-PKU12 was co-injected with 1.3 x 1014 vp of rAAV2/1-PKU16 into m. 
gastrocnemius of female Pahenu2/2 mice. Since the titer of vector AAV2/1-PKU3.3 was 
too low to reach therapeutic dose (as described above), vector AAV2/1-PKU56 was 
used as control instead (therapeutic dose: 1.2 x 1012, Rebuffat et al., 2010). Two 
doses of AAV2/1-PKU56 were applied, 1.7 x 1012 (low dose) to a male mouse and 
2.2 x 1012 (high dose) to a female mouse. The control female mouse was injected 
with a slightly higher concentration of AAV2/1-PKU56 because of the known sexual 
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dimorphism of hepatic AAV transduction in Pahenu2/2 mice probably caused by an 
androgen-dependent pathway. A summary of blood L-Phe levels are shown in Fig. 
28. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Blood L-Phe levels of Pahenu2/2 mice co-injected with AAV2/1-PKU12 and AAV2/1-PKU16 
or the therapeutic AAV2/1-PKU56 (µmol/l). AAV2/1-PKU56 injected Pahenu2/2 mice are indicated by 
black lines; co-injected AAV2/1-PKU16 and AAV2/1-PKU12 injected Pahenu2/2 mice are indicated by 
gray lines; Low dose are indicated by straight lines; High dose are indicated by dotted lines. 
Therapeutic range is indicated below 360 µmol/l L-Phe. 
 
Surprisingly, none of injected Pahenu2/2 mice showed clearance of blood L-Phe to 
therapeutic levels (<360 µmol/l), not even the control injected PKU mice (AAV2/1-
PKU56). Nevertheless, the male mouse showed lowered L-Phe levels and the fur 
colour of the AAV2/1-PKU56 injected Pahenu2/2 mice changed and revealed dark 
patches, which was more prominent in the male mouse then in the female mouse 
indicating a transient expression and/or mild efficacy of the virus (Fig. 29 A-D). 
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Figure 29: Pictures of AAV2/1-PKU56-injected Pahenu2/2 mice 50 days after injection.  (A-B) Males. (C-
D) Females. 
 
Although potential therapeutic doses of AAV2/1-PKU56 were injected into the 
Pahenu2/2 mice, there was no therapeutic effect leading to the assumption that either 
the titer was incorrect calculated or the transfection efficacy of the AAV2/1 vectors 
were not high enough. Although, almost 10 to 100 times more then the reported 
therapeutic dose of AAV2/1-PKU5 was injected for AAV2/1-PKU12 and AAV2/1-
PKU16 into Pahenu2/2 mice, there was no lowering of L-Phe below 360 µmol/l. It was 
described that i.p. injection of 1.0 μmol BH4/g body weight into a transgenic 
Tg/Pahenu2 mouse, which expresses mGch1 and mPah in muscle, showed transient 
lowering of blood L-Phe 6 h after injection (<360 µmol/l), which was reversed after  
24 h (Ding et al., 2008). Since the injected amount of AAV2/1-PKU16 was very high, 
it was investigated if at least i.p. injection of BH4 would lead to correction of blood L-
Phe levels after 6 h similar to the Tg/Pahenu2 mouse. Therefore, two male mice, one 
pre-injected with 1.3 x 1014 vp AAV2/1-PKU16 14 days before, and one not-injected 
Pahenu2/2 control mouse received an i.p. injection of 1.0 μmol BH4/g body weight. 
Blood L-Phe was measured after 6, 28 and 76 h after injection shown in Fig. 30. 
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Figure 30: Blood L-Phe levels of 1.0 μmol BH4/g body weight i.p. injected Pahenu2/2 mice (µmol/l). 
AAV2/1-PKU16 pre-injected Pahenu2/2 mouse is indicated by a black line; not pre-injected Pahenu2/2 
mouse is indicated by a gray line. Therapeutic range is indicated below 360 µmol/l L-Phe. 
 
Unexpectedly, blood L-Phe levels were not lowered below 360 µmol/l after 6 h of BH4 
injection in the AAV2/1-PKU16 pre-injected Pahenu2/2 mouse, indicating either that the 
potential therapeutic dose of AAV2/1-PKU16 was not reached or that the time point 
of potentially transient low L-Phe was missed. No further investigations were 
performed. Therefore, it is still unclear if mPah can be separated from mGch1 and 
mPts and lead to therapeutic efficacy. In summary, the original plan to generate PKU 
mouse model by using rAAV2/1 expressing mGch1 and mPts for BH4 production in 
muscle failed.  
 
 
4.2.4.3 Evaluation of distribution and expression of PAH in muscle in 
combination with Luc 
 
To investigate the distribution of PAH in muscle, 7.2 x 1010 vp (low dose) or 1.2 x 1011 
vp (high dose) of AAV2/1-PKU11.2 was injected into the m. gastrocnemius muscle of 
both legs in a Pahenu2/2 mouse. With this experiment it should be also verified that the 
rAAV2/1 is restricted to the injected hind limb muscles and not spreading to other 
muscle areas of the body. IVIS results and blood L-Phe levels are represented in Fig. 
31 A-C showing the restricted expression and distribution of AAV2/1-PKU11.2 in m. 
gastrocnemius of the injected hind limbs up to 71 days. 
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Figure 31: IVIS and blood L-Phe level results of AAV2/1-PKU11.2 injected limb muscles of Pahenu2/2 
mice with low and high dose before (day 0) and after injection (day 6, 13 and 71). (A) IVIS pictures of 
Luc expression. (B) IVIS graph of Luc expression (p/sec). (C) Blood L-Phe (µmol/l). Low dose injected 
mouse is indicated by black line; high dose injected mouse is indicated by gray line; right leg is 
indicated by straight lines; left leg is indicated by dotted lines; LD, low dose; HD, high dose. 
Therapeutic range is indicated below 360 µmol/l L-Phe. 
 
Although, vector AAV2/1-PKU11.2 showed low PAH expression in vitro, there was 
clearly detectable Luc signaling in vivo. At the beginning, both doses showed equally 
Luc expression up to 13 days (Fig. 31 A-B). In contrast, at day 21 the higher dose 
injected mouse showed almost no Luc expression, which recovered at day 71, 
whereas the low dose injected mouse showed high and stable Luc expression up to 
71 days after injection (Fig. 31 A-B). As expected, the blood L-Phe levels was not 
influenced by rAAV2/1 treatment (Fig. 31 C).  
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4.2.5 DISCUSSION 
 
Unfortunately, generation of a PKU mouse which produces BH4 in muscle by injecting 
rAAV2/1 expressing the two genes mGch1 and mPts, could not be achieved. With 
such a mouse model, non-viral gene therapy could have been optimized by only 
injecting a MC vector containing mPah, which is easier to monitor in comparison to 
the triple-cystronic approach. So far, it is still unknown if the triple-cistronic mPah-
mGch1-mPts genes lead to correction of cPKU when separated and co-expressed in 
vivo due to the fact that not even the control therapeutic AAV2/1-PKU56 injected 
Pahenu2/2 mice showed lowered L-Phe levels (<360 µmol/l). One possibility would be 
that the titer was not calculated correctly. Titer recalculation of a rAAV2/1 aliquot with 
a known titer led to similar results. Therefore, it seems unlikely that miscalculation is 
the reason for the non-therapeutic efficacy. Another potential cause could be that the 
produced rAAV2/1 had too low transfection efficacy. All in vitro tested rAAV2/1 
showed enzyme activity according to the virus titer either low (AAV2-PKU3.3 or 11.2) 
or high (AAV2-PKU16 or 12). Although the measured in vitro enzyme activity of 
AAV2/1-PKU11.2 was very low, there was stable Luc expressed up to 71 days in 
vivo. In contrast, AAV2/1-PKU16 or 12 showed higher virus titer and enzyme activity 
in vitro but surprisingly their co-expression did not lead to L-Phe lowering in vivo. 
Even i.p. injection of BH4 did not lead to blood L-Phe lowering after 6 h in a 14 days 
pre-injected AAV2/1-PKU16 Pahenu2/2 mouse. Perhaps it is necessary to increase the 
doses of BH4 and measure blood L-Phe levels in shorter time intervals. Another 
mysterious phenomenon was that the control vector AAV2/1-PKU56 did not show 
blood L-Phe lowering in vivo, although it seemed that blood L-Phe was halved 
especially for the male mouse indicating some effect, which was also indicated by the 
changes of their fur coat by revealing dark patches, which was more prominent in the 
male mouse. Unfortunately, PAH enzyme activity of the control virus AAV2/1-PKU56 
was not measured in vitro (cell culture), which would validate expression. Overall, it is 
rather unclear why the AAV2/1 vectors were not therapeutic. Probably it is a 
combination of too low titer and limited transgene expression. Determination of vector 
genome copy numbers in the treated mouse muscle tissues and/or the transduction 
frequency as judged from immunohistology against GTPCH or PTPS are definitively 
needed to better understand the limitations and to continue with future analyses. 
Furthermore, it is unclear in how far the two found but not yet described mutations in 
AAV2-PKU3 (mPah p.E376K and mPts p.E77G) and AAV2-PKU5 (mPah p.E376K), 
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influenced the gene expression. Therefore, a mutation analysis for their enzyme 
activity would be interesting. Furthermore, analysis of the injected muscle tissue for 
the mRNA expression, vector copy number, and enzyme activity can be performed.  
 
The second goal of showing mPah expression and distribution in muscle was 
achieved although the therapeutic dose of mPah in muscle could not be elucidated. 
Injection of AAV-PKU11.2 into m. gastrocnemius of Pahenu2/2 mice showed that the 
Luc was only expressed in the injected hind limbs up to 71 days. Surprisingly, the 
mouse with the lower injected dose had higher and more stable expression than the 
mouse injected with the higher dose. It could be hypothesized from these preliminary 
results that too high Luc expression levels could be inhibitory. Further studies need to 
be done with larger animal groups to confirm these preliminary results. 
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5. SUPPLEMTARY INORMATION 
 
5.1 Cloning of plasmids 
 
AAV2-PKU3: CMV-mPah (c.230A>G; p.E77G)-EMCV-IRES-mGch1-FMDV-IRES-
mPts (c.1126G>A, p.E376K)-WPRE-pA (one disrupted ITR site) 
 
AAV2-PKU3.1: CMV-mPah (c.230A>G; p.E77G)-EMCV-IRES-mGch1-FMDV-IRES-
mPts-WPRE-pA (one disrupted ITR site) 
 
AAV2-PKU3.3: CMV-mPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-WPRE-pA (one 
disrupted ITR site) 
 
AAV2-PKU3.3: CMV-mPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-WPRE-pA 
(corrected ITR site) 
 
AAV2-PKU11.1: CMV-mPah-EMCV-IRES-Luc-WPRE-pA (one disrupted ITR site) 
 
AAV2-PKU11.2: CMV-mPah-EMCV-IRES-Luc-WPRE-pA (corrected ITR site) 
 
AAV2-PKU12: CMV-mGch1-FMDV-IRES-mPts-WPRE-pA 
 
AAV2/8-PKU13: CBA-mPts-EMCV-IRES-Luc-pA 
 
AAV2-PKU16: CMV-mPah-WPRE-pA 
 
MC.PKU100: CMV-mPah (c.230A>G; p.E77G)-EMCV-IRES-mGch1-FMDV-IRES-
mPts (c.1126G>A, p.E376K)-EMCV-IRES-S/MAR-BGHpA 
 
MC.PKU101: CMV-mPah (c.230A>G; p.E77G)-EMCV-IRES-mGch1-FMDV-IRES-
mPts-EMCV-IRES-S/MAR-BGHpA 
 
pMC.PKU102: CMV-mPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-EMCV-IRES-
Luc-S/MAR-BGHpA 
 
MC.PKU104: CMV-mPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-WPRE-pA 
 
MC.PKU105: CMV-mPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-BGHpA 
 
MC.PKU106: CMV-mPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-S/MAR-BGHpA 
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MC.PKU108: CMV-mcoPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-WPRE-pA 
 
MC.PKU109: CMV-mcoPah-EMCV-IRES-mGch1-FMDV-IRES-mPts-pBGHA 
 
MC.PKU114: CMV-mcoPah-IVS1B-EMCV-IRES-mGch1-FMDV-IRES-mPts-WPRE-
pA 
 
MC.PKU115: CMV-mcoPah-IVS1B-EMCV-IRES-mGch1-FMDV-IRES-mPts-pA 
 
MC.PKU116: CMV-mcoPah-EMCV-IRES-mcoGch1-FMDV-IRES-mcoPts-WPRE-pA 
 
MC.PKU117: CMV-mcoPah-EMCV-IRES-mcoGch1-FMDV-IRES-mcoPts-pA 
 
MC.PKU118: CMV-mcoPah-IVS1B-EMCV-IRES-mcoGch1-FMDV-IRES-mcoPts-
WPRE-pA 
 
MC.PKU119: CMV-mcoPah-IVS1B-EMCV-IRES-mcoGch1-FMDV-IRES-mcoPts-pA 
 
MC.PKU121: CMV-Luc-BGHpA 
 
PLASMID: mcoGch1-FMDV-IRES-mcoPts 
The mPts and mGch1 genes were codon optimized and synthesized by GenScript 
USA Inc. (Piscataway, USA) in the pUC57 vector. 
 
PLASMID: CBA-mPts-EMCV-IRES-mTh-FMDV-IRES-mTph2 
Synthesized by GeneArt® Life technology (Regensburg, Germany) in the pMA 
vector. 
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